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GENERAL INTRODUCTION • 1
Ageing and senescence
As humans grow older, the structures and 
functions of their bodies deteriorate. As a 
consequence, their risks of disability, dis-
ease, and death increase. It is an omen of 
the various confusions and controversies 
existing in the research on this process 
that the process itself has no universally 
accepted designation.
In line with renowned gerontologists, we 
distinguish between ageing and senes-
cence.1-5 Ageing refers to the mere passage 
of time. It encompasses all changes that 
occur in the body during time, whether 
their effects are detrimental, beneficial, or 
negligible. The progress of ageing is indi-
cated by one’s chronological age, which can 
be easily deduced from a birth registry. Se-
nescence is part of ageing. It refers to the 
deterioration of the body’s structures and 
functions and encompasses specifically 
the detrimental changes that appear with 
ageing. The progress of senescence is indi-
cated by one’s biological age, although it is 
still elusive how one’s biological age can be 
precisely determined.6-10
Apart from senescence, ageing is accom-
panied by changes that are beneficial to 
the body’s structures and functions. Such 
changes take place in a programmed order 
early in life as growth and development, 
are brought about by the body as regenera-
tion when it repairs its damaged parts, for 
example during the healing of a fractured 
bone,11 and can be effectuated by medical 
interventions, like the replacement of stem 
cells, which is called rejuvenation.12 Ageing 
is also accompanied by changes that are, 
as far as we know, neither detrimental nor 
beneficial to the body. A classic example is 
the greying of hair. These changes are sim-
ply spoken of as age-related changes.13
Some researchers are accustomed to de-
note the senescence of cells in particular as 
senescence and to denote the senescence 
of individuals or populations as ageing.14-18 
However, as will be substantiated hereaf-
ter, there is no reason to fundamentally 
separate cellular senescence from senes-
cence of individuals or populations.
Senescence at different levels
Senescence is generally attributed to an 
accumulation of random damage to the 
human body.14,19-22 During life, the body 
is exposed to a wide variety of intrinsic 
stressors from within the body and extrin-
sic stressors from without the body. Ex-
amples of intrinsic stressors include DNA 
replication errors, spontaneous chemical 
reactions, and metabolic waste products. 
Examples of extrinsic stressors include 
pathogens, radiation, and mechanical forc-
es. A stressor may at any moment damage 
the body’s structure and function. In the 
case of sufficient damage, death may fol-
low. In other cases, damage repair mech-
anisms, with which the body’s cells and 
tissues are equipped, are activated. Some 
of the acquired damage can be repaired 
fully by these mechanisms, after which the 
body will have regenerated and recovered. 
Some damage can be repaired only partly 
or not at all, will irreversibly remain, and 
become apparent as dysfunction, disabili-
ty, or disease. If a stressor affects the dam-
age repair mechanisms, the accumulation 
of further damage is accelerated.
12
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Alternative theories attribute senescence 
to other processes than the accumulation 
of random damage. A noteworthy theory, 
which is discussed in more detail in Chap-
ter 5 of this thesis,23 proposes that senes-
cence may be the result of persistent devel-
opmental processes.24,25 Nonetheless, these 
theories too acknowledge that the damag-
ing effects of such processes are crucial in 
the causation of senescence.23-26
As schematically shown in Figure 1.1, the 
accumulation of damage occurs in the body 
at different levels of complexity. Stressors 
may damage the structure and function 
of a molecular component of a cell, an en-
tire cell, an organ or tissue, or the body as 
a whole. Much research is devoted to the 
mechanisms of senescence at the molec-
ular-cellular level.17,27,28 Important roles 
have been attributed to DNA damage,29-33 
the effects of metabolic waste products 
such as reactive oxygen species,34-37 the 
various forms of dysfunction that are ob-
served in senescent cells,27,38 the accumu-
lation of senescent cells in tissues,15,18,27,39 
and chronic smouldering inflammation 
called inflammageing.40
The effects of damage acquired at low-
er levels seep through to higher levels of 
complexity in the body.20,21,24,28,41 Molecular 
damage underlies cellular senescence.17,27,38 
Senescent cells secrete numerous sig-
nalling factors that induce senescence of 
other cells17,27,38 and systemic symptoms 
of senescence, such as chronic smoulder-
ing inflammation.42 Cellular senescence 
causes dysfunction and disease of tissues, 
such as impaired wound healing, cancer, 























Figure 1.1 • Schematic overview of the 
accumulation of damage at different 
levels in the body during senescence. 
Intrinsic and extrinsic stressors, in interac-
tion, damage the human body at different 
levels of complexity. The damage at the 
lower levels seeps through to the higher 
levels. The damage at the higher levels 
probably also drips down to the lower lev-
els. ROS: reactive oxygen species. AGE: 
advanced glycation end products.
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ular and cellular senescence are the basis 
of disorders characterised by similar clin-
ical features of accelerated senescence.46 
The accumulation of damage in the body’s 
structures and functions and the develop-
ment of disabilities and diseases culminate 
in an increasing risk of death.2,19,20,24,41,47-49
Measuring senescence 
at the population level
As senescence manifests at different levels, 
it follows that it can be measured at differ-
ent levels. For example, it can be measured 
at the molecular-cellular level through 
DNA lesions and cell cycle arrests, at the 
level of tissues and organs through inflam-
mation and vascular calcification, and at 
the level of the body as a whole through 
instability and physical disability. In this 
thesis, we measure senescence in human 
populations. At the population level, se-
nescence is defined as an increase in the 
risks of dysfunction, disease, and death 
with increasing chronological age.2,19,47,50,51 
A constant risk of death during ageing 
marks the absence of senescence.52,53
Knowledge of senescence can be obtained 
by studying molecules, cells, individuals, 
but also populations. These approaches are 
fundamentally different, but yield equally 
valuable and complementary insights. Ob-
serving and comparing populations with 
different characteristics is especially rele-
vant in order to understand how the course 
of senescence can vary, what determinants 
account for this variation, and what pre-
ventive measures can ameliorate the se-
nescence process.54,55
Aims of this thesis
In Part I of this thesis we investigate how 
a population’s senescence can be measured 
through the increase in mortality with age. 
In Part II of this thesis we investigate how 
senescence can be measured through the 
increase in morbidity in a non-western 
population and thus be compared with 
the senescence process in western popula-
tions. A more detailed introduction to each 
research question is given at the opening 
of each part of this thesis.
14
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Age patterns of mortality
Humans die at any moment in their lives. 
As a result of senescence, the risk of death 
increases with chronological age.
The Panel on the next page shows three 
manners in which a population’s senes-
cence can be visualised with age patterns 
of mortality.1,2 Firstly, the number of in-
dividuals that have survived from birth 
decreases with age until the entire popu-
lation has died and this decrease quickens 
with age (Figure A in the Panel). Secondly, 
the number of individuals that have died is 
greater at higher than at lower ages (Figure 
B in the Panel). Thirdly, the mortality rate 
increases with age (Figure C in the Panel). 
As explained in the Panel, the age patterns 
of a population’s survival, deaths, and mor- 
tality rate are directly related and can be 
derived from each other.
If senescence is the consequence of an 
accumulation of damage during life, it is 
plausible that senescence starts at con-
ception. However, only from adolescence 
onward can senescence be discerned in 
age patterns of mortality. Early in life, the 
decline in survival slackens, the number of 
deaths decreases, and the mortality rate 
falls (Panel). Age patterns of mortality are 
the net result of senescence together with 
its opposing forces of growth, develop-
ment, and regeneration. The balance be-
tween these processes determines whether 
an age pattern displays senescence. Early 
in life, growth, development, and regen-
eration dominate senescence and are of 
main influence on mortality.3-6 During 
life, growth and development regress or 
derail and the body’s capacity to regener-
ate diminishes.7 When sufficient time has 
elapsed and enough damage has accumu-
lated, a deterioration in the body’s struc-
tures and functions becomes visible as an 
increase in the risk of death. This is sche-
matically shown in Figure 2.1.
Although some gerontologists have drawn 
attention to the importance of early-life 
mortality for research on senescence,4,5 
we depart from the customary approach to 
leave out of consideration that mortality is 
high immediately after birth and decreases 
during childhood to its lowest levels in ad-
olescence. Senescence is, in that manner, 
studied from adolescence onward, when 
mortality starts to increase with age. We 
will discuss the relevance of patterns of 
early-life mortality in Chapter 4 of this 
thesis.8
Modelling age patterns 
of mortality
Age patterns of mortality are commonly 
described using parametric models. Such 
models suit analytical purposes that are 
not or not well served by non-parametric 
models: they are capable of estimating age 
patterns of mortality continuously, thus 
for each specific age or age category, their 
estimated age patterns are precise and 
smooth, they can be used to assess the ef-
fects of measured variables on age patterns 
of mortality, and they enable the extrapo-
lation and prediction of mortality beyond 
the observed ages and along alterations in 
these variables.16,17
A wide variety of parametric models ex-
ists that describe age patterns of mortal-
22
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Panel • A population’s 
senescence visualised with 
age patterns of mortality
Age patterns of mortality are shown 
for different years in the Netherlands.14 
The proportion of individuals that have 
survived from birth to a given age (A) 
and the proportion of individuals that 
have died at a given age (B) are shown 
relatively to the total number of in-
dividuals that have died at any age 
during life. The age pattern of deaths 
can be derived from the age pattern of 
survival, because the number of deaths 
at any age is the difference in the num-
ber of survivors between that age and 
the consecutive age, which equals the 
negative derivative function of the age 
pattern of survival. An age-specific 
mortality rate (C) can be interpreted 
as the rate at which individuals die at 
a given age. It describes the number of 
deaths per person-year, which is the 
number of deaths per period of time 
lived by the individuals in the popula-
tion of that age. It can be derived from 
the age pattern of survival as the num-
ber of deaths relative to the number of 
survivors at any age, which equals the 
negative derivative function of the log-
arithmically transformed age pattern 
of survival.
Equations are given that describe the 
age patterns of survival S, deaths d, 
and mortality rate m non-parametri- 
cally1 as dependent on the number of 
living individuals l at age t and ac-
cording to the Gompertz model9-13 as 
dependent on the model’s parameters 
α and γ.
S(t) = l(t) / l(0)
S(t) = exp(– α/γ (exp(γ t) – 1))
d(t) = l(t) – l(t+1) = – S’(t) = – l’(t)
d(t) = α eγ t exp(– α/γ (exp(γ t) – 1))
m(t) = – S’(t) / S(t) = – l’(t) / l(t)
m(t) = – ln(S(t))’ = – ln(l(t))’
m(t) = α eγ t
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ity, among which the exponential model, 
gamma model, log-logistic model, Weibull 
model, and Gompertz model.17 The Gom-
pertz model is most commonly used in re-
search on senescence.11,13,18,19
The British mathematician and actuary 
Benjamin Gompertz (1779–1865) was the 
first to observe that mortality rates in-
crease exponentially with age in human 
populations and captured his observation 
mathematically as the model that was later 
named after him.19,20 The Gompertz model 
describes the age pattern of a population’s 
mortality rate as dependent on two param-
eters α and γ (see the Panel). The mortality 
rate equals α at age t = 0. An age in ado-
lescence, around which mortality is lowest 
during life, is chosen as t = 0, because the 
Gompertz model cannot account for the 
decrease in early-life mortality. From this 
age onward, the mortality rate is modelled 
to increase exponentially from the mini-
mal level α to the extent of γ.
The Gompertz model can be extended with 
a third parameter β that adds to the expo-
nential increase in mortality in an age-in-
dependent manner. This model is known as 
the Gompertz-Makeham model.9,11,13 As the 
parameter β is negligible in human popu-
lations, the Gompertz model is preferred 
over the Gompertz-Makeham model.13,21,22
Measuring senescence 
through age patterns of mortality
A population’s senescence can be meas-
ured through its age patterns of mortality 
in various manners. From the age pattern 
of survival, the mean, median, and maxi-
mal lifespan can be calculated. From the 
age pattern of deaths, the mean, median, 
and modal age at death can be calculated. 
The mean lifespan equals the mean age at 
death; both are more commonly referred 
to as the life expectancy.23 These measures 
of senescence each represent a different 
aspect of a population’s age pattern of sur-
vival or deaths and should be applied in a 
supplementary manner. However, as these 
measures summarise the varying levels 
of mortality throughout life in a single 
age-independent constant, they are little 
informative about its age pattern.23,24
 
Since senescence manifests in human pop-
ulations as an increase in mortality rate 
with age, senescence is preferably and com- 
monly measured through age patterns of 
mortality rates. This can be achieved by 
evaluating the age pattern of a population’s 
Figure 2.1 • Schematic illustration of 
the age pattern of mortality as a net 
result of senescence as well as growth, 
development, and regeneration. Similar 
schemes have been proposed by others.15 
Conc.: conception.
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mortality rate, by graphically comparing 
the age patterns of different populations, 
and by calculating the age-specific differ-
ences of their mortality rates.2,25-27
The classical measure of a 
population’s senescence rate
The Gompertz model is often preferred for 
modelling age patterns of mortality rates 
because it has the following advantage. 
When the Gompertz model is transformed 
logarithmically, the mortality rate increas-
es linearly with age from adolescence on-
ward. This linear increase is described by 
the model as: ln m(t) = ln α + γ t (compare 
with the Panel). The visual assessment of 
linear age patterns is much easier than 
that of exponential age patterns, as illus-
trated by Figure 2.2. Moreover, the linear 
increase in the mortality rate, thus the 
slope of the straight curve, is solely de-
scribed by the model’s parameter γ, as this 
parameter equals the derivative function of 
the aforementioned logarithmically trans-
formed model. Differences in the slope of 
the straight curves are easily discernible 
on a logarithmic scale (Figure 2.2b).
The linear increase in the mortality rate on 
a logarithmic scale, thus the slope of the 
straight curve described by γ, is classically 
equated with the population’s senescence 
rate. Both consciously and unconsciously 
this interpretation is widely used to inter-
pret research on senescence.
From the linear increase in the mortali-
ty rate on a logarithmic scale, the period 
of time can be calculated during which a 
population’s mortality rate doubles. This 
mortality rate doubling time (MRDT) is 
directly related to the slope of the straight 
curve described by γ: MRDT = ln 2 / γ. 
The MRDT has been proposed as a more 
comprehensible variant of the slope of the 
straight curve as the measure of a popula-
tion’s senescence rate.28
Critique of the classical measure 
of a population’s senescence rate
Although originally the Gompertz mod-
el is a purely empirical model, it has ac-
quired the status of a law or dogma that 
is thought to apply universally to the age 
patterns of mortality rates of human pop-
ulations.19,21,29,30 Yet, the use of the linear 
increase in the mortality rate on a loga-
rithmic scale, described by the model’s pa-
rameter γ, as a measure of a population’s 
senescence rate is a theoretical assumption 
that has never been empirically tested. 
Meanwhile, it has been objected that this 
measure of a population’s senescence rate 
may be false.31-35
The critique concerns the logarithmic trans- 
formation of the Gompertz model, which is 
necessary for the model to adopt a linear 
age pattern.35 This can be illustrated by the 
following observation.
At the end of the Second World War, civil-
ians in Indonesia were caught as prisoners 
of war in a Japanese concentration camp. 
The conditions of life, which were similar 
for all prisoners, were harsh. They slept in 
crowded barracks on a small mattress, a 
couple of planks, or bare stones. Infectious 
diseases thrived. Hunger was common-
place with estimated average rations of 
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1250 kcal per day.36 When the age pattern 
of their mortality rate is compared with 
that of Australian civilians in the same 
years on a logarithmic scale, the age pat-
terns increase linearly with age and the 
increases of both populations are equal, 
as shown in Figure 2.3a. The parallel log-
arithmic age patterns are classically inter-
preted to demonstrate that the senescence 
rate of a human population is equal in ad-
verse and aff luent environments.2,37,38
However, as shown in Figure 2.3b, when 
the same age patterns of mortality rates 
are examined on an absolute scale, they 
increase exponentially and the difference 
in mortality rate between both popula-
tions grows with age. Interestingly, the 
comparison of these populations was 
originally made without any logarithmic 
transformation. The crude age patterns 
of the mortality rates were reported to 
diverge and interpreted as follows: „The 
harm done to the [prisoners of war] man-
ifests itself in the increased death rate 
and can be put down to a process of rapid 
pathologic ageing. Of course the death rate 
is not the only indication of this process; 
there are many more, but the others are, 
although clearly visible, difficult to take 
down in figures. The premature greying 
of the hair, the excessive wrinkling of the 
skin, the difficulty in walking, the general 
hypotony of the musculature, the monoto-
ny in thought, the difficulty experienced in 
realising and analysing present problems, 
the predominance of past memories – all 
these and many more signs pointed in the 
same direction. But as mentioned before, 
the death rate as a symptom has two defi-
nite advantages: it is calculable and it is 
irreversible.”39
It is generally ignored that logarithmic 
transformation renders an additive model 
into a multiplicative model. The increase 
in the mortality rates on a logarithmic 
scale, thus the slope of the straight curves 
Figure 2.2 • Visuali- 
sation of mortality 
rates on an absolute 
scale and on a loga- 
rithmic scale. Identi-
cal mortality rates for 
different years in the 
Netherlands are shown 
on an absolute (A) and 
on a logarithmic scale 
(B). According to the 
Gompertz model, mor-
tality rates increase 
exponentially with age 
on an absolute scale, 
but linearly with age on 
a logarithmic scale.
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described by γ, ref lects the factor by which 
the mortality rates are multiplied as the 
age increases by one year (Figure 2.3a). 
The increase in the mortality rates on an 
absolute scale reflects the factor that is 
added to the mortality rate as the age in-
creases by one year (Figure 2.3b). In oth-
er words, when a linear age pattern of the 
mortality rate shifts upwards but remains 
parallel on a logarithmic scale, the differ-
ence in its crude exponential age pattern is 
unmasked on an absolute scale.35
For the mathematical assessment of a bi-
ological interaction, the use of additive 
models rather than multiplicative models 
is recommended.40 From a multiplicative 
point of view, the equal increases in mor-
tality rates with age across different envi-
ronments suggests an absent interaction 
between the environment and the senes-
cence process, but such an interaction be-
comes apparent by comparing their in-
creases from an additive point of view.
Figure 2.3 • Age patterns of mortality 
rates of prisoners of war and civilians 
during the Second World War. The age 
patterns are shown on a logarithmic scale, 
as is classically done (A), and on an ab-
solute scale (B). The dotted tangent lines 
indicate the rates at which the mortali-
ty rates increase on an absolute scale at 
the age of 70 years (C).35 The data of the 
prisoners of war were derived from their 
original publication36 and those of the civil-
ians from the Human Mortality Database.47 
Figure A has also been presented by oth-
ers.2,37,38
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Following this line of reasoning, it has been 
proposed that a population’s senescence 
rate should not be measured as the linear 
increase in its mortality rate on a logarith-
mic scale, but could be measured as the 
exponential increase in its mortality rate 
on an absolute scale. The latter increase is 
mathematically described by the derivative 
function of the exponential age pattern of 
the mortality rate. In Figure 2.3c, tangent 
lines at the age of 70 years illustrate the 
derivative functions and estimate the in-
creases in the mortality rates at that age. 
According to the derivative function, the 
mortality rates increase more with age in 
the prisoners of war as compared with the 
civilians, indicating that the senescence 
rate is higher in an adverse environment.35
When the linear increases in the mortality 
rates on a logarithmic scale, described by 
γ, are interpreted as the senescence rates 
of both populations, their senescence rates 
would be not only invariant across differ-
ent environments, but even unaffected 
by chronological age (Figure 2.3a). This 
would imply that the senescence rate of a 
20-year-old civilian equals the senescence 
rate of an 80-year-old prisoner of war.35 
This classical interpretation runs coun-
ter to the fact that all molecular-cellular, 
physiological, and epidemiological mark-
ers of senescence rise or fall with age.41-46 
By contrast, when their senescence rates 
are measured as the increases in their 
mortality rates on an absolute scale by us-
ing the derivative function, the mortality 
rates increase more at higher ages, thus the 
senescence rates are higher at higher ages. 
This alternative conclusion is in line with 
the age-dependency of the markers of se-
nescence.
 
Partitioning of intrinsic and 
extrinsic mortality
The classical interpretation of the Gom-
pertz model’s parameter γ as a measure of 
a population’s senescence rate is based on 
the assumption that mortality is caused 
by two independent mechanisms. On one 
hand, intrinsic mortality would result from 
senescence unrelated to the environment. 
On the other hand, extrinsic mortality 
would result from environmental hazards 
unrelated to senescence. While the Gom-
pertz model’s parameter γ is thought to re-
f lect intrinsic mortality, the parameter α is 
thought to reflect extrinsic mortality.13,19,35 
This classical line of thinking is supported 
by observations of stable senescence rates 
across different environments such as de-
scribed above.
However, when the derivative function of 
the Gompertz model is used as a meas-
ure of a population’s senescence rate, the 
increase in mortality rate with age is not 
solely described by γ, but dependent on 
both parameters. In addition, according to 
the derivative function, senescence rates 
vary across different environments. This 
raises the question whether intrinsic and 
extrinsic mortality are biological or merely 
mathematical phenomena.
28
PART I • MEASURING SENESCENCE THROUGH MORTALITY
References
1. Elandt-Johnson R. C., Johnson N. L. Survival 
Models and Data Analysis. John Wiley and 
Sons, New York, NY, USA, 1980.
2. Arking R. The Biology of Aging: Obser-
vations and Principles. Oxford University 
Press, New York, NY, USA, 2006: 26-53.
3. Milne E. M. G. When does human ageing be-
gin? Mech. Ageing Dev. 2006; 127: 290-297.
4. Levitis D. A. Before senescence: the evolu-
tionary demography of ontogenesis. Proc. R. 
Soc. B Biol. Sci. 2011; 278: 801-809.
5. Levitis D. A., Martínez D. E. The two halves of 
U-shaped mortality. Front. Genet. 2013; 4: 31.
6. Salinari G., De Santis G. On the beginning of 
mortality acceleration. Demography 2015; 
52: 39-60.
7. Galliot B. Mechanisms of regeneration. Curr. 
Top. Dev. Biol. 2014; 108: 2-346.
8. Koopman J. J. E., Rozing M. P., et al. Calcu-
lating the rate of senescence from mortality 
data: an analysis of data from the ERA-EDTA 
Registry. J. Gerontol. A Biol. Sci. Med. Sci. 
2015, in press. (Chapter 4 of this thesis.)
9. Finch C. E. Longevity, Senescence, and the 
Genome. University of Chicago Press, Chica-
go, IL, USA, 1990: 14, 22.
10. Witten M. Quantifying the concepts of rate 
and acceleration/deceleration of aging. 
Growth Dev. Aging 1989; 53: 7-16.
11. Pletcher S. D. Model fitting and hypothesis 
testing for age-specific mortality data. J. 
Evol. Biol. 1999; 12: 430-439.
12. Pletcher S. D., Khazaeli A. A., Curtsinger J. W. 
Why do life spans differ? Partitioning mean 
longevity differences in terms of age-specif-
ic mortality parameters. J. Gerontol. A Biol. 
Sci. Med. Sci. 2000; 55a: 381-389.
13. Ricklefs R. E., Scheuerlein A. Biological im-
plications of the Weibull and Gompertz mod-
els of aging. J. Gerontol. A Biol. Sci. Med. Sci. 
2002; 57: 69-76.
14. Van Bodegom D., Bonneux L., et al. Dutch 
Life Expectancy from an International Per-
spective. Leyden Academy on Vitality and 
Ageing, Leiden, the Netherlands, 2010. Avail- 
able at www.leydenacademy.nl/reports/dutch 
_life_expectancy_october_2010. Data were 
derived from the Human Mortality Database 
(HMD). University of California, Berkeley, 
CA, USA and Max Planck Institute for Demo-
graphic Research, Rostock, Germany, 2013. 
Available at www.mortality.org. Accessed in 
December 2014.
15. Munch S. B., Mangel M. Evaluation of mor-
tality trajectories in evolutionary biodemog-
raphy. Proc. Natl. Acad. Sci. USA 2006; 103: 
16604-16607.
16. Harrell F. E. Parametric survival models. 
Regression Modeling Strategies. Springer, 
New York, NY, USA, 2001: 413-442.
17. Garson G. D. Parametric Survival Analysis. 
Statistical Associates Publishers, Asheboro, 
NC, USA, 2012.
18. Finch C. E. Longevity, Senescence, and the 
Genome. University of Chicago Press, Chica-
go, IL, USA, 1990: 13.
19. Olshansky S. J., Carnes B. A. Ever since Gom-
pertz. Demography 1997; 34: 1-15.
20. Gompertz B. On the nature of the function 
expressive of the law of human mortality and 
on a new mode of determining the value of 
life contingencies. Phil. Trans. R. Soc. Lond. 
1825; 115: 513-583.
21. Golubev A. How could the Gompertz-Make-
ham law evolve? J. Theor. Biol. 2009; 258: 
1-17.
22. Baudisch A. The pace and shape of ageing. 
Methods Ecol. Evol. 2011; 2: 375-382.
23. Canudas-Romo V. Three measures of longev-
ity: time trends and record values. Demogra-
phy 2010; 47: 299-312.
24. Wilmoth J. R., Horiuchi S. Rectangulari-
zation revisited: variability of age at death 
within human populations. Demography 
1999; 36: 475-495.
25. Finch C. E. Longevity, Senescence, and the 
Genome. University of Chicago Press, Chica-
go, IL, USA, 1990: 12-32.
26. Wilmoth J. R. Demography of longevity: past, 
present, and future trends. Exp. Gerontol. 
2000; 35: 1111-1129.
27. Burger O., Baudisch A., Vaupel J. W. Human 
mortality improvement in evolutionary con-
text. Proc. Natl. Acad. Sci. USA 2012; 109: 
18210-18214.
28. Finch C. E., Pike M. C., Witten M. Slow mor-
29
INTRODUCTION TO PART I • 2
tality rate accelerations during aging in some 
animals approximate that of humans. Sci-
ence 1990; 249: 902-905.
29. Economos A. C. Rate of aging, rate of dying 
and the mechanism of mortality. Arch. Ger-
ontol. Geriatr. 1982; 1: 3-27.
30. Vaupel J. W. Biodemography of human age-
ing. Nature 2010; 464: 536-542.
31. Driver C. The Gompertz function does not 
measure ageing. Biogerontology 2001; 2: 61-
65.
32. Yashin A. I., Ukraintseva S. V., Boiko S. I., 
Arbeev K. G. Individual aging and mortality 
rate: how are they related? Soc. Biol. 2002; 
49: 206-217.
33. Driver C. A further comment on why the 
Gompertz plot does not measure aging. Bio-
gerontology 2003; 4: 325-327.
34. Masoro E. J. Caloric restriction and aging: 
controversial issues. J. Gerontol. A Biol. Sci. 
Med. Sci. 2006; 61: 14-19.
35. Rozing M. P., Westendorp R. G. J. Parallel 
lines: nothing has changed? Aging Cell 2008; 
7: 924-927.
36. Bergman R. A. M. Who is old? Death rate in 
a Japanese concentration camp as a criterion 
of age. J. Gerontol. 1948; 3: 14-17.
37. Jones H. B. The relation of human health to 
age, place, and time. In: Birren J., ed. Hand-
book of Aging and the Individual: Psycho-
logical and Biological Aspects. University of 
Chicago Press, London, UK, 1959: 336-363.
38. Finch C. E. Longevity, Senescence, and the 
Genome. University of Chicago Press, Chica-
go, IL, USA, 1990: 20, 21, 665.
39. Bergman R. A. M. Who is old? Death rate in 
a Japanese concentration camp as a criterion 
of age. J. Gerontol. 1948;3:16. The original 
enumeration was shortened.
40. Greenland S., Rothman K. J. Concepts of in-
teraction. In: Rothman K. J., Greenland S., 
eds. Modern Epidemiology. Lippincott Wil-
liams and Wilkins, Philadelphia, PA, USA, 
1998: 329-342.
41. Warner H. R. Current status of efforts to 
measure and modulate the biological rate 
of aging. J. Gerontol. A Biol. Sci. Med. Sci. 
2004; 59: 692-696.
42. Crimmins E., Vasunilashorn S., Kim J. K., Al-
ley D. Biomarkers related to aging in human 
populations. Adv. Clin. Chem. 2008; 46: 161-
216.
43. Rae M. J., Butler R. N., et al. The demograph-
ic and biomedical case for late-life inter-
ventions in aging. Sci. Transl. Med. 2010; 2: 
40cm21.
44. Sprott R. L. Biomarkers of aging and disease: 
introduction and definitions. Exp. Gerontol. 
2010; 45: 2-4.
45. Niccoli T., Partridge L. Ageing as a risk factor 
for disease. Curr. Biol. 2012; 22: r741-r752.
46. López-Otín C., Blasco M. A., et al. The hall-
marks of aging. Cell 2013; 153: 1194-1217.
47. Human Mortality Database (HMD). Univer-
sity of California, Berkeley, CA, USA and Max 
Planck Institute for Demographic Research, 
Rostock, Germany, 2013. Available at www.
mortality.org. Accessed in December 2014.

31
3MEASURING SENESCENCE RATES USING THE GOMPERTZ MODEL
3
Published as:
J. J. E. Koopman, M. P. Rozing, A. Kramer, D. J. de Jager, D. Ansell,
J. M. J. De Meester, K. G. Prütz, P. Finne, J. G. Heaf, R. Palsson,
R. Kramar, K. J. Jager, F. W. Dekker, R. G. J. Westendorp.
Senescence rates in patients with end-stage renal disease:
a critical appraisal of the Gompertz model.
Aging Cell 2011; 10: 233-238

33
MEASURING SENESCENCE RATES USING THE GOMPERTZ MODEL • 3
Background • The most frequently used model to describe the exponen-
tial increase in mortality rate with age is the Gompertz model. Logarith-
mically transformed, the model conforms to a straight curve, of which the 
slope is classically interpreted as a population’s senescence rate. Earlier, 
it has been proposed that the derivative function of the Gompertz model 
is a superior measure of the senescence rate.
Methods • We tested both measures of the senescence rate in a popula-
tion of patients with end-stage renal disease derived from the ERA-EDTA 
Registry. It is clinical dogma that patients on dialysis experience accel-
erated senescence, whereas those with a functional kidney transplant 
have mortality rates comparable to the general population. We calculated 
the age-specific mortality rates for European patients on dialysis (n = 
274 221; follow-up = 594 767 person-years), for European patients with 
a functioning kidney transplant (n = 61 286; follow-up = 345 024 per-
son-years), and for the general European population.
Results • We found a higher mortality rate, but a less steep slope of the 
logarithmic mortality curve in patients on dialysis compared with both 
patients with a functioning kidney transplant and the general population 
(p < 0.001). A classical interpretation of the Gompertz model would imply 
that the senescence rate in patients on dialysis is lower than in patients 
with a functioning transplant and lower than in the general population. 
In contrast, the derivative function of the Gompertz model yielded the 
highest senescence rate for patients on dialysis, whereas the senescence 
rate was similar in patients with a functioning transplant and the general 
population.
Conclusion • We conclude that a population’s senescence rate is better 
measured by the derivative function of the Gompertz model than by the 
slope of the logarithmically transformed Gompertz model.
In 1825, Benjamin Gompertz observed that 
human mortality rates increase exponen-
tially with age.1 Since then, no other defi-
nition of senescence has gained so much 
common acceptance.2 Mathematically, the 
model is known as the Gompertz model 
and has become the most frequently used 
model of senescence.3,4 The model de-
scribes the mortality rate at a given age 
with parameters α and γ. When trans-
formed logarithmically, the model con-
forms to a straight curve. The slope of this 
straight curve represents the increase in 
mortality rate on a logarithmic scale and is 
determined by parameter γ.
The Gompertz model fits mortality data 
very firmly, but it is purely empirical. Still, 
many investigators have tried to attrib-
ute biological properties to the estimat-
ed parameters. Based on mortality data 
from animal experiments5-8 and historical 
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changes in human mortality patterns,9-11 
the slope of the logarithmically trans-
formed mortality curve has classically 
been defined as the species-specific se-
nescence rate.2,12 However, based on theo-
retical considerations, the validity of this 
slope as a measure of the senescence rate 
has been criticised.13-15 We have previously 
proposed to use the increase in mortality 
rate on an absolute scale instead, as de-
scribed by the derivative function of the 
Gompertz model.16
This work aims to empirically test both the 
classical and the newly proposed measure 
of the senescence rate in patients with end-
stage renal disease. For this, we have cal-
culated the age-specific mortality rates of a 
very large population of European patients 
with end-stage renal disease, compris-
ing both patients on dialysis and patients 
with a functioning kidney transplant, us-
ing the general European population as a 
reference. It has been widely recognised 
that patients on dialysis show accelerated 
senescence as compared with the general 
population.17-20 Patients on dialysis have 
higher mortality rates.21-23 Moreover, they 
suffer from age-related diseases with a 
higher frequency and more rapid progres-
sion, among which cardiovascular diseas-
es,22-26 the metabolic syndrome and insulin 
resistance,27,28 cognitive impairment and 
dementia,29 metabolic bone disease,30 and 
dysfunction of the immune system.31,32 
Many of these patients are classified as 
frail.33-35 Biologically, this clinically ac-
celerated senescence is attributed to dis-
turbed levels of metabolites and signalling 
molecules, such as urea, advanced glyco-
sylation end products, homocysteine, and 
endothelin.18,19,36-39 After transplantation, 
the age-related diseases in these patients 
improve and the age pattern of mortality of 
these patients converts toward the pattern 
of the general population.25,40,41 Therefore, 
these populations provide an excellent op-
portunity to assess different measures of 
the senescence rate, as a valid measure of 
senescence rate should reflect these dif-
ferences in senescence rates by attributing 
the highest senescence rate to patients on 
dialysis and a lower senescence rate to pa-
tients with a functioning kidney transplant 
and the general population.
Methods
Study population
The study population of patients with end-
stage renal disease was derived from the 
Registry of the European Renal Associa-
tion–European Dialysis and Transplant 
Association (ERA-EDTA Registry),42 which 
records European patients who receive re-
nal replacement therapy, either dialysis or 
kidney transplantation. Via national and 
regional registries, individual patient data 
were derived from Austria, the Flemish 
speaking region of Belgium, the French 
speaking region of Belgium, Denmark, 
Finland, Greece, Iceland, the Netherlands, 
Norway, Romania, Sweden, the United 
Kingdom, and from several regions in Ita-
ly and Spain. Data were gathered during a 
period beginning between 1985 and 2007, 
and ending at 1 January 2008 for four 
regions in Spain and Italy, and 1 January 
2009 for the other regions and countries. 
For each individual patient, the following 
parameters were collected at baseline: 
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country or region of origin, date of birth, 
gender, primary cause of renal failure, and 
date and modality of first renal replace-
ment therapy. Data on history of renal re-
placement therapy with dates and changes 
of modality and date were collected during 
follow-up. Primary renal diseases were 
classified according to the ERA-EDTA 
Registry’s coding system.42
Mortality rates were calculated based on 
the follow-up data contributed by each in-
dividual patient, separated for follow-up 
on dialysis treatment and follow-up with 
a functioning kidney transplant. In case 
of the dialysis group, follow-up began six 
months after initiation of dialysis treat-
ment, to account for acute treatment-re-
lated mortality,43 and lasted until death, 
transplantation, recovery of renal func-
tion, loss to follow-up, or censoring at 
1 January 2008 or 2009. In case of the 
patients with a functioning transplant, 
follow-up began six months after trans-
plantation, to account for acute surgery-re-
lated mortality,40,44 and lasted until death, 
transfer to dialysis due to transplant fail-
ure, loss to follow-up, or censoring at 1 
January 2008 or 2009. For both treatment 
groups, per 5-year age group, the number 
of deaths was divided by the years of fol-
low-up, yielding the age-specific mortality 
rates.
Reference population
Mortality data of the general European 
population were available through the 
Human Mortality Database (HMD)45 and 
Eurostat.46 For the countries in our study, 
the population and death figures were 
retrieved from the HMD for each 5-year 
age category and for the years of data 
contribution. For Greece, Romania, and 
Spain, these mortality data were down-
loaded from Eurostat, as they were not 
available in the HMD. For the calculation 
of age-specific mortality rates of the gen-
eral European population, per 5-year age 
groups and years of participation, the sum 
of all deaths was divided by the sum of all 
inhabitants of the participating countries.
Analyses
The application of the Gompertz model 
is limited to mortality data between the 
ages of approximately 20 and 80 to 90 
years.4 Moreover, after the age of 85 years, 
available mortality data were scarce. Fol-
low-up after this age comprised 15 638 
person-years (2.52%) and 8360 deaths 
(5.83%) for the patients on dialysis and 
175 person-years (0.05%) and 25 deaths 
(0.26%) for the patients with a functioning 
kidney transplant. Therefore, data on pa-
tients below the age of 20 years and from 
the age of 85 years onward were excluded 
from this study.
The Gompertz curves were characterised 
by estimating the values of the parameters 
of the Gompertz model on the age-specif-
ic mortality data as well as the statistical 
significance of the differences in the model 
parameters between the treatment groups. 
The parameters α and γ are mathemati-
cally described by the Gompertz model as 
m(t) = α eγ t, where m(t) is the mortality 
rate and t is the age in years. The calcu-
lations were performed by fitting the par-
ametric proportional hazards Gompertz 
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model47 on the individual patient data and 
by linear regression on the aggregated data 
of the general European population.
The classical senescence rates were given 
by γ, of which the values were derived by 
the aforementioned determination of the 
model parameters. In addition, according 
to the newly proposed method that we have 
described earlier,16 the derivative function 
of the Gompertz model was applied to the 
mortality rates to estimate the senescence 
rates. For that, the values of the model pa-
rameters, determined as described above, 
were incorporated in the model’s deriva-
tive function: m’(t) = α γ eγ t.
The management of the ERA-EDTA Reg-
istry database, the calculations of the 
age-group-specific mortality rates of the 
study population, and the linear regression 
analyses were carried out using PASW Sta-
tistics 17.0 (SPSS, Chicago, IL, USA). Line-
ar regression was performed by the linear 
mixed model with the natural logarithms 
of the mortality rates as dependent var-
iable, treatment group as factor, and age 
as covariate. All these calculations were 
repeated using Stata ⁄SE 10.1 (StataCorp, 
College Station, TX, USA). The fitting of 
the Gompertz model was performed using 
Stata ⁄SE 10.1.
Table 3.1 • General characteristics of the study population of patients with end-
stage renal disease






By number of patients
Total number of patients 290 510 274 221 61 286
Men, % 61.1 61.2 62.7
Age, median (iqr) years
     at first treatment 64.6 (52.0–73.3) 65.0 (52.7–73.5) 49.2 (38.3–58.6)
     at death 71.0 (62.7–77.1) 71.1 (62.8–77.1) 60.5 (51.5–68.2)
Follow-up per patient,
     median (iqr) years 1.8 (0.3–4.7) 1.3 (0.2–3.1) 4.5 (1.4–8.7)
By years of follow-up
Total years of follow-up,
     person-years (%) 942 458 594 767 (63.1) 345 024 (36.6)
Men, % 60.4 59.3 62.2
As patients could successively undergo dialysis treatment and kidney transplantation, pa-
tients can be represented in both the patient group on dialysis and the patient group with 
a functioning transplant. Iqr: interquartile range.
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Results
Table 3.1 shows the basic characteristics 
of the study population, both presented 
as the total number of patients and by the 
number of years of follow-up. As starting 
dialysis treatment or receiving kidney 
transplantation occurred more than once 
in some patients, part of the population (n 
= 58 387 or 20.1%) contributed follow-up 
to both treatment modalities. The number 
of these consecutive treatment modalities 
ranged between 1 and 11 per patient.
Figure 3.1a shows the mortality rates per 
5-year age groups for patients on dialy-
sis, for patients with a functioning kidney 
transplant, and for the general population. 
In all groups, mortality rates increased 
exponentially with age from adolescence 
onward. For each age group, the mortality 
rate of the dialysis patients was the high-
est, whereas the mortality rate of patients 
with a functioning transplant was higher 
than that of the general population. After 
transformation of the mortality rates to a 
logarithmic scale, the mortality rates of all 
three groups conformed to straight curves 
from the age of 20 years and onward (Fig-
ure 3.1b). The r2 values of these straight 
curves, indicating the fit of the Gompertz 
model, were 0.998 for patients on dial-
ysis, 0.992 for patients with a function-
ing transplant, and 0.986 for the general 
population. Again, for each age group, the 
mortality rate of the patients on dialysis 
was the highest, the mortality rate of the 
group with a functioning transplant was 
intermediate, and the mortality rate of the 
general population was the lowest.
Figure 3.1 • Age patterns of mortality 
rates of patients on dialysis, patients 
with a functioning kidney transplant, 
and the general population on a linear 
scale (A) and a logarithmic scale (B). 
Logarithmic transformation of the mortali-
ty rates yields straight curves, of which the 
slopes have classically been interpreted as 
senescence rates. For the mortality rates 
of the patients on dialysis and with a func-
tioning transplant, the estimates are given 
with 95% confidence intervals. The fol-
low-up in person-years for each treatment 
modality is shown in a table.
Age 20–39 40–59 60–79 80–84
54,801 170,078 330,071 45,107
85,643 173,004 96,474 1,133
38
PART I • MEASURING SENESCENCE THROUGH MORTALITY
The quantitative description of the age 
patterns of the mortality rates by the Gom-
pertz model’s parameters is presented in 
Table 3.2. The intercept or basal mortality 
rate α was highest in patients on dialysis, 
intermediate in patients with a function-
ing kidney transplant, and lowest in the 
general population (p < 0.001). The slope 
γ of the straight curves was lowest in the 
patients on dialysis, intermediate in the 
patients with a functioning transplant, 
and highest in the general population (p < 
0.001). The corresponding mortality rate 
doubling time was highest in the dialysis 
patients, intermediate in the patients with 
a functioning transplant, and lowest in the 
general population.
We performed various additional analy-
ses. Stratification of the mortality rates of 
patients on renal replacement therapy by 
gender, primary renal disease, and coun-
try of origin yielded similar results. Strat-
ification by calendar year, for which the 
data were divided into two periods from 
1985 through 1996, and from 1997 through 
2008, yielded similar results. Inclusion of 
only the first treatment period on dialysis 
or with a functioning transplant, did not 
affect the outcome. Furthermore, adjust-
ment for duration of follow-up for different 
treatment modalities did not substantially 
influence the results (data not shown).
Next, we estimated the increase in the 
mortality rates on an absolute scale as de-
scribed by the derivative function of the 
Gompertz model to determine the senes-
cence rates for the various groups. The de-
rivative function yielded estimates for the 
age-specific senescence rates as depicted 
in Figure 3.2. At every age, the senescence 
rate was highest in patients on dialysis as 
compared with the patients with a func-
tioning kidney transplant and the general 
population. Contrary to a fixed senescence 
rate as determined by the Gompertz mod-
el’s parameter γ, these senescence rates 
increased with age. This increase was 
greatest in patients on dialysis. Senescence 
rates estimated by the derivative function 
of the Gompertz model became similar to 
Table 3.2 • Quantitative description of the Gompertz model’s parameters




ln α -4.75 (-4.71 to -4.79) -7.71 (-7.58 to -7.83) 9.55
α × 10-2 0.86 (0.83 to 0.90) 0.04 (0.04 to 0.05) 0.01
γ × 10-2 4.29 (4.23 to 4.35) 6.70 (6.49 to 6.90) 8.50
MRDT 16.17 (15.95 to 16.40) 10.35 (10.05 to 10.68) 8.16
Estimated values of the Gompertz model’s parameters for the mortality rates of patients 
on dialysis, patients with a functioning kidney transplant, and the general population. 
The mortality rate doubling times (MRDT) are derived from γ as MRDT = ln 2 ⁄ γ and are 
given in years.48 The values of α were derived from those of ln α. The estimates are given 
with 95% confidence intervals. All estimates of the parameters were significantly different 
among the three groups and from zero (p < 0.001).
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those of the general population when the 
patients with end-stage renal disease had 
a functioning kidney transplant. These es-
timates do not preclude that age-specific 
mortality rates are higher in patients with 
a functioning transplant than in the gener-
al population for every age category.
Discussion
In this work, based on the commonly used 
Gompertz model, we have tested two meas-
ures of a population’s senescence rate us-
ing a population of patients with end-stage 
renal disease as a model of accelerated se-
nescence. The Gompertz model describes 
the mortality rate m(t) at a given age t with 
parameters α and γ as:
 m(t) = α eγ t (3.1)
The parameter α determines the mortal-
ity rate at the intercept, also referred to 
as the basal mortality rate, and is usually 
set at adolescence. The parameter γ de-
termines the rate at which the mortality 
rate increases with age.4,48 On a logarith-
mic scale, the mortality rates conform to a 
straight curve, which is described as:
 ln m(t) = ln α + γ t (3.2)
On the logarithmic scale, variation in α 
results in a parallel shift of the straight 
curve, whereas variation in γ results in a 
different slope. The slope of the curve has 
classically been regarded as an estimate of 
the senescence rate.2,12 As an alternative 
estimate of the senescence rate, we have 
proposed to use the derivative function of 
the Gompertz model,16 described as:
 m’(t) = α γ eγ t (3.3)
Using the mortality data of a unique and 
unprecedented large population of patients 
with end-stage renal disease, both the 
classical measure of the senescence rate, 
based on the slope of the straight curve 
determined by γ, and the newly proposed 
measure of the senescence rate, estimated 
by the derivative function of the Gompertz 
model, were obtained. We showed that the 
mortality rates were highest and the slope 
of the straight curve was lowest in patients 
Figure 3.2 • Age patterns of 
senescence rates of patients on 
dialysis, patients with a func-
tioning kidney transplant, and 
the general population. It is em-
phasised that, in contrast to the 
mortality rates in Figure 3.1, these 
curves depict senescence rates. 
According to the newly proposed 
method, the senescence rates were 
calculated using the derivative func-
tion of the Gompertz model. Values 
of the Gompertz model’s parame-
ters, as presented in Table 3.2, were 
incorporated into this function.
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on dialysis. In patients with a functioning 
transplant, the mortality rates and the 
slope were intermediate. In the general 
population, the mortality rates were low-
est, but the slope was highest compared 
with both patient groups. The classical 
interpretation of the parameters of the 
Gompertz model should lead to the conclu-
sion that the senescence rate in patients on 
dialysis is lower than the senescence rates 
in patients with a functioning transplant 
and the general population. Moreover, 
successful kidney transplantation lowered 
the mortality rates, but would increase the 
senescence rate. This interpretation of the 
parameter estimates is in sharp contrast 
with the clinical notion that patients on 
dialysis experience an accelerated senes-
cence, whereas after transplantation, their 
age pattern of the mortality rates shifts to-
ward the pattern of the general population.
We have presented the derivative function 
of the Gompertz model as an alternative 
measure of the senescence rate. This meas-
ure yielded senescence rates that were 
highest in patients on dialysis compared 
with patients with a functioning transplant 
and the general population. The senes-
cence rates in the patients with a function-
ing transplant and the general population 
were similar, although the mortality rates 
were higher in patients with a functional 
transplant than in the general population 
for every age category. Only at the highest 
ages, the senescence rate of patients with a 
functioning transplant slightly lagged be-
hind that of the general population, prob-
ably due to preferential selection of healthy 
patients for transplantation. In contrast to 
the classical interpretation of parameter γ 
as a measure of the senescence rate, this 
result is consistent with the higher senes-
cence rates observed in patients on dialy-
sis compared with the general population 
and with the presumed return to normal 
mortality patterns after successful kidney 
transplantation.
From literature, it is well known that α and 
γ are inversely related.10,49 Mathematical 
calculations show that this relationship be-
tween both parameters is necessary, called 
the Strehler-Mildvan correlation.50 This 
correlation is in conflict with the classical 
interpretation of the Gompertz model. Ac-
cepting γ to represent the senescence rate 
and α to represent non-senescent mortal-
ity, both parameters should not be inter-
dependent. This paradox is solved when 
using the derivative function as a measure 
for senescence rate: it relates both param-
eters to the senescence rate (Equation 3).
The interpretation of the Gompertz model 
has been subject to scrutiny of other schol-
ars.2,51,52 The critical difference between 
their analyses and ours is the logarithmic 
transformation. Until now, measures for 
the senescence rate have been relative, 
which is an immediate consequence of any 
logarithmic transformation. In contrast, 
the approach we have applied here is based 
on the non-transformed mortality rates, 
rendering a measure for the absolute se-
nescence rate, as we have proposed in our 
earlier paper.16
It has to be noted that a distinction must be 
made between the clinical senescence rate 
on individual level and the demographic 
senescence rate on the population level. 
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The Gompertz model, based on aggregat-
ed mortality data, is used to estimate the 
senescence rate on the population level. 
Whether classical or novel, its interpreta-
tion provides the demographic senescence 
rate. Unlike implied by some studies, the 
individual senescence rate cannot be di-
rectly inferred from the demographically 
determined senescence rate.50,53
While Benjamin Gompertz was the first to 
introduce a mortality model, many alter-
native models have since been proposed 
that fit human mortality rates even bet-
ter.3,54-56 The quest here is not to arrive at 
the best statistical fit of the data, but to 
obtain parameters that can be estimated 
empirically and represent biological phe-
nomena. The approach that is presented to 
estimate the senescence rate using the de-
rivative function of the Gompertz model is 
such an attempt. This model is applicable 
to any model that fits mortality patterns. 
It is solely based on the definition of senes-
cence as an increase in mortality rate with 
age and is independent of any biological 
interpretation of the model from which 
it is derived, as long as the model fits the 
mortality data. Other models may even be 
preferred over the Gompertz model, as the 
Gompertz model is limited to fit mortality 
data between adolescence and the age of 
80 to 90 years.4 Similarly, the approach 
presented here is applicable to the deter-
mination of senescence rates of non-hu-
man species, among which often used 
experimental animal models in which the 
effects of environmental factors and geno-
type could be assessed. It would, therefore, 
be worthwhile to test empirically the valid-
ity of this interpretation of the derivative 
function for alternative models and alter-
native species as well.
In conclusion, this study shows that empir-
ical testing of parameter γ of the Gompertz 
curve as a measure of a population’s senes-
cence rate failed to identify the high senes-
cence rate in patients with end-stage renal 
disease on dialysis and did not identify the 
improvement when these patients under-
went kidney transplantation. In contrast, 
the recently proposed alternative meas-
ure of the senescence rate, determined by 
the derivative function of the Gompertz 
model, estimated the highest senescence 
rates for dialysis patients, and recognised 
the improved prognosis of patients with a 
functioning kidney transplant. Thus, we 
propose to use the derivative function of 
the Gompertz model to estimate the senes-
cence rate.
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Background • A population’s senescence rate can be inferred from the 
rate at which its mortality rate increases with age. Such a senescence 
rate is generally estimated from parameters of a mathematical model fit-
ted to the age pattern of the mortality rate. However, such models have 
limitations and underlying assumptions. Notably, they do not fit mortality 
rates at low and high ages.
Methods • We developed a novel method to directly calculate senescence 
rates from the increase in mortality rate without modelling the mortality 
rates. We applied the different methods to age-group-specific mortality 
data from the ERA-EDTA Registry, including patients with end-stage renal 
disease on dialysis, who are known to suffer from increased senescence 
rates (n = 302 455), and patients with a functioning kidney transplant (n 
= 74 490).
Results • From the age of 20 to 70 years, senescence rates were compa-
rable when calculated with or without a model. However, when using non- 
modelled mortality rates, senescence rates were obtained at low and 
high ages that remained concealed when using modelled mortality rates. 
At low ages senescence rates were negative, while senescence rates de-
clined at high ages.
Conclusion • Senescence rates can be calculated directly from non-mod-
elled mortality rates, overcoming the disadvantages of an indirect esti-
mation based on modelled mortality rates.
Across populations and species, mortality 
rates exhibit different age patterns.1 Mor- 
tality rates can increase, be constant, or 
decrease with age. Demographers interpret 
increasing mortality rates at the popula-
tion level as a manifestation of senescence 
at the organismal level. Likewise, they 
interpret constant or decreasing mortali- 
ty rates as a manifestation of absent senes-
cence.2-5 Senescence is a result of manifold 
biological mechanisms that lead to an in-
creasing vulnerability to death. Although 
biologists have made strong effort at explai- 
ning and measuring senescence, the nature 
of these biological mechanisms remains 
unclear and a reliable biomarker of senes-
cence is lacking.6,7 Moreover, it is continu-
ously debated whether senescence and dis-
ease are distinct or related phenomena.4,8
The rate of mortality can be regarded as a 
speed function: it expresses the number of 
deaths per unit of time comparably with 
the speed of a car that is expressed as the 
number of driven metres per unit of time. 
It follows that an increase in mortality 
rate corresponds with an acceleration of 
mortality, while a decrease in mortality 
rate corresponds with a deceleration of 
mortality, similar to the acceleration or 
deceleration of the car.9,10 As senescence 
is represented by an increase in mortal-
ity rate with age, the rate of senescence 
can be calculated from the acceleration of 
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mortality and is expressed as the increase 
in mortality rate per year of age.9,11 As an 
advantage to both demographers and biol-
ogists, this approach requires neither any 
assumptions on the age pattern of acceler-
ations and decelerations of mortality nor 
on the biological mechanisms underlying 
the process of senescence.
In this study, we describe and test a method 
to calculate the rate of senescence directly 
from non-modelled age-specific mortali- 
ty rates. This method can be used at all 
ages and is free of biological assumptions. 
It is purely based on the definition of se-
nescence as the increase in mortality rate 
with age and calculates the rate of senes-
cence as the acceleration of mortality with 
age. We apply this method to mortality 
data of patients with end-stage renal dis-
ease who are either on dialysis therapy or 
have undergone kidney transplantation. 
Patients on dialysis therapy are biologi-
cally and clinically known to suffer from 
increased senescence rates.12-16 Mortality 
rates and senescence rates in patients with 
a functioning transplant are lower than in 




Data were provided by the Registry of the 
European Renal Association–European 
Dialysis and Transplant Association (ERA- 
EDTA Registry), which records the treat-
ment and survival history of European pa-
tients receiving renal replacement therapy, 
either dialysis or kidney transplantation.18 
Patients were included when renal replace-
ment therapy was started during a period 
from 1985 through 2011. Follow-up ended 
on 1 January 2012. Individual patient data 
were available from 1985 for Austria, the 
French-speaking region of Belgium, Fin-
land, Greece, Iceland, the Netherlands, 
Norway, and Scotland, from 1994 for the 
Flemish-speaking region of Belgium, from 
1990 for Denmark, from 2006 for Roma-
nia, from 1991 for Sweden, and from 1997 
for England, Wales, and Northern Ireland. 
In addition, individual patient data were 
available for several regions in France 
from 2008, for several regions in Italy, 
including data from 2007 for Abruzzo, 
Aosta Valley, Basilicata, Emilia-Romagna, 
Sardinia, Umbria, and Veneto, and from 
1997 for Calabria, and for several regions 
in Spain, including data from 1985 for An-
dalusia, from 2002 for Aragon, from 1995 
for Asturias, from 1992 for Basque Coun-
try, from 1985 for Catalonia, from 1994 
for Cantabria, from 2003 for Castile-La 
Mancha, from 2002 for Castile and León, 
from 2005 for Extremadura, from 2007 for 
Galicia, and from 1992 for Valencia.
 
Mortality rates were calculated based on 
the follow-up data contributed by each 
individual patient, separated for follow- 
up during dialysis and follow-up with a 
functioning transplant. For patients on 
dialysis, follow-up started six months after 
initiation of dialysis therapy, to account for 
early treatment-related mortality, and last-
ed until death, transplantation, recovery of 
renal function, loss to follow-up, or censor-
ing on 1 January 2012. For patients with a 
functioning transplant, follow-up started 
six months after transplantation, to ac-
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count for acute surgery-related mortality, 
and lasted until death, transfer to dialysis 
due to transplant failure, loss to follow-up, 
or censoring at 1 January 2012. For both 
treatment groups, the age-specific mortal-
ity rates were derived by dividing the num-
ber of deaths by the years of follow-up per 
5-year age group.
Reference population
As a reference, mortality rates were also 
calculated for the general European pop-
ulation. Numbers of deaths and popula-
tion sizes were derived from Eurostat for 
the countries and regions included in this 
study.19 For each 5-year age group, the 
number of deaths was divided by the popu-
lation size, both summed for the countries 
and regions and the years during which the 
countries and regions contributed data. As 
data were mostly available up to the age of 
100, we excluded mortality rates from that 
age onward.
Analyses
To compare the use of non-modelled morta- 
lity rates with the use of modelled mortali-
ty rates, the mortality rates were modelled 
with the Gompertz model and senescence 
rates were estimated as previously de-
scribed (Chapter 3 of this thesis).12 The 
Gompertz model is mathematically de-
scribed as m(t) = α eγ t, where m(t) is the 
mortality rate at age t in years and α and 
γ are the model’s parameters. The minimal 
mortality rate at t = 0 is determined by α, 
while the subsequent exponential increase 
in mortality rate with age is determined by 
γ. On a logarithmic scale, the model con-
forms to a straight line, which is described 
by ln m(t) = ln α + γ t. The slope of this line 
is determined by γ, describes the accelera-
tion of mortality on the logarithmic scale, 
and estimates the relative senescence rate. 
The derivative function of the Gompertz 
model describes the acceleration of mor-
tality on an absolute scale, estimates the 
absolute senescence rate, and is mathe-
matically described by m’(t) = α γ eγ t. Con- 
sidering the applicability of the model, 
mortality data were included for the ages 
of 20 to 85 years.12,20
The method proposed here calculates the 
absolute senescence rate directly from 
non-modelled mortality rates on an ab-
solute scale. The method is based on the 
mathematical definition of a derivative 
function.21 In general, for a given function 
y = f(x), the derivative function is f ’(x) = 
dy / dx, where d denotes an infinitesimal 
change in y or x. In the case of mortality 
rate m calculated for age t, the notations y 
and x are replaced: m’(t) = dm / dt. When 
we take d as small as possible, dt corre-
sponds to the difference in age between 
two age groups and dm equals the differ-
ence in mortality rate between both age 
groups. Using this method, we calculate 
the rate at which the mortality rate chang-
es, thus the acceleration of mortality, be-
tween two age groups on average. Applied, 
we calculated the senescence rate of an age 
group as the mortality rate of the following 
age group minus the mortality rate of the 
age group of interest, divided by the differ-
ence in age between both age groups, the 
latter constantly being 5 years because of 
the use of 5-year age groups.
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We excluded mortality rates from the anal-
yses when the number of person-years was 
less than 200 per 5-year age group. Pa-
tients on dialysis aged 100 years and older 
were excluded, corresponding to less than 
0.01% of follow-up and 0.01% of deaths. 
Patients with a functioning transplant aged 
90 years and older were excluded, corre-
sponding to 0.02% of follow-up and 0.05% 
of deaths. Due to the nature of this meth-
od, senescence rates could not be calcu-
lated for the highest age group. It was not 
necessary to exclude mortality data for the 
lowest age groups.
The calculations of the age-specific mor-
tality rates were performed using SPSS 
Statistics 20 (IBM, Armonk, NY, USA). The 
Gompertz model was fitted to the mortal-
ity data using Stata/SE 12.1 (StataCorp, 
College Station, TX, USA), as previously 
described.12
Results
Table 4.1 provides the general character-
istics of the study population of patients 
with end-stage renal disease on dialysis or 
with a functioning kidney transplant. As 
patients could successively undergo dialy-
sis treatment and kidney transplantation, 
some patients contributed follow-up to 
both treatment groups; this was the case 
for 59 781 patients (18.8%) and 554 809 
years of follow-up (41.5%). The maximum 
number of different treatment periods per 
patient was 13.
In Figure 4.1, the different methods to in-
fer senescence rates from mortality rates 
are compared. For comparison with the 
method proposed here, we replicated 
the estimations of senescence rates from 
mortality data that were modelled by the 
Gompertz model, as described previously 
(Chapter 3 of this thesis).12 Figures 4.1a 
and 4.1b show the modelled mortality rates 
against age on a logarithmic scale and the 
relative senescence rates estimated from 
the model’s parameters. According to this 
method, senescence rates were constant 
with age, lowest in patients on dialysis, 
intermediate in patients with a function-
ing transplant, and highest in the general 
population. Figures 4.1c and 4.1d show the 
modelled mortality rates against age on an 
absolute scale and the absolute senescence 
rates estimated from the model’s parame-
ters. According to this method, senescence 
rates increased with age, were highest in 
patients on dialysis, intermediate in pa-
tients with a functioning transplant, and 
lowest in the general population.
 
Figure 4.1e shows the crude non-modelled 
mortality rates against age on an absolute 
scale. For both patients on dialysis and 
patients with a functioning transplant, 
the exponential increase in mortality rates 
from the age of 20 to at least 70 years pro-
vided visual justification for the applica-
tion of the Gompertz model. However, in 
both groups, at lower and higher ages mor-
tality rates deviated from the exponential 
increase and the Gompertz model was not 
applicable. Before the age of 20 years, mor-
tality rates decreased with age. From the 
age of 70 to 90 years onward, the exponen-
tial increase in mortality rates levelled off. 
At all ages, mortality rates were highest in 
patients on dialysis and lowest in the gen-
eral population.
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Figure 4.1f shows the absolute senes-
cence rates as calculated directly from 
the non-modelled mortality rates by the 
method proposed here. In contrast with 
the results obtained when using modelled 
mortality rates, senescence rates could be 
calculated for all ages. From the age of 20 
to approximately 70 years, the absolute se-
nescence rates were comparable to those 
determined with the derivative function of 
the Gompertz model (Figure 4.1d). Using 
this direct calculation from non-modelled 
mortality rates, senescence rates were neg-
ative below the age of 5 years and increased 
thereafter in the general population. In 
patients with a functioning transplant, se-
nescence rates were negative below the age 
of 20 years, then increased until the age of 
75 years, after which they decreased to a 
similar level as in the general population. 
In patients on dialysis, senescence rates 
were negative below the age of 15 years and 
were more pronounced than in patients 
with a functioning transplant and the 
general population. Above this age, their 
senescence rates increased until the age of 
90 years, after which they decreased to a 
lower level than in the general population.
Table 4.1 • General characteristics of the study population of patients with end-
stage renal disease






By number of patients
Total number of patients 317 168 302 455 74 490
Men, % 61.5 61.5 62.7
Age, median (iqr) years
     at first treatment 64.1 (51.0–73.7) 65.0 (52.4–74.1) 48.6 (36.9–58.6)
     at death 72.2 (63.5–78.8) 73.1 (64.8–79.3) 63.5 (54.7–70.6)
Follow-up per patient,
     median (iqr) years 2.7 (1.1–5.6) 2.0 (0.9–3.8) 5.4 (2.3–9.8)
By years of follow-up
Total years of follow-up,
     person-years (%) 1 337 832 841 109 (62.9) 496 723 (37.1)
Men, % 60.6 59.8 62.0
As patients could successively undergo dialysis treatment and kidney transplantation, pa-
tients can be represented in both the patient group on dialysis and the patient group with 
a functioning transplant. Iqr: interquartile range.
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Discussion
The aim of this study is to describe and em-
pirically test a method for calculating the 
rate of senescence directly from non-mod-
elled mortality rates. This method strictly 
follows the definition of senescence as 
the increase in mortality rate with age.2-5 
In line with this definition, the method 
calculates the senescence rate as the ac-
celeration of mortality with age, similar 
to the calculation of a derivative function. 
We validated our method by applying it to 
mortality data of patients with end-stage 
renal disease on dialysis, who are known 
to suffer from increased senescence rates, 
and of patients with a functioning kidney 
transplant, who have senescence rates that 
approach those of the general population. 
As an immediate advantage, this method 
yielded senescence rates for low and high 
ages that remained unrevealed when using 
modelled mortality rates.
We compared the outcomes of different 
methods to determine senescence rates 
from mortality rates. Classically, mortal-
ity rates are modelled by the Gompertz 
model and subsequently presented on a 
logarithmic scale, rendering easily com-
parable straight lines of which the slopes 
are determined by a single parameter of 
the Gompertz model (Figure 4.1a). Senes-
cence rates are derived from the increase 
in these lines and are thus fixed with age 
(Figure 4.1b).2,22-24 Due to the logarithmic 
scale, this method estimates the senes-
cence rate as the relative acceleration of 
mortality with age. However, it has been 
theoretically objected that the estimation 
of the senescence rate from the relative ac-
celeration of mortality with age is false25-27 
and that the senescence rate should be 
defined instead as the absolute acceler-
ation of mortality with age (Chapter 2 of 
this thesis).11 According to this view, we 
have proposed to model mortality rates 
on an absolute scale (Figure 4.1c). Earli-
er, we have demonstrated that senescence 
rates can be adequately derived from the 
absolute acceleration of mortality with 
age, using the derivative function of the 
Gompertz model (Figure 4.1d; Chapter 3 
of this thesis).12 Contrary to the relative 
senescence rates, but in line with biolog-
ical and clinical knowledge, the absolute 
senescence rates were highest in patients 
on dialysis and lowest in the general popu-
lation. The principle of using the derivative 
function can be applied to any model of the 
age pattern of a mortality rate.
Modelled mortality data are not always 
preferably used over crude mortality data. 
The ability of mathematical models to 
describe mortality is limited to a specific 
age range. The Gompertz model does not 
fit mortality rates at the lowest and high-
est ages.20,28 This is explained by the fact 
that these models necessarily mould mor-
tality data into a prescribed pattern. The 
Gompertz model assumes mortality rates 
to increase exponentially with age.28 The 
mortality rates at the lowest and highest 
ages in patients on dialysis and patients 
with a functioning transplant deviated 
from an exponential increase with age, 
which became only apparent when assess-
ing non-modelled mortality rates (Figure 
4.1e). Models as the Gompertz model do 
not account for such deviating age patterns 
of mortality rates that may be valuable 
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PART I • MEASURING SENESCENCE THROUGH MORTALITY
to measure, as will be discussed hereaf-
ter. Moreover, these models, which are by 
themselves of only mathematical nature, 
are mistakenly interpreted biological-
ly.28-30 Apart from the Gompertz model, 
the Weibull model and the logistic model 
are often used without any of them supe-
riorly fitting age patterns of mortality. The 
choice of a model is consequently based on 
biological assumptions explaining the age 
pattern that is imposed by the model.28,31 
As we have shown previously (Chapter 3 of 
this thesis),12 such a biological meaning is 
generally attributed to the mathematical 
parameters of the Gompertz model, but 
has no empirical foundation and is biolog-
ically invalid.11,25-27 An alternative method 
has been proposed to calculate senescence 
rates from non-modelled mortality rates, 
but only on a logarithmic scale, thus ren-
dering relative senescence rates.32,33
Here we extend our earlier analyses by ap-
plying a method that circumvents the need 
to first model mortality rates for the calcu-
lation of senescence rates on an absolute 
scale (Figures 4.1e and 4.1f). From the age 
of 20 to approximately 70 years, the senes-
cence rates calculated by this method were 
similar to those estimated by the deriva-
tive function of the Gompertz model. How-
ever, this method additionally offers the 
possibility to calculate senescence rates for 
low and high ages that are unaccounted for 
by the Gompertz model.
At low ages, the method proposed here 
disclosed negative senescence rates. Se-
nescence rates were more negative in pa-
tients on dialysis than in patients with a 
functioning transplant and in the general 
population. Negative senescence rates 
at low ages have not been frequently ad-
dressed for humans, as changes in mor-
tality are mainly studied from adolescence 
onward. For several non-human species it 
has been recognised that mortality rates 
decline during life, a finding which has 
been termed negative senescence.34 At the 
beginning of human life, negative senes-
cence is universally observed as a decline 
in mortality rate caused by processes that 
are distinct from senescence. It may be the 
result of a reduction in children’s vulnera-
bility during development and growth or of 
a reduction in a population’s vulnerability 
due to the early death of the frailest chil-
dren and the selective survival of healthier 
children.35,36 In the cases of dialysis thera-
py37 and kidney transplantation,38 develop-
ment and growth are impaired in children, 
although the deficits are partly compensat-
ed at a later age. The negative senescence 
rates in both groups more likely arise 
from a sharp decline in mortality rate due 
to early death of the frailest patients and 
the selective survival of healthier patients. 
Particularly in the lowest patients, mor-
tality rates are high due to the underlying 
renal disease, congenital disorders that are 
associated with pædiatric renal disease, 
and the complications of dialysis therapy 
or transplantation.39-41 The more negative 
senescence rates in children on dialysis as 
compared with children with a function-
ing transplant and the general population 
can be explained as they display higher 
mortality rates at the lowest ages with a 
subsequent sharper decline in mortality 
and improved growth. In addition, their 
negative senescence rates may be more 
pronounced due to a stronger effect of se-
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lective survival of the less frail patients: as 
those selected for transplantation are rela-
tively healthier,40 the survival probabilities 
of children admitted to dialysis vary more 
than those of children undergoing kidney 
transplantation and in the general popula-
tion. Negative senescence early in life has 
received little attention of gerontologists, 
but interacts closely with senescence later 
in life.36 It would be interesting to include 
the age at which negative senescence rates 
turn into positive rates in studies on senes-
cence. Comparable turning points in the 
age pattern of senescence rates have been 
studied, but only at higher ages.42
At high ages, the method proposed here 
uncovered declining senescence rates that 
are not accounted for by many models. The 
phenomenon of levelling mortality rates, 
and thus declining senescence rates, at 
high ages has been described in different 
populations.2,43 Heterogeneity in survival 
patterns due to individual differences in 
frailty is thought to bring about levelling 
mortality rates.44 In selected homogene-
ous populations, mortality rates continue 
to increase exponentially up to the high-
est ages.45 The decline in senescence rates 
in patients on dialysis and patients with a 
functioning transplant can be explained by 
the selective survival to the higher ages of 
the relatively healthier patients and by the 
selection of relatively healthier patients 
to undergo these therapies at higher ages. 
That the senescence rates in patients with 
a functioning transplant declined at lower 
ages compared with patients on dialysis 
suggests that these selective processes are 
stronger in this group, probably because 
of the reluctance to perform kidney trans-
plantation in older patients. Senescence 
rates in the general population did not 
decrease, probably because heterogeneity 
effects emerge at higher ages in large pop-
ulations with low senescence rates.2,43 The 
method proposed here can be applied to 
further study declines in senescence rates 
in populations at the highest ages.
This study investigated methods that de-
termine senescence rates at the population 
level. The senescence rate of an individual 
cannot be inferred directly from the senes-
cence rate of the population to which he 
belongs.26 Still, the increased senescence 
rates in patients on dialysis can be attrib-
uted to biological and clinical mechanisms 
that have been observed and promote se-
nescence in the individual patients.8,46 In 
patients with end-stage renal disease as 
well as in older people in the general pop-
ulation, podocytes lining the epithelium of 
glomeruli show signs of damage and dys-
function, resulting in glomerulosclerosis 
and reduced glomerular filtration.47 Renal 
dysfunction causes accumulation of min-
eral and uræmic toxins, oxidative stress, 
and systemic inflammation, which are nor-
mally seen at high ages. These processes 
promote cellular senescence through DNA 
damage, mitochondrial dysfunction, and 
telomere shortening. Widespread cellular 
injury and dysfunction lead to increased 
risks and rates of atherosclerosis, cardiac 
disease, cancer, immune deficiency, cog-
nitive impairment, sarcopenia, and oste-
oporosis. These disorders, together with 
dialysis therapy itself, again induce further 
hæmodynamic and immunological distur-
bances and loss of renal function. Even-
tually, these disorders lead to increased 
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mortality rates.12-16,47-50 The method pro-
posed here can be applied to compare the 
senescence rates of different populations, 
to identify populations with increased or 
decreased senescence rates, and to evalu-
ate the effects of interventions on the se-
nescence rate.
The method presented here has several 
advantages. As it does not use modelled 
mortality rates, it can be applied to any 
mortality data, at all ages, and independ-
ent of species, geographic origin, calendar 
period, and birth cohort. As it does not 
mould the mortality rates into a prescribed 
age pattern, it closely follows the crude 
mortality data, does not discard any mor-
tality data, and is very sensitive to changes 
in the senescence rate. Particularly those 
patterns of mortality that are not predict-
ed by models may be informative about 
the process of senescence, as illustrated 
earlier for low and high ages. Finally, as 
this method is free of assumptions about 
the age pattern of mortality or the biolog-
ical determinants underlying these pat-
terns, it can only be interpreted based on 
its mathematical meaning. It measures 
the acceleration of mortality with age and 
thereby, given the definition of senescence 
as the increase in mortality rate with age, 
describes the senescence rate.
The use of non-modelled mortality data 
for the calculation of the senescence rate 
also has disadvantages. First, substan-
tial amounts of age-specific crude data 
are required to prevent high variability 
in the estimates due to measurement er-
ror. Although large cohorts were available 
in this study, the senescence curves that 
were calculated with the proposed method 
show more variability than those calculat-
ed with the Gompertz model. We excluded 
age groups with few observations; each of 
these comprised less than 25 person-years 
of follow-up. Each age group included in 
the study comprised more than 200 per-
son-years of follow-up. It is difficult to 
determine a level above which variability 
is unacceptably high. We cannot distin-
guish whether variability has arisen from 
measurement error or real age-related ef-
fects, which are both suppressed by mod-
elling. Much of the variability depends on 
the width of the age groups for which the 
mortality rates have been calculated. This 
width can be adjusted in this method to 
reduce the effect of data variability. This 
reduction in variability will probably ren-
der the senescence rates more similar to 
those calculated from modelled mortality 
data. Furthermore, this method can be 
extended with techniques to smoothen 
the senescence curves, but that again in-
troduces modelling based on statistical 
or biological assumptions. Second, the se-
nescence rate can only be determined for 
those age groups with available mortality 
data. Without a model of the age pattern 
of mortality, extrapolation to other ages is 
not possible.
In conclusion, this study shows how the 
absolute rate of senescence can be calculat-
ed directly from age-specific non-modelled 
mortality rates. The methodology is sim-
ple, sensitive to changes in mortality with 
age, free of limitations in its applicability, 
and does not require any biological inter-
pretation of mathematical models.
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Intrinsic and extrinsic mortality are often separated in order to under-
stand and measure senescence. Intrinsic mortality is assumed to be a 
result of senescence and to increase with age, whereas extrinsic mortal-
ity is assumed to be a result of environmental hazards and be constant 
with age. However, allegedly intrinsic and extrinsic mortality have an ex-
ponentially increasing age pattern in common. Theories of senescence 
assert that a combination of intrinsic and extrinsic stressors underlies 
the increasing risk of death. Epidemiological and biological data support 
that the control of intrinsic as well as extrinsic stressors can alleviate the 
senescence process. We argue that senescence and death can be better 
explained by the interaction of intrinsic and extrinsic stressors than by 
classifying mortality itself as being either intrinsic or extrinsic. Recogni-
tion of the tight interaction between intrinsic and extrinsic stressors in 
the causation of senescence leads to the recognition that senescence is 
not intractable, but malleable through the environment.
To understand and measure how senes-
cence leads to an increase in the rate of 
mortality, many clinicians and scholars 
separate intrinsic and extrinsic mortality. 
Intrinsic mortality is envisioned as the 
result of processes of physical and func-
tional degradation originating within the 
human body. As these processes arise with 
increasing age, intrinsic mortality would 
represent senescence. Extrinsic mortality 
is seen as the result of hazards from the 
environment. As the human body is ex-
posed to these hazards uniformly across 
ages, extrinsic mortality would not rep-
resent senescence and would be constant 
during life.1-3 While intrinsic and extrinsic 
mortality are often separated implicitly, 
their separation influences biomedical re-
search, clinical practice, and public health.
Different classifications of intrinsic and 
extrinsic mortality have been proposed, 
without any having received general ac-
ceptance. Meanwhile, the assumption that 
causes of death originate in either the in-
trinsic senescence process or the extrinsic 
environment has never been formally test-
ed. Here, we compare the age patterns of 
typical examples of allegedly intrinsic and 
extrinsic mortality, discuss theories of the 
intrinsic and extrinsic causes of senes-
cence, and summarise epidemiological and 
biological data on intrinsic and extrinsic 
causes of senescence. We argue that the 
partitioning between intrinsic and extrin-
sic mortality is not meaningful.
 
Intrinsic and extrinsic mortality 
have exponentially increasing age 
patterns
Figure 5.1 shows the traditional and alter-
native investigations of the age patterns of 
allegedly intrinsic and extrinsic mortality. 
As a traditional investigation, the numbers 
of intrinsic and extrinsic deaths as pro-
portions of the total number of deaths are 
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plotted against age (Figure 5.1a). The pro-
portions give the impression that intrin-
sic mortality concentrates at higher ages, 
while extrinsic mortality concentrates at 
lower ages. However, since they do not re-
f lect any differences in the total number of 
deaths, the proportions of either intrinsic 
or extrinsic deaths cannot be compared 
directly between ages. By contrast, when 
the absolute numbers of intrinsic and ex-
trinsic deaths are plotted against age, the 
numbers of either intrinsic or extrinsic 
deaths can be compared between ages and 
both intrinsic and extrinsic mortality con-
centrate at the highest ages (Figure 5.1b). 
As another traditional investigation, rates 
of intrinsic and extrinsic mortality are 
plotted against age on a logarithmic scale 
Figure 5.1 • Traditional and alternative investigations of the age patterns of al-
legedly intrinsic mortality due to senescence and extrinsic mortality due to the 
environment. Intrinsic mortality includes death due to ischæmic heart disease (ICD-10 
codes I20–I25), diabetes mellitus (E10–E14), and cancer (C00–C97). Extrinsic mortality 
includes death due to infectious diseases (A00–B99) and due to so-called external causes 
(V01–Y98), among which accidents and natural disasters. Data have been derived from 
the European Detailed Mortality Database of the World Health Organization for 31 Europe-
an countries and Israel in 2009 or 2010.43 In panels B and D, allegedly intrinsic mortality is 
plotted on the left axis and allegedly extrinsic mortality on the right axis.
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(Figure 5.1c). The logarithmic rates give 
the impression that intrinsic mortality in-
creases continuously, while extrinsic mor-
tality is almost constant with age. Howev-
er, on a logarithmic scale, multiplicative 
changes are revealed while absolute 
changes are concealed. We have previously 
illustrated that interpretations of multi-
plicative changes in mortality rates with 
age do not necessarily apply to the absolute 
changes in the same mortality rates (Chap-
ter 2 of this thesis).4 Plotting allegedly in-
trinsic and extrinsic mortality on an abso-
lute scale reveals an exponential increase 
with age for both (Figure 5.1d). Whereas 
the traditional investigations seem to sup-
port a distinction between the age patterns 
of intrinsic and extrinsic mortality, the 
alternative investigations reveal that both 
intrinsic and extrinsic mortality have ex-
ponentially increasing age patterns.
In Figure 5.2, the age patterns of mortal-
ity rates are shown on an absolute scale 
for typical examples of allegedly intrinsic 
and extrinsic causes of death.1,2 Minor dif-
ferences between the age patterns can be 
observed. Mortality rates due to cancer 
start increasing at earlier ages. Mortality 
rates due to accidents are slightly elevated 
throughout adulthood. Mortality rates due 
to natural disasters are elevated from the 
age of 50 to 60 years and decrease slightly 
from the age of 60 to 75 years. However, 
the rates of intrinsic and extrinsic mortal-
ity share the common feature of an expo-
nential increase with the highest values at 
the highest ages.
The age patterns of incidence rates for 
the same typical examples of allegedly in-
trinsic and extrinsic disorders can also be 
compared. Although minor differences can 
be observed, the incidence rates of intrin-
sic and extrinsic disorders share the com-
mon feature of an exponential increase to a 
maximum at the highest ages, as shown in 
Figure 5.3.
 
Intrinsic and extrinsic stressors 
interact in the causation of 
senescence
The human body is exposed to intrinsic 
stressors originating within and extrin-
sic stressors originating outside the body. 
During life, the repetitive exposure to 
these stressors leads to an accumulation 
of permanent damage, which leads to dys-
function, disease, and ultimately death.5 
The various damages that have been ac-
quired up to a certain age increase the 
body’s vulnerability to be damaged by 
intrinsic and extrinsic stressors at sub-
sequent ages. As senescence amounts to 
the increasing risks of disease and death, 
senescence is a consequence of the ac-
cumulation of damages from intrinsic as 
well as extrinsic sources.5,6 For example, 
senescence is partly attributed to damage 
to the DNA, which is induced by intrinsic 
stressors such as spontaneous chemical 
reactions, replication errors, and meta-
bolic waste products, but also by extrinsic 
stressors such as radiation and viruses. 
Damage impairs the DNA’s repair function, 
decreases its resistance to further damage 
caused by intrinsic and extrinsic stress-
ors, and increases the risks of disease and 
death.7
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Figure 5.2 • Age patterns of mortality rates for typical examples of allegedly in-
trinsic mortality due to senescence and extrinsic mortality due to the environ-
ment. As typical examples of intrinsic mortality, death due to ischæmic heart disease 
(ICD-10 codes I20–I25), diabetes mellitus (E10–E14), and cancer (C00–C97) have been 
included. As typical examples of extrinsic mortality, death due to infectious diseases 
(A00–B99), accidents such as transport accidents, falls, drowning, and exposure to me-
chanical forces (V01–X29), and natural disasters such as excessive heat or cold, lightning, 
earthquakes, storms, and floods (X30–X39) have been included. Data have been derived 
from the European Detailed Mortality Database of the World Health Organization for 31 
European countries and Israel in 2009 or 2010.43 Mortality rates are given as numbers of 
deaths per 1000 person-years (py) with 95% confidence intervals.
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Figure 5.3 • Age patterns of incidence rates for typical examples of allegedly in-
trinsic disorders due to senescence and extrinsic disorders due to the environ-
ment. As typical examples of intrinsic disorders, ischæmic heart disease (ICD-10 codes 
I20–I25), diabetes mellitus (E10–E14), and cancer (C00–C97) have been included. As typ-
ical examples of extrinsic disorders, infectious diseases (A00–B99) and disorders due to 
accidents such as transport accidents, falls, drowning, and exposure to mechanical forces 
(V01–X29) and due to natural disasters such as excessive heat or cold, lightning, earth-
quakes, storms, and floods (X30–X39) have been included. Data have been derived from 
the European Hospital Morbidity Database of the World Health Organization for 26 Europe-
an countries and Israel in 2008, 2009, or 2010.44 Incidence rates are given as numbers of 
hospital discharges per 1000 person-years (py) with 95% confidence intervals.
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Other processes than damage accumula-
tion are identified as the cause of senes-
cence by alternative theories. Notably, 
senescence is attributed to a continuation 
and hyperfunction of processes that fa-
cilitate development early in life.8 These 
developmental processes originate within 
the body and may be regarded as intrinsic 
stressors, but are inextricably linked with 
the body’s environment. The developmen-
tal processes are, as early as their intrau-
terine onset, modulated by environmen-
tal conditions such as nutrition.9,10 Later 
in life, the overgrowth of developmental 
processes only causes senescence in com-
bination with stressors from the environ-
ment. For example, cellular senescence is 
explained by excessive cell growth induced 
by developmental growth factors, which 
depend on environmental signals such as 
nutrient levels. The cell growth only leads 
to cellular senescence when the cell cycle 
has been arrested by intrinsic stressors 
such as oxidative stress and oncogenes or 
by extrinsic stressors such as chemical tox-
ins and radiation.8
Traditional biological theories explain the 
evolution of senescence by separating in- 
trinsic and extrinsic mortality. They pro-
pose that extrinsic mortality due to the en- 
vironment constrains survival up to high 
ages, as a result of which selective pressure 
declines with increasing age. The decline 
in selective pressure facilitates the occur- 
rence of senescence, which appears as in-
trinsic mortality.11,12 However, empirical 
studies have failed to consistently confirm 
a relationship between the level of extrin- 
sic mortality and the process of senes-
cence.3,12 It has been theoretically demon-
strated that the level of extrinsic mortality 
cannot explain the evolution of senescence, 
unless extrinsic stressors are acknowl-
edged to interact with and to be modulated 
by the body’s vulnerability that declines 
with age.13,14
It is a fundamental theorem in biology that 
every phenomenon is explained by the in-
teraction of genes and environments. From 
this point of view, it is a misconception to 
equate genes with causal factors within 
the body and the environment with those 
outside it.10 Rather, the effects of genes are 
modulated by the environment and vice 
versa.15 Disease and death are not either 
genetic or environmental, but of mixed ge-
netic and environmental origin.16 Yet, little 
attention is given to gene-environment 
interaction in the context of senescence.10 
The intrinsic and extrinsic stressors to 
which the human body is exposed can be 
regarded as genetic and environmental 
stressors that interact to exert detrimen-
tal effects. These effects again interact 
with the body’s genetic susceptibility and 
increase its vulnerability to further detri-
mental effects, ending in senescence and 
death. Since senescence and death are the 
outcomes of both genes and the environ-
ment, they cannot be partitioned as either 
intrinsic or extrinsic. This is ref lected by 
the exponential increasing age patterns 
that allegedly intrinsic and extrinsic mor-
tality have in common.
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Intrinsic and extrinsic stressors 
interact in epidemiological and 
biological studies on senescence
Epidemiological and biological data sup-
port that senescence is a result of the in-
teraction between intrinsic and extrinsic 
stressors. Cardiovascular disease, diabetes 
mellitus, and cancer are typically regarded 
as determined by intrinsic senescence, but 
are meanwhile largely attributable to haz-
ards that originate in the environment, in-
cluding tobacco and alcohol use, sunlight, 
pollution, an excessive dietary composi-
tion, and a minimal necessity of physical 
activity.17 These environmental hazards 
affect the structure and functioning of the 
genome and are required for the develop-
ment of disease.6,7 Even the accelerated bo- 
dily deterioration caused by well-defined 
genetic substrates as in Huntington’s and 
Duchenne’s diseases is influenced by the 
environment.18,19 As a consequence, envi-
ronmental interventions can prevent or 
postpone cardiovascular disease, diabetes 
mellitus, and cancer.20-22
Infectious diseases, accidents, and natu-
ral disasters require environmental risk 
factors, but cannot be uncoupled from the 
body’s vulnerability that increases with 
age. Senescence of the immune system 
increases the risk of infectious diseases.23 
The immune system is influenced by mi-
croorganisms and other environmental 
factors, like smoking, sunlight, and die-
tary components and meanwhile plays an 
essential role in the pathogenesis of car-
diovascular disease and cancer.6,24 Com-
mensal and infectious microorganisms can 
induce or prevent diseases attributed to se-
nescence, including autoimmune disease, 
cardiovascular disease, neuropsychiatric 
disease, and cancer.24 Even the risk of be-
ing affected by seemingly fully stochastic 
hazards is age-dependent. Sensory, cogni-
tive, and executive dysfunctions, disabil-
ity, and multimorbidity that accumulate 
with age predispose to burns, chokes, falls, 
traffic accidents, and other environmental 
hazards.25-27
That the senescence process depends on 
both intrinsic and extrinsic stressors be-
comes apparent when populations across 
different environments are compared. For 
example, both western populations and 
populations exposed to endemic infec-
tions, malnutrition, and physical labour 
share similar declines in muscle strength 
and heart rate variability with age (Chap-
ters 8 and 11 of this thesis).28,29 This indi-
cates that the senescence process contains 
components that are independent of the 
environment. On the other hand, while 
senescence in western populations is ac-
companied by a predominance of allegedly 
intrinsic disorders like cardiovascular dis-
ease and diabetes mellitus, these disorders 
are uncommon up to the highest ages in 
the populations exposed to endemic infec-
tions, malnutrition, and physical labour 
(Chapters 9 and 10 of this thesis).30,31 This 
indicates that the senescence process is 
shaped by the environment.
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Relevance to biomedical research, 
clinical practice, and public health
Senescence is commonly defined to en-
compass deleterious, progressive, and in-
trinsic age-related changes that culminate 
in death. The intrinsic nature of senes-
cence is understood as being independent 
of modifiable environmental factors.32 This 
traditional definition is rooted in a sepa-
ration of intrinsic mortality due to senes-
cence and extrinsic mortality due to the 
environment, neglects the tight interaction 
between intrinsic and extrinsic stressors 
as causes of senescence, but influences 
biomedical research, clinical practice, and 
public health.
Firstly in biomedical research, intrin-
sic and extrinsic mortality are separated 
when measuring the senescence process. 
Mathematical models are used in such a 
manner that distinct parameters account 
for intrinsic and extrinsic mortality.3,33 For 
example, one parameter of the Gompertz 
model describes the minimal risk of dying 
during adolescence and is used as a meas-
ure of extrinsic mortality. Another param-
eter describes the increase in mortality 
rate over subsequent ages, which is linear 
when plotted on a logarithmic scale, as 
shown in Figure 5.1c. The single parameter 
that determines this linear increase is used 
as a measure of intrinsic mortality. Mod-
els like the Gompertz model are applied to 
interpret the effects of experimental inter-
ventions as affecting either the intrinsic 
rate of senescence or the extrinsic age-in-
dependent risk of dying. A change in the 
minimal risk of dying is interpreted as a 
change in the environmental risk of dying, 
while a change in the linear increase of the 
logarithmic mortality rate is interpreted 
as a change in the rate of senescence.34,35 
We have previously criticised such a bio-
logical interpretation of the mathemati-
cal parameters.4 We have argued that the 
rate of senescence should be measured by 
the increase in mortality rate with age on 
an absolute scale, as shown in Figure 5.1d 
(Chapter 3 of this thesis).36 The absolute 
increase in mortality rate is determined 
by both parameters of the Gompertz mod-
el. This illustrates that allegedly intrinsic 
and extrinsic mortality should not be par-
titioned to correctly measure the rate of 
senescence, which is essential for research 
on senescence.
 
Others have argued similarly that studies 
on the relationship between environmen-
tal hazards and senescence are handi-
capped as models and experiments do not 
take into account the interaction between 
the environmental hazards and the body’s 
increasing vulnerability with age. This in-
teraction is essential to understand how 
the environment has facilitated the evolu-
tion of senescence and how environmental 
factors continue to shape the senescence 
process.12,14 The comparison of populations 
across different environments is essential 
for unravelling the intrinsic and extrinsic 
components of the senescence process. 
Here, we focus on the senescence process 
in western human populations. Our ar-
gumentation can be further investigated 
by comparing human populations living 
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across different environments and by rear-
ing animal models in different environ-
ments. Such research on the interaction 
between the environment and senescence 
will be valuable and may yield results that 
are different from those of traditional in-
vestigations.12,36
Secondly in clinical reasoning, disease and 
death are classified as intrinsic or extrin-
sic in an attempt to better understand and 
target the senescence process. Disorders 
such as cardiovascular disease, diabetes 
mellitus, and cancer are considered as de-
generative disorders that progress intrin-
sically with increasing age. Curative and 
preventive endeavours focus on the senes-
cence process, but the role of environmen-
tal factors in their causation is underesti-
mated.37,38 Conversely, disorders such as 
infectious diseases, accidents, and natural 
disasters are considered as environmental, 
but the effect of age on the risks of these 
disorders is underestimated. Alternatively, 
senescence and death are not explained by 
a single cause, but by intrinsic and extrin-
sic stressors that congregate with age and 
each constitute partial causes.16 Strategies 
to combat senescence and death need to 
take into account their different intrinsic 
and extrinsic causes to be successful, as 
has been recently pled for infectious dis-
eases.39
Underlying pathogenic processes are sort-
ed similarly. In dermatology, for example, 
the deteriorating synthesis of intersti-
tial proteins is attributed to intrinsic se-
nescence, while sun-induced damage is 
thought to constitute extrinsic environ-
mental damage.40 However, also molecu-
lar and cellular phenomena of senescence 
and environmental damage are extensively 
interconnected.6 The damage in the skin 
that is accrued with increasing age is due 
to both the deteriorating protein synthesis 
and sunshine.
Thirdly in public health, the distinction 
between intrinsic and extrinsic mortality 
is misleading when designing preventive 
strategies against senescence and environ-
mental hazards. Above, we have described 
that disorders attributed to senescence can 
be prevented by environmental interven-
tions and that the old are most vulnerable 
to be struck by environmental hazards. 
Consequently, prevention of mortality due 
to cardiovascular disease, diabetes melli-
tus, and cancer should not only be sought 
in a delay of the senescence process, but 
may be more readily attained by confin-
ing the exposure to their environmental 
risk factors. Prevention of mortality due 
to infectious diseases, accidents, and nat-
ural disasters should particularly aim at 
protecting the frail elderly. Hygienic pre-
cautions and vaccination against conta-
gions are essential, participation in traffic 
requires safety measures that compensate 
for disabilities, and the old skin should 
be protected as it is easily bruised or sun-
burnt. Especially lifestyle interventions 
seem effective, such as limiting sun expo-
sure to delay senescence of the skin.
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Conclusion
When intrinsic mortality due to senes-
cence and extrinsic mortality due to the 
environment are separated, senescence is 
accepted as an intractable side effect of in-
creasing age while environmental hazards 
are taken as bad luck. In contrast, when in-
trinsic and extrinsic stressors are acknowl-
edged to interact tightly in the causation 
of senescence, disease, and death, new 
perspectives arise with both a bad and a 
good outlook. The bad news is: all mor-
tality is related to senescence. The risk 
of allegedly extrinsic mortality increases 
exponentially with age just like allegedly 
intrinsic mortality, because they are both 
attributable to degeneration of the human 
body’s structures and functions. The good 
news is: all mortality is related to the en-
vironment. The risk of allegedly intrinsic 
mortality increases with age, but is just 
as well dependent on environmental haz-
ards. A proper understanding of the tight 
interaction between intrinsic and extrinsic 
stressors recognises that senescence is not 
intractable, but malleable through the en-
vironment. Knowledge on this interaction 
leads the way to identify environmental 
stressors that cause senescence and can 
be targeted to prevent senescence.41,42 To 
reach this goal, intrinsic and extrinsic 
mortality should be reunited in mathemat-
ical models when measuring senescence, 
in clinical reasoning when explaining se-
nescence, and in public health when allo-
cating prevention and intervention.
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Tά τε γὰρ ὑπερβάλλοντα γυμνάσια ϰαὶ τὰ ἐλλείποντα φϑείρει τὴν ἰσχύν, 
ὁμοίως δὲ ϰαὶ τὰ ποτὰ ϰαὶ τὰ σιτία πλείω ϰαὶ ἐλάττω γινόμενα φϑείρει τὴν 
ὑγίειαν, τὰ δὲ σύμμετρα ϰαὶ ποιεῖ ϰαὶ αὔξει ϰαὶ σῴζει.
Both the exceeding and the shortcoming exercises ruin the strength,
and likewise the drinks and the foods that become too much and too little
ruin the health, while those that are moderate
produce and increase and preserve them.
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Senescence from a 
global perspective
As a result of senescence, the risks of 
dysfunction and disease in human popu-
lations increase with chronological age. 
With vast amounts of empirical data and 
theoretical knowledge, the senescence pro-
cess has been characterised extensively in 
western populations. Here, senescence is 
well known to be predominantly marked 
by cardiovascular disease, diabetes melli-
tus, and cancer.1-3
By contrast, as illustrated in Figure 6.1, 
very little research is performed on senes-
cence in non-western populations, such as 
in Africa.4-9 The course of senescence and 
its relation with disease in these popu-
lations remains obscure. Meanwhile, the 
study of senescence in these populations is 
valuable for both western and non-western 
populations. It can unveil new causes of se-
nescence-related diseases, facilitate the in-
vestigation of their possible causes that are 
rare or ubiquitous in western populations, 
enable the unravelling of the link between 
infectious diseases and senescence-related 
diseases, and support the design of local 
research agendas and public health poli-
cies to combat these diseases.4-6,8
Figure 6.1 • Research 
is almost exclusively 
performed in west-
ern populations. On 
map A, each country 
is displayed according 
to its actual size. On 
map B, each country 
is drawn such that its 
size reflects the num-
ber of scientific arti-
cles published in 2001 
by authors resident in 
that country relative 
to the size of its total 
population. The maps 
were obtained from 
Worldmapper and ad-
justed by B.W. Florijn. 
Copyright of the Sasi 
Group at the Univer-
sity of Sheffield and 
Mark Newman at the 
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Senescence from an 
environmental perspective
Next to age, lifestyle is the most important 
risk factor of the diseases that are related 
to senescence in western populations.11-15 A 
western lifestyle is aff luent and sedentary. 
Industrialisation, technological innova-
tion, urbanisation, and economic growth 
have allowed foods to become abundantly 
available and enriched with energy and 
at the same time have greatly reduced the 
need for exercise in daily life.16-19 It has 
been established that a western lifestyle 
interferes with the body’s physiology, for 
example by causing inflammation, and 
that it leads to obesity, dyslipidæmia, hy-
pertension, cardiovascular disease, diabe-
tes mellitus, and cancer.12,20
Where the aforementioned advancements 
have not yet taken place, food supply de-
pends on the harvest and climate, hunger 
is frequent, and physical exertion is indis-
pensable for subsistence. To know how the 
inhabitants of such regions senesce means 
to know whether the diseases that are re-
lated to senescence in western countries 
arise largely independent of a western life-
style or rather as its consequences.
Improvements in hygiene and public health 
have restrained infectious diseases in 
western populations, whereas in non-west-
ern populations infectious diseases are the 
main cause of disease and death. In those 
regions where a western lifestyle is cur-
rently emerging, it coexists with local tra-
ditional non-western lifestyles. As a con- 
sequence, an expansion of obesity, cardio- 
vascular disease, and diabetes mellitus is 
accompanied by the persistence of malnu-
trition and infectious diseases. This is re-
ferred to as the double burden of disease. 
While infections induce inflammation, the 
diseases that are related to senescence in 
western populations also have an inflam-
matory nature. It is postulated, therefore, 
that frequent exposure to infections ex-
cites these diseases,21-24 but, unfortunately, 
studies on this postulation have seldom 
been conducted in populations without a 
western lifestyle.
Senescence from an 
evolutionary perspective
The history of modern human populations 
dates back to about 250 000 years ago and 
those of their hominin predecessors mil-
lions of years more. During most of human 
history, survival was severely comprised 
by malnutrition and infectious diseases. 
Only since a few decades and only in wes-
tern populations, these threats have been 
largely overcome. These harsh environ-
mental demands have exerted strong selec-
tive pressures through many generations. 
These pressures have promoted qualities 
that matched the environment, in par-
ticular thrifty and proinflammatory qual-
ities.25,26 Thriftiness refers to the metabolic 
efficiency to ingest, process, and store 
nutrients. An immune system is proin-
flammatory when it aggressively fights 
pathogens and other potentially injurious 
agents.
The thrifty and proinflammatory qualities 
that have been promoted during human 
evolution are in mismatch with the envi-
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ronment in modern western populations. 
When food is abundant, physical activity is 
needless, and infectious diseases are un-
common, thriftiness and inflammation lead 
to obesity, dyslipidæmia, hypertension, car- 
diovascular disease, diabetes mellitus, and 
cancer. From this point of view, the diseas- 
es that arise during senescence in western 
populations are, at least partly, attributa- 
ble to conflicts between out-dated genes in 
a brand-new environment.16,20,22,25-27
In non-western populations where the 
present environment resembles the harsh 
environments in which humans have 
evolved, the selective pressures in the past 
environments match more closely with 
those in the present environments. The 
thrifty and proinflammatory qualities that 
have long been promoted are still needed 
for survival in these populations. If the 
diseases related to senescence in western 
populations are attributed to a mismatch 
between genes and the environment, it is 
expected that these diseases arise less fre-
quently during senescence in non-western 
populations. However, it has only infre-
quently been studied whether the thrifty 
and proinflammatory qualities cause dis-
eases during senescence in non-western as 
in western populations.
Measuring senescence through 
morbidity in a traditional African 
population
With an eye to the three preceding per-
spectives, we have studied senescence in a 
traditional rural African population with-
out a western lifestyle in one of the least 
developed regions of Ghana. Previously, 
this population has been characterised 
extensively with regard to its age patterns 
of mortality and fertility, its lifestyle and 
culture, the presence of infectious diseas-
es, and the genetic and physiological deter-
minants of inflammation.28-34
An impression of the lifestyle, culture, and 
environment of the Ghanaian study popu-
lation is given by the pictures on the fol-
lowing pages.
In this population, we have measured se-
nescence through morbidity, focussing on 
handgrip strength and cardiovascular dis-
ease. Loss of handgrip strength is a widely 
used measure of senescence.35-39 Cardio-
vascular disease is the most prevalent dis-
ease related to senescence in western pop-
ulations.40-42 As described in more detail in 
the following chapters, we have assessed 
the age patterns of handgrip strength and 
various cardiovascular disease, the pres-
ence of their determinants, and their rela-
tions to mortality in older inhabitants.
By studying senescence in this traditional 
African population without a western life-
style, we aim to clarify whether the diseas-
es related to senescence in western popu-
lations arise largely independent of such a 
lifestyle, as is suggested when senescence 
is regarded as a process intrinsic to the 
human body, or are rather consequences of 
such a lifestyle. If a decrease in handgrip 
strength and an increase in cardiovascular 
disease are observed in this population 
similarly to western populations, a western 
lifestyle is not a prerequisite for their oc-
currence during senescence, inflammation 
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due to infections may be an alternative 
cause, and a mismatch between genes and 
the western environment does not satisfy 
as an evolutionary explanation of the se-
nescence process. If a decrease in handgrip 
strength and an increase in cardiovascular 
disease are absent in this population as 
opposed to western populations, a western 
lifestyle is a prerequisite for their occur-
rence during senescence, inflammation 
due to infections cannot by itself be a suffi-
cient cause, and a mismatch between genes 
and the western environment is reinforced 
as an evolutionary explanation of the se-
nescence process.
Figure 6.2 • Signboard at the office in the Ghanaian research area. By courtesy of 
A.D. Pieterse. Reproduced with permission.
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Figure 6.4 • Clothes and grains being dried in a courtyard in the Ghanaian re-
search area. By courtesy of H. Sanchez-Faddeev. Reproduced with permission.
Figure 6.3 • A typical compound household in the Ghanaian research area. By cour- 
tesy of D. van Bodegom. Reproduced with permission.
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Figure 6.5 • Transportation across a river in the Ghanaian research area. By cour-
tesy of D. van Bodegom. Reproduced with permission.
Figure 6.6 • A borehole well in the Ghanaian research area. By courtesy of L. May. 
Reproduced with permission.
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Figure 6.7 • Milling of grain in the Ghanaian research area. By courtesy of D. van Bode- 
gom. Reproduced with permission.
Figure 6.8 • A household’s kitchen and, in the background, a field of grain in the 
Ghanaian research area. By courtesy of T. Menger. Reproduced with permission.
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Figure 6.10 • A herd of cattle being grazed in the Ghanaian research area. By cour- 
tesy of L. May. Reproduced with permission.
Figure 6.9 • A herd of cattle being led through the town of Garu near the Ghana-
ian research area. By courtesy of A.D. Pieterse. Reproduced with permission.
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Figure 6.11 • A market in the Ghanaian research area. By courtesy of D. van Bode-
gom. Reproduced with permission.
Figure 6.12 • Different foods sold at a market in the Ghanaian research area. By 
courtesy of H. Sanchez-Faddeev. Reproduced with permission.
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Figure 6.13 • Children washing in a tropical rain shower in the Ghanaian research 
area. By courtesy of T. Egberts. Reproduced with permission.
95
INTRODUCTION TO PART II • 6
Figure 6.15 • A health care clinic in the Ghanaian research area. By courtesy of T. 
Egberts. Reproduced with permission.
Figure 6.14 • A brewery of pito beer in the Ghanaian research area. By courtesy of 
T. Egberts. Reproduced with permission.
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Background • It has recently been shown that the capacity of the innate 
immune system to produce cytokines relates to skeletal muscle mass 
and muscle strength in older persons. The interleukin-10 (IL10) gene 
regulates the production capacities of IL10 and tumour necrosis factor α 
(TNFα). In rural Ghana, IL10 gene variants associated with different pro-
duction capacities of IL10 and TNFα are enriched compared with Euro-
pean populations. In this setting, we explored the association between 
these gene variants and muscle strength.
Methods • Among 554 Ghanaians aged 50 years and older, we deter-
mined 20 single nucleotide polymorphisms (SNPs) in the IL10 gene, pro-
duction capacities of IL10 and TNFα in whole blood upon stimulation with 
lipopolysaccharide (LPS), and handgrip strength as a proxy for skeletal 
muscle strength. We distinguished proinflammatory haplotypes associat-
ed with low IL10 production capacity and anti-inflammatory haplotypes 
with high IL10 production capacity.
Results • We found that distinct haplotypes of the IL10 gene associated with 
handgrip strength. A proinflammatory haplotype with a population frequen- 
cy of 43.2% was associated with higher handgrip strength (p = 0.015). 
An anti-inflammatory haplotype with a population frequency of 7.9% was 
associated with lower handgrip strength (p = 0.006).
Conclusion • In conclusion, variants of the IL10 gene contributing to a pro- 
inflammatory cytokine response associate with higher muscle strength, 
whereas those contributing to an anti-inflammatory response associate 
with lower muscle strength. Future research needs to elucidate whether 
these effects of variation in the IL10 gene are exerted directly through 
its role in the repair of muscle tissue or indirectly through its role in the 
defence against infectious diseases.
Interleukin-10 (IL10) is an anti-inflam-
matory cytokine with important regula-
tory effects on inflammatory responses. 
It downregulates the antigen presenting 
function and inhibits the production of 
proinflammatory cytokines like tumour 
necrosis factor α (TNFα) by various im-
mune cells.1 In mice, immune cells produc-
ing cytokines are crucial for the repair of 
skeletal muscle tissue.2-5 We have recently 
shown that a higher TNFα production ca-
pacity of immune cells is positively related 
to muscle mass and muscle strength in a 
middle-aged Dutch population.6
The capacity to produce IL10 and TNFα 
upon whole-blood stimulation with li-
popolysaccharide (LPS) varies between 
individuals. This variation is for more 
than 50% attributable to genetic determi-
nants.7-9 The IL10 gene is highly polymor-
phic10-12 and its haplotypes are transcribed 
differently.13 This interindividual variation 
is extended by variation in the IL10 hap-
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lotype structure and distribution between 
ethnicities.10,14 We have earlier reported 
that specific IL10 gene variants are en-
riched in Ghanaian elderly living under 
adverse conditions.12 These variants have 
functional significance: some are related 
to a proinflammatory cytokine production 
capacity, with lower IL10 and higher TNFα 
levels upon whole-blood stimulation with 
LPS, while others are related to an inverse 
anti-inflammatory response.12,15,16 Inter-
estingly, this IL10 haplotype structure is 
less present in European populations liv-
ing under aff luent conditions,12,14 possibly 
because balanced selection has conserved 
this haplotype structure in populations 
under adverse conditions. The function-
al variation in the genetic determinants 
of cytokine production capacity forms a 
meaningful instrument to study the effects 
of different cytokine production capacities 
largely free from confounding and reverse 
causality.17
For this study, we had the unique oppor-
tunity to study handgrip strength of in-
dividuals aged 50 years and older in the 
Ghanaian population of which we have 
characterised the IL10 gene variants and 
their effects on cytokine production ca-
pacity.12,15,16 This study aims to investigate 
the relation between the pro- and anti- 
inflammatory IL10 gene variants, which 
are not present in European populations, 
and handgrip strength as a proxy of over-
all muscle strength. To account for the 
possible effects of ill health on handgrip 
strength, the analyses were also performed 




This study was performed in a remote, 
rural, and underdeveloped area in the Up-
per East Region in Ghana in West Africa. 
The vast majority of the inhabitants are 
involved in non-commercial agriculture 
performed by manual labour. Infectious 
diseases are the main causes of death.18 
The prevalence of human immunodeficien-
cy virus (HIV) is low (< 4%) compared with 
other sub-Saharan regions.18 Since 2002, 
we have followed a horticultural popula-
tion in the Garu-Tempane District in the 
Upper East Region, comprising approxi-
mately 25 000 inhabitants living in 32 vil-
lages. For each household, we determined 
the household property value and the soci-
oeconomic status in 2007 according to the 
Demographic and Health Survey method.19 
Elaborate descriptions of the research pop-
ulation have been given elsewhere.12,19-21
Ethical approval was given by the Ethi-
cal Review Committee of Ghana Health 
Services, the Committee Medical Ethics 
of Leiden University Medical Center, and 
by the local chiefs and elders. Because of 
illiteracy, informed consent was obtained 
orally from the participants in the local 
language. A consent form was read out to 
each participant with an explanation on 
the purpose and conduction of this re-
search project.
DNA collection and genotyping
We collected buccal swabs between 2002 
and 2006 of 4336 individuals.12 Common 
genetic variation (minor allele frequency 
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≥ 5%) in the IL10 gene region was deter-
mined by genotyping 20 SNPs, selected 
from the Yoruba population in the Hap- 
Map database (release #21, r2 = 0.8) and 
genotyped using mass spectrometry (Se-
qeunom, San Diego, CA, USA). All SNPs 
were in Hardy-Weinberg equilibrium, with 
one exception where a minor deviation 
was observed.12 We have recently reported 
that population stratification is unlike-
ly to influence associations with genetic 
variation in autosomal genes, as analysis 
of autosomal DNA, mtDNA and y-chro-
mosomal genetic variation patterns in the 
research area revealed that women-me-
diated gene f low is nearly fully random, 
whereas men-mediated gene f low is highly 
reduced.22 This genetic substructure is an 
immediate result of the patrilocal society. 
We addressed residual population strati-
fication by adjusting all analyses for tribe. 
Familial relatedness among individuals 
was addressed by adjusting all analyses for 
household.
Handgrip strength and BMI
Handgrip strength and body mass index 
(BMI) were measured in 2009 and 2010 
in 923 individuals aged 50 years and old-
er, recruited independently from the ge-
netic samples. Data on the IL10 gene were 
available for 554 of them. We consecutively 
visited all villages in the research area, 
in which we set up a mobile fieldwork 
station. We approached all individuals 
aged 50 years and older and brought less 
mobile participants by car. Inclusion was 
limited by the duration of both field vis-
its. Individuals did not participate if they 
were unable to leave the house, were ab-
sent from the research area for a longer 
period or refused participation. Handgrip 
strength was measured using a calibrat-
ed Jamar hand dynamometer (Sammons 
Preston, Bolingbrook, IL, USA) with the 
participant in an upright position and the 
arm of the measured hand unsupported 
parallel to the body. The width of the dy-
namometer’s handle was adjusted to each 
participant’s hand size so that the middle 
phalanges rested on the inner handle. The 
participants were instructed to exert max-
imal force once by each hand. We used 
the highest measurement of both hands 
in our analyses. Body height and weight 
were measured by a calibrated length scale 
and weighing scale. A BMI of 18.5 kg/m2 
or lower was defined as underweight and 
a BMI above 18.5 kg/m2 as a normal BMI, 
according to the classification of the Food 
and Agriculture Organization and World 
Health Organization.23,24
Cytokine production capacity
The production capacities of IL10 and 
TNFα were measured in blood samples 
that were taken in 2005, 2006, or 2008. 
Previous publications, studying measure-
ments from these years separately, have 
reported the procedure by which the blood 
samples were processed.15,16,25 Venous blood 
was locally incubated with Escherichia coli 
LPS, the supernatants frozen and shipped 
for measurement of cytokine concentra-
tions in the Netherlands by enzyme-linked 
immunosorbent assay (ELISA). The proce-
dure has been reported to have a small in-
traindividual compared with the interindi-
vidual variation9 and to be replicable with 
an interval of two years in this research 
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area.16,25 We combined the measurements 
from all three years of 1177 individuals 
of whom data on the IL10 gene were also 
available.
Analyses
The program Haploview (Broad, Cam-
bridge, MA, USA)26 was used to test for 
Hardy-Weinberg equilibrium. Statistical 
analyses were performed with SPSS Sta-
tistics 20 (IBM, Armonk, NY, USA) and 
Stata/SE 12.0 (StataCorp, College Station, 
TX, USA). The relations between IL10 gene 
SNPs and haplotype copies, cytokine pro-
duction capacities, and handgrip strength 
were assessed by linear mixed models. 
These analyses were adjusted for age, sex, 
and tribe as fixed factors and household 
as a random factor. Analyses with hand-
grip strength were additionally adjusted 
for height as a fixed factor. Cytokine con-
centrations were natural-logarithmically 
transformed due to skewedness and stand-
ardised as z scores per sex27 within each 
year of measurement. The z scores of 2005, 
2006, and 2008 were averaged into one 
z score per individual. Haplotypes were 
defined as proinflammatory if associated 
with lower levels of IL10 and higher levels 
of TNFα upon stimulation with LPS. Hap-
lotypes were defined as anti-inflammatory 
if associated with higher levels of IL10 and 
lower levels of TNFα upon stimulation with 
LPS.12 In all haplotype analyses, the poste-
rior probabilities of pairs of haplotypes per 
individual, as estimated by PHASE,28 were 
used as weights.
Table 7.1 • General characteristics of the Ghanaian study population
Men Women
Number of individuals 196 358
Age, years 73.0 (9.2) 63.4 (9.2)
Tribe, n (%)
     Bimoba 142 (72.4) 252 (70.4)
     Kusasi 44 (22.4) 84 (23.5)
     Mamprusi 2 (1.0) 12 (3.4)
     Busanga 2 (1.0) 8 (2.2)
     Fulani 2 (1.0) 1 (0.3)
     other 4 (2.0) 1 (0.3)
Number of households 190 299
Household property value, median (iqr) US$ 1028 (580–1782) 1183 (585–2055)
Height, cm 166.0 (6.8) 157.9 (6.7)
Weight, kg 49.4 (7.8) 45.4 (7.5)
Body mass index, kg/m2 17.9 (2.3) 18.2 (2.5)
Body mass index ≤ 18.5 kg/m2, n (%) 113 (57.6) 204 (57.0)
Handgrip strength, kg 29.2 (8.1) 23.4 (5.9)
Data are presented as means with standard deviations unless specified otherwise. Iqr: 
interquartile range.
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Results
Table 7.1 displays the characteristics of 
554 individuals aged 50 years and older 
of whom IL10 gene variants and handgrip 
strength were known. Their characteristics 
were similar as compared with all 4336 in-
dividuals of whom IL10 gene variants were 
measured and with all 923 individuals of 
whom handgrip strength was measured 
(data not shown). Approximately half of 
them had a BMI of 18.5 kg/m2 or lower, 
which is regarded as underweight.23,24 
Mean handgrip strength (with standard 
deviation) was 27.3 (7.6) kg for those with 
a normal BMI and 24.1 (6.7) kg for those 
with underweight. Table 7.2 shows that 
handgrip strength did not differ between 
tribes.
IL10 gene variants and 
cytokine production capacity
It has been previously shown that several 
SNPs in the IL10 gene region influence the 
production capacities of IL10 and TNFα 
measured in two independent groups in 
2006 and 2008 in this research area.12,16 
First, we confirmed that these relations 
were present in 1177 individuals of whom 
IL10 gene variants were known and of 
whom measurements of cytokine produc-
tion capacities were combined from 2005, 
2006, and 2008 (Figure 7.1a). When re-
stricting this group to the individuals of 
whom handgrip strength was also known 
(n = 457), a similar pattern was present 
(Figure 7.1b).
It has been previously shown that the SNPs 
in the IL10 gene region constitute two 
haplotypes that influence the production 
capacities of IL10 and TNFα: a proinflam-
matory haplotype 1 and an anti-inflam-
matory haplotype 3.12,16 We reanalysed the 
relations between the haplotypes of the 
IL10 gene and cytokine production capac-
ities in the 1177 individuals of whom IL10 
gene variants were known and of whom 
measurements of cytokine production ca-
pacities were combined from 2005, 2006, 
and 2008. We confirmed an additive ge-
netic effect for both haplotypes. With each 
additional copy of the proinflammatory 
haplotype 1, z scores of IL10 production 
capacity were 0.08 lower (standard error 
(SE) = 0.04; p = 0.028) and z scores of 
TNFα production capacity were 0.11 higher 
(SE = 0.04; p = 0.001). With each addition-
al copy of the anti-inflammatory haplotype 
3, z scores of IL10 production capacity 
were 0.19 higher (SE = 0.07; p = 0.005) 
and z scores of TNFα were 0.10 lower (SE 
= 0.07; p = 0.167). When restricting this 
group to the individuals of whom handgrip 
strength was also known (n = 457), simi-





Bimoba 394 26.6 (0.3)
Kusasi 128 26.8 (0.6)
Mamprusi 14 26.3 (1.7)
Busanga 10 30.7 (2.0)
Fulani 3 21.9 (3.6)
Other 3 27.7 (2.8)
p value 0.30
Handgrip strength is presented as means 
with standard errors, adjusted for age and 
sex. Differences in handgrip strength be-
tween tribes were tested with ANCOVA.
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lar patterns were found (data not shown). 
Haplotype 2 was not related with the pro-
duction capacities of IL10 (p = 0.813) or 
TNFα (p = 0.364) and was used in this 
study as a negative control. Results were 
not different between men and women.
IL10 gene variants and handgrip strength
Figure 7.2a shows the 20 genotyped SNPs 
in the IL10 gene region. Most of the SNPs 
tag a single linkage disequilibrium (LD) 
block. The haplotype structure and the 
frequencies of these haplotypes were pre-
viously calculated for all individuals of 
whom IL10 gene variants were measured 
(n = 4336).12 Haplotype frequencies and 
Hardy-Weinberg equilibria of the SNPs 
were not materially different when re-
stricting this group to the individuals of 
whom handgrip strength was also known 
(Tables 7.3 and 7.4). Furthermore, allelic 
frequencies were not different between 
tribes, with a few exceptions between 
small and large tribes (Table 7.5).
Figure 7.2b shows that in the individuals 
of whom IL10 gene variants and handgrip 
strength were known, carriers of dis-
tinct SNPs had higher or lower handgrip 
strength when compared with non-carri-
ers. The pattern followed the predefined 
Figure 7.1 • Associations 
of IL10 gene SNPs with 
cytokine production ca- 
pacities. The relations are 
shown between the minor 
allele of each IL10 gene 
SNP and the production ca- 
pacities of IL10 and TNFα 
for (A) individuals of whom 
IL10 gene variants and 
cytokine production ca-
pacities were known (n = 
1177) and (B) individuals 
of whom IL10 gene vari-
ants, cytokine production 
capacities, and handgrip 
strength were known (n = 
457). Cytokine production 
capacities are expressed 
as z scores with standard 
errors for carriers of at 
least one copy of the minor 
allele, adjusted for age, 
sex, tribe, and household. 
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Figure 7.2 • Associ-
ations of IL10 gene 
SNPs with handgrip 
strength. Schematic 
overview of the IL10 
gene region with the 
locations of the geno-
typed SNPs indicated 
by vertical lines (A). 
Pairwise linkage dis-
equilibrium (LD) as 
observed in the entire 
genotyped population 
(n = 4336) is depicted 
in greyscale. Popula-
tion frequencies of the 
different haplotypes 
(if > 1%) are present-
ed with the minor al-
leles of each SNP indi-
cated in bold (B).12 The 
relation between the 
minor allele of each 
IL10 gene SNP and 
handgrip strength for 
individuals of whom 
IL10 gene variants and 
handgrip were known 
(C; n = 554). Handgrip 
strength is expressed 
as the deviance from 
the population’s mean 
in kilograms (kg) with 
standard errors for 
carriers of at least one 
copy of the minor al-
lele, adjusted for age, 
sex, tribe, household, 





































































































 H1 T C T C G A T A T T C T A C G C  0.432
 H2 T C T C A G C C G C G C A T T T  0.080
 H3 A G A T A G C C G C G C G C G C  0.079
 H4 T C T C G A C C G C C C A C T C  0.067
 H5 T C T T G A C C G C C T A C G C  0.053
 H6 A G A C G A C C G C C C A C T C  0.040
 H7 A G A T A G C C G C G C A C G C  0.035
 H8 T G T T A A C C G C C C A C T C  0.030
 H9 A G A C A G C C G C G C A C G C  0.022
 H10 T C T C G A T A T T C T A C T C  0.022
 H11 T C T C G A C C G C C T A C G C  0.016
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anti-inflammatory and proinflammatory 
haplotype structures shown in Figure 7.2a 
and Figure 7.1. Results were not different 
between men and women.
Figure 7.3 shows handgrip strength for 
carriers and non-carriers of the proin-
flammatory haplotype 1 and the anti-in-
f lammatory haplotype 3. We observed 
an additive genetic effect on handgrip 
strength, which increased with each addi-
tional copy of the proinflammatory haplo-
type 1 and decreased with each additional 
copy of the anti-inflammatory haplotype 
3. Among individuals with a normal BMI, 
the positive association between the proin-
flammatory haplotype 1 and handgrip 
strength was equally strong (p for interac-
tion = 0.398) and the negative association 
between the anti-inflammatory haplotype 
3 and handgrip strength was stronger (p 
for interaction = 0.009). Both haplotypes 
were not associated with BMI, neither in 
all individuals nor in those with BMI above 
18.5 kg/m2 (p > 0.200). Contrary to haplo-
types 1 and 3, haplotype 2 was not associ-
ated with handgrip strength (p = 0.922). 
Results were not different between men 
and women.
Cytokine production capacity and 
handgrip strength
Figure 7.4 shows that IL10 and TNFα 
production capacities were not related to 
handgrip strength, although an increase in 
IL10 production capacity concurred with 
a declining trend in handgrip strength 
among individuals with a normal BMI. 
When stratifying by sex, IL10 production 
capacity was not associated with hand-
grip strength in either men or women (p 
> 0.800), while TNFα production capacity 
was positively associated with handgrip 
strength in men (n = 128; p = 0.007) but 
not in women (n = 329; p = 0.819).
Discussion
We found that distinct haplotypes of the 
IL10 gene, associated with variation in the 
cytokine production capacities of immune 
cells, were related to handgrip strength 
in rural Ghana. A proinflammatory hap-
lotype with a population frequency of 
43.2% was associated with higher hand-
Table 7.3 • Haplotype frequencies of 
the IL10 gene in the Ghanaian study 






















Differences in haplotype frequencies be- 
tween both populations were tested with 
the Pearson chi-squared test.
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p = 0.015 p = 0.030 p < 0.001p = 0.006
All individuals (n = 554)
Individuals with BMI > 18.5 kg/m2 (n = 237)
Figure 7.3 • Associations of IL10 gene haplotypes with handgrip strength in all 
individuals and in individuals with a normal BMI. Handgrip strength for individuals 
of whom IL10 gene variants and handgrip were known (n = 554) presented as means with 
standard errors, adjusted for age, sex, tribe, household, and height (p values for trends). 
A BMI of 18.5 kg/m2 or lower is regarded as underweight.23,24 For the haplotype structures 
and frequencies, see Figure 7.2A.
Figure 7.4 • Association of cytokine production capacities with handgrip strength 
in all individuals and in individuals with a normal BMI. Handgrip strength for individ-
uals of whom IL10 gene variants, cytokine production capacities, and handgrip strength 
were known (n = 457) presented as means with standard errors, adjusted for age, sex, 
tribe, household, and height (p values for trends). A BMI of 18.5 kg/m2 or lower is regard-
ed as underweight.23,24
All individuals (n = 457)
Individuals with BMI > 18.5 kg/m2 (n = 201)
p = 0.853 p = 0.280 p = 0.757 p = 0.512
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Table 7.4 • Locations and minor allele frequencies of the IL10 gene SNPs in the 
Ghanaian study population and in the entire genotyped population






MAF HWE MAF HWE
rs4072226 C/T promotor 0.463 0.936 0.456 0.865
rs6667202 C/A promotor 0.499 0.851 0.484 0.602
rs6676671 T/A promotor 0.195 0.870 0.200 0.832
rs10494879 C/G promotor 0.269 0.823 0.284 0.025
rs1800890 T/A promotor 0.192 0.822 0.201 0.865
rs6703630 C/T promotor 0.206 0.579 0.220 0.066
rs1800893 G/A promotor 0.256 0.005 0.284 0.196
rs1800896 A/G promotor 0.260 0.064 0.284 0.401
rs1800871 C/T promotor 0.509 0.984 0.470 0.302
rs1800872 C/A promotor 0.506 0.811 0.472 0.034
rs3024490 G/T intron 0.523 0.695 0.484 0.013
rs1554286 C/T e/i boundary 0.500 0.433 0.468 0.157
rs1878672 C/G intron 0.228 0.072 0.244 0.612
rs3024496 T/C exon 0.393 0.928 0.425 0.043
rs3024498 A/G exon 0.066 0.904 0.083 0.129
rs4844553 C/T 3’ UTR 0.080 0.963 0.096 0.084
rs7548373 G/T 3’ UTR 0.282 0.790 0.297 0.190
rs7512090 C/T 3’ UTR 0.126 0.681 0.132 0.084
rs13376708 G/A 3’ UTR 0.320 0.784 0.327 0.273
rs4390174 A/G 3’ UTR 0.290 0.981 0.282 0.630
Alleles indicate major/minor alleles. MAF: minor allele frequency. HWE: p values for Har-
dy-Weinberg equilibrium. E/i boundary: boundary between an exon and an intron. 3’ UTR: 
three prime untranslated region.
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Table 7.5 • Minor allele frequencies of the IL10 gene SNPs per tribe
IL10 SNP Bimoba Kusasi Mamprusi Busanga Fulani Other p value
n 394 128 14 10 3 3
rs4072226 0.443 0.516 0.536 0.400 0.500 0.500 0.29
rs6667202 0.524 0.429 0.464 0.550 0.250 0.400 0.10
rs6676671 0.186 0.213 0.250 0.300 0.000 0.200 0.25
rs10494879 0.367 0.276 0.286 0.350 0.167 0.300 0.48
rs1800890 0.183 0.211 0.250 0.300 0.000 0.125 0.33
rs6703630 0.194 0.238 0.250 0.300 0.000 0.300 0.12
rs1800893 0.261 0.262 0.154 0.222 0.167 0.000 0.20
rs1800896 0.260 0.264 0.231 0.300 0.177 0.200 0.87
rs1800871 0.509 0.508 0.429 0.550 0.833 0.500 0.79
rs1800872 0.506 0.504 0.429 0.550 0.833 0.500 0.77
rs3024490 0.527 0.512 0.429 0.556 0.833 0.500 0.92
rs1554286 0.503 0.500 0.364 0.500 0.833 0.333 0.71
rs1878672 0.227 0.238 0.154 0.462 0.167 0.100 0.80
rs3024496 0.398 0.399 0.423 0.350 0.177 0.250 0.34
rs3024498 0.059 0.089 0.071 0.001 0.000 0.000 0.56
rs4844553 0.087 0.075 0.036 0.000 0.000 0.000 0.044
rs7548373 0.300 0.258 0.250 0.056 0.000 0.200 0.009
rs7512090 0.141 0.105 0.105 0.000 0.038 0.000 0.003
rs13376708 0.308 0.352 0.357 0.250 0.167 0.600 0.23
rs4390174 0.275 0.321 0.321 0.350 0.667 0.200 0.19
Differences in minor allele frequencies between tribes were tested with the linear-by-lin-
ear association test.
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grip strength, while an anti-inflammatory 
haplotype with a population frequency of 
7.9% was associated with lower handgrip 
strength. These associations were most 
outspoken after exclusion of individuals 
with underweight.
We investigated the effect of IL10 gene 
variants as genetic determinants of the 
ex vivo production capacities of IL10 and 
TNFα by various immune cells in blood.12,16 
The impact of genetic variants on the cy-
tokine production capacity by specific 
immune cells is not precisely known, but 
whole blood stimulation with LPS has been 
shown to particularly reflect the variance 
in cytokine production by monocytes.9 
Using genetic determinants, the analyses 
of the influence of cytokine production ca-
pacity on muscle strength are largely free 
from confounding and reverse causality.17 
This is an advantage compared with earli-
er research in which cytokine production 
capacity was only measured on the pheno-
typic level.6
Mice studies have shown that repair and 
maintenance of skeletal muscle tissue 
are dependent on the innate immune sys-
tem.2-5 Critical for this role of the innate 
immune system are monocytes infiltrating 
muscle tissue after injury29,30 and produc-
ing proinflammatory cytokines, of which 
most notably TNFα.31,32 As a counterbal-
ance, the anti-inflammatory cytokine 
IL10 downregulates the proinflammatory 
functioning of monocytes and the produc-
tion of proinflammatory cytokines such 
as TNFα33 and is associated with deceler-
ation of skeletal muscle regeneration.5 In 
humans, we have recently reported that a 
higher capacity to produce proinflamma-
tory cytokines, including TNFα, coexists 
with higher muscle strength and muscle 
mass.6 We now show that the same associ-
ations exist between genetic determinants 
of the cytokine production capacity and 
handgrip strength. These findings support 
that cytokine production capacity might 
be important for human muscle repair and 
maintenance as well.
As an alternative explanation of the asso-
ciation between the IL10 gene variants and 
muscle strength, proinflammatory IL10 
gene variants might yield a better resist-
ance to infectious diseases and thereby 
a better resistance to muscle wasting due 
to disease. Cytokine production capacity 
is related to the incidence and severity of 
infectious diseases.34 In rural Ghana, in-
fectious diseases are the main causes of 
death18 and we have earlier observed in 
this research area that carriers of a proin-
flammatory IL10 gene haplotype have a 
survival advantage when drinking from 
pathogen-rich sources like open wells and 
rivers.12 Others have found another anti- 
inflammatory genetic variant associated 
with a higher IL10 production capacity to 
be more prevalent among tuberculosis pa-
tients compared with healthy controls in 
Gambia.35 Such a mechanism could explain 
why no relation between a SNP on the IL10 
gene and handgrip strength was found in 
a European population living in an envi-
ronment where the pathogenic burden is 
relatively low.36
Infectious diseases and malnutrition, 
which are common in this research 
area,18,21,37-39 are closely associated with 
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underweight.23 In an attempt to account 
for the possible effects of ill health on 
handgrip strength, we repeated the anal-
yses after exclusion of individuals with 
underweight. Among individuals with a 
normal BMI, we found an equal relation 
between the proinflammatory haplo-
type and a stronger relation between the 
anti-inflammatory haplotype and muscle 
strength. Moreover, we found that the hap-
lotypes that were associated with handgrip 
strength were not associated with BMI. 
These findings indicate that the relation 
between IL10 gene variants and handgrip 
strength is unlikely to be largely shaped by 
differences in health.
Although IL10 gene variants were related to 
handgrip strength, the production capacity 
of IL10 was not associated with handgrip 
strength. As a possible explanation, mono-
cytes activated by a proinflammatory stim-
ulus like LPS migrate into injured muscle 
tissue and change only after two days into 
macrophages with an anti-inflammatory 
phenotype.2 We measured the cytokine 
production capacity of IL10 24 hours after 
stimulation with LPS, which could have 
been too early to measure the maximum 
IL10 production capacity. In addition, IL10 
is known to have autoregulatory effects, as 
it strongly inhibits IL10 mRNA synthesis 
in LPS-activated monocytes.40 This could 
have diluted the IL10 production capacity 
measurement. Another explanation is that 
the relation might be confounded. Firstly, 
depletion of muscle tissue by malnutrition 
or disease could have disrupted the ben-
eficial role of IL10 production capacity in 
muscle repair and maintenance. As BMI 
is likely to reflect muscle mass in this lean 
population, the stronger relation between 
IL10 gene variants and handgrip strength 
in the higher BMI stratum points at this 
possibility. Secondly, infectious diseases 
might have interfered with our measure-
ments of IL10 cytokine production capac-
ity. Earlier, we have shown that infectious 
diseases are highly endemic in the re-
search area and induce a proinflammatory 
immune response.39 The relation between 
the IL10 gene variants and cytokine pro-
duction capacity was less outspoken in 
the smaller group with available data on 
handgrip strength, possibly due to such 
environmental factors.25 Thirdly, physical 
activity attenuates the production capacity 
of monocytes41 but meanwhile improves 
muscle strength.42 In this population, 
physical activity is of vital importance 
due to the manual labour in farming and 
housekeeping that is necessary for sub-
sistence up to the highest ages. Fourthly, 
while we measured cytokine production in 
whole blood, muscle tissue is recognised 
to be a cytokine producing organ itself. Al-
though little has been reported about the 
muscle-specific production of IL10, the 
IL10 gene might exert its effects in muscle 
tissue in an autocrine and paracrine man-
ner.43 Such a mechanism would not be re-
vealed by the analysis of cytokine produc-
tion capacity in whole-blood samples.
While we observed no relation between 
IL10 production capacity and handgrip 
strength, we observed a positive relation 
between TNFα production capacity and 
handgrip strength in men, but not in wom-
en. This finding is in agreement with previ-
ous research in Europeans.6 A men-specif-
ic positive relation has been found between 
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TNFa production capacity upon stimula-
tion with LPS, a toll-like receptor 4 (TLR4) 
agonist, and muscle mass and strength. A 
women-specific positive relation has been 
found between TNFα production capacity 
upon stimulation with Pam3Cys-SK4, a 
TLR2/1 receptor agonist, and muscle mass. 
These findings indicate that in skeletal 
muscle tissue, the TLR4 pathway is pre-
dominant in men and the TLR2/1 pathway 
is predominant in women.
Our study has some limitations. Firstly, as 
in all genetic association studies, we can-
not exclude that the IL10 gene variants are 
in linkage disequilibrium with variants of 
other genes that affect handgrip strength. 
However, we have previously described 
that this is unlikely, because resequencing 
of the IL10 gene region and its surround-
ings did not result in any variants addi-
tional to the SNPs that were genotyped in 
the IL10 gene.12 Secondly, we did not doc-
ument possible epigenetic variation in the 
IL10 gene. There is growing evidence that 
caloric intake and dietary composition 
modify epigenetic marks,44,45 which can 
influence transcription of the IL10 gene 
in immune cells.46 Malnutrition, being 
common in the research area,18,21,37,38 could 
thereby affect the relation between the 
IL10 gene and muscle strength. Lastly, this 
is a cross-sectional study, while it would 
be valuable to associate IL10 gene vari-
ants with longitudinal decline in handgrip 
strength with age.
In conclusion, this study shows that IL10 
gene variants associate with the produc-
tion capacities of IL10 and TNFα and 
strongly relate to handgrip strength in ru-
ral Africa. A haplotype reflecting a proin-
flammatory immune response associates 
with higher muscle strength, while a hap-
lotype reflecting an anti-inflammatory 
immune response associates with lower 
muscle strength, especially after exclusion 
of individuals with underweight. Future 
studies are needed to elucidate whether 
variants of the IL10 gene determine hand-
grip strength through their role in the re-
pair of skeletal muscle tissue directly or 
indirectly through their role in the defence 
against infectious diseases.
Acknowledgements
We are grateful for the dedicated assis-
tance of the local staff of the research team 
in the Garu-Tempane District in Ghana 
and for the help of A. G. C. Boef, dr. U. K. 
Eriksson, dr. L. May, T. Menger, and H. 
Sanchez-Faddeev. This research was sup-
ported by the Netherlands Foundation for 
the Advancements of Tropical Research 
(WOTRO 93-467), the Netherlands Organ-
ization for Scientific Research (NWO 051-
14-050), the European Union funded Net-
work of Excellence LifeSpan (FP6 036894), 
MYOAGE (HEALTH-2007-2.4.5-10) and 
a grant of the Board of Leiden University 
Medical Center, and Stichting Dioraphte. 
None of these organisations had any role 
in the design, analysis, interpretation, or 
report of the study.
115
AN INFLAMMATORY GENETIC DETERMINANT OF HANDGRIP STRENGTH • 7
References
1. Hofmann S. R., Rösen-Wolff A., Tsokos G. C., 
Hedrich C. M. Biological properties and reg-
ulation of IL-10 related cytokines and their 
contribution to autoimmune disease and tis-
sue injury. Clin. Immunol. 2012; 143: 116-127.
2. Arnold L., Henry A., et al. Inflammatory 
monocytes recruited after skeletal muscle 
injury switch into anti-inflammatory mac-
rophages to support myogenesis. J. Exp. Med. 
2007; 204: 1057-1069.
3. Bencze M., Negroni E., et al. Proinflamma-
tory macrophages enhance the regenerative 
capacity of human myoblasts by modifying 
their kinetics of proliferation and differenti-
ation. Mol. Ther. 2012; 20: 2168-2179.
4. Deng B., Wehling-Henricks M., et al. IL-10 
triggers changes in macrophage phenotype 
that promote muscle growth and regenera-
tion. J. Immunol. 2012; 189: 3669-3680.
5. Gao Y., Li Y., et al. Loss of STAT1 in bone mar-
row-derived cells accelerates skeletal muscle 
regeneration. PLoS One 2012; 7: e37656.
6. Beenakker K. G. M., Westendorp R. G. J., et al. 
Proinflammatory capacity of classically acti-
vated monocytes relates positively to muscle 
mass and strength. Aging Cell 2013; 12: 682-
689.
7. Westendorp R. G. J., Langermans J. A., et al. 
Genetic influence on cytokine production and 
fatal meningococcal disease. Lancet 1997; 
349: 170-173.
8. De Craen A. J. M., Posthuma D., et al. Her-
itability estimates of innate immunity: an 
extended twin study. Genes Immun. 2005; 6: 
167-170.
9. Damsgaard C. T., Lauritzen L., et al. Whole-
blood culture is a valid low-cost method to 
measure monocytic cytokines: a comparison 
of cytokine production in cultures of human 
whole-blood, mononuclear cells and mono-
cytes. J. Immunol. Methods 2009; 340: 95-
101.
10. Eskdale J., Gallagher G., et al. Interleukin 10 
secretion in relation to human IL-10 locus 
haplotypes. Proc. Natl. Acad. Sci. USA 1998; 
95: 9465-9470.
11. Kube D., Rieth H., et al. Structural character-
isation of the distal 50 flanking region of the 
human interleukin-10 gene. Genes Immun. 
2001; 2; 181-190.
12. Kuningas M., May L., et al. Selection for ge-
netic variation inducing proinflammatory 
responses under adverse environmental con-
ditions in a Ghanaian population. PLoS One 
2009; 4: e7795.
13. Kurreeman F. A., Schonkeren J. J., et al. 
Transcription of the IL10 gene reveals al-
lele-specific regulation at the mRNA level. 
Hum. Mol. Genet. 2004; 13: 1755-1762.
14. Moraes M. O., Santos A. R., et al. Interleukin-10 
promoter haplotypes are differently distrib-
uted in the Brazilian versus the Dutch pop-
ulation. Immunogenetics 2003; 54: 896-899.
15. May L., Van den Biggelaar A. H. J., et al. Ad-
verse environmental conditions influence 
age-related innate immune responsiveness. 
Immun. Ageing 2009; 6: 7.
16. Boef A. G. C., May L., et al. The influence of 
genetic variation on innate immune activa-
tion in an environment with high infectious 
pressure. Genes Immun. 2012; 13: 103-108.
17. Davey Smith G., Ebrahim S. ‘Mendelian 
randomization’: can genetic epidemiology 
contribute to understanding environmental 
determinants of disease? Int. J. Epidemiol. 
2003; 32: 1-22.
18.  Annual Report 2004 Upper East Regional 
Health Administration. Ghana Health Ser-
vice (GHS), Accra, Ghana, 2005. Available at 
www.ghanahealthservice.org/rhditems.php? 
ghs&ghsscid=5&ghsrid=4.
19. Van Bodegom D., May L., et al. Socio-eco-
nomic status by rapid appraisal is highly cor-
related with mortality risks in rural Africa. 
Trans. R. Soc. Trop. Med. Hyg. 2009; 103: 
795-800.
20. Meij J. J., Van Bodegom D., et al. Quali-
ty-quantity trade-off of human offspring 
under adverse environmental conditions. J. 
Evol. Biol. 2009; 22: 1014-1023.
21. Koopman J. J. E., Van Bodegom D., Jukema 
J. W., Westendorp R. G. J. Risk of cardiovas-
cular disease in a traditional African popu-
lation with a high infectious load: a popula-
tion-based study. PLoS One 2012; 7: e46855. 
(Chapter 9 of this thesis.)
116
PART II • MEASURING SENESCENCE THROUGH MORBIDITY
22. Sanchez-Faddeev H., Pijpe J., et al. The in-
fluence of clan structure on the genetic var-
iation in a single Ghanaian village. Eur. J. 
Hum. Genet. 2013; 21: 1134-1139.
23. Shetty P. S., James W. P. T. Body mass index: 
a measure of chronic energy deficiency in 
adults. FAO Food Nutr. Pap. 1994; 56: 1-57.
24. World Health Organization (WHO). Diet, 
nutrition and the prevention of chronic dis-
eases. World Health Organ. Tech. Rep. Ser. 
2003; 91: 6.
25. May L., Van Bodegom D., et al. Performance 
of the whole-blood stimulation assay for as-
sessing innate immune activation under field 
conditions. Cytokine 2009; 45: 184-189.
26. Barrett J. C., Fry B., Maller J., Daly M. J. Hap-
loview: analysis and visualization of LD and 
haplotype maps. Bioinformatics 2005; 21: 
263-265.
27. Aulock S. V., Deininger S., et al. Gender dif-
ference in cytokine secretion on immune 
stimulation with LPS and LTA. J. Interferon 
Cytokine Res. 2006; 26: 887-892.
28. Stephens M., Smith N. J., Donnelly P. A new 
statistical method for haplotype reconstruc-
tion from population data. Am. J. Hum. Gen-
et. 2001; 68: 978-989.
29. Lu H., Huang D., Ransohoff R. M., Zhou L. 
Acute skeletal muscle injury: CCL2 expres-
sion by both monocytes and injured muscle is 
required for repair. FASEB J. 2011; 25: 3344-
3355.
30. Nguyen M. H., Cheng M., Koh T. J. Impaired 
muscle regeneration in ob/ob and db/db mice. 
ScientificWorldJournal 2011;11:1525-1535.
31. Warren G. L., Hulderman T., et al. Physiological 
role of tumor necrosis factor α in traumatic 
muscle injury. FASEB J. 2002; 16: 1630-1632.
32. Chen S. E., Gerken E., et al. Role of TNF-α 
signaling in regeneration of cardiotoxin-in-
jured muscle. Am. J. Physiol. Cell Physiol. 
2005; 289: c1179-c1187.
33. Mosser D. M., Zhang X. Interleukin-10: new 
perspectives on an old cytokine. Immunol. 
Rev. 2008; 226: 205-218.
34. Mege J. L., Meghari S., et al. The two faces of 
interleukin 10 in human infectious diseases. 
Lancet Infect. Dis. 2006; 6: 557-569.
35. Awomoyi A. A., Marchant A., et al. Interleu-
kin-10, polymorphism in SLC11A1 (formerly 
NRAMP1), and susceptibility to tuberculosis. 
J. Infect. Dis. 2002; 186: 1808-1814.
36. Dato S., Krabbe K. S., et al. Commonly stud-
ied polymorphisms in inflammatory cytokine 
genes show only minor effects on mortality and 
related risk factors in nonagenarians. J. Ger-
ontol. A Biol. Sci. Med. Sci. 2010; 65: 225-235.
37. Hesselberg J., Yaro J. A. An assessment of the 
extent and causes of food insecurity in north-
ern Ghana using a livelihood vulnerability 
framework. GeoJournal 2006; 67: 41-55.
38.  Ghana Demographic and Health Survey 
2008. Ghana Statistical Service, Ghana 
Health Service, and ICF Macro, Accra, Ghana, 
2009: 179-221. Available at dhsprogram.com/ 
publications/publication-fr221-dhs-final-re-
ports.cfm.
39. Boef A. G. C., May L., et al. Parasitic infec-
tions and immune function: effect of hel-
minth infections in a malaria endemic area. 
Immunobiology 2013; 218: 706-711.
40. De Waal Malefyt R., Abrams J., et al. Inter-
leukin 10 (IL-10) inhibits cytokine synthesis 
by human monocytes: an autoregulatory 
role of IL-10 produced by monocytes. J. Exp. 
Med. 1991; 174: 1209-1220.
41. Walsh N. P., Gleeson M., et al. Position state-
ment. Part one: immune function and exer-
cise. Exerc. Immunol. Rev. 2011; 17: 6-63.
42. Ferreira M. L., Sherrington C., et al. Physi-
cal activity improves strength, balance and 
endurance in adults aged 40–65 years: a sys-
tematic review. J. Physiother. 2012; 58: 145-
156.
43. Pedersen B. K., Febbraio M. A. Muscles, exer-
cise and obesity: skeletal muscle as a secreto-
ry organ. Nat. Rev. Endocrinol. 2012; 8: 457-
465.
44. Li Y., Daniel M., Tollefsbol T. O. Epigenetic 
regulation of caloric restriction in aging. 
BMC Med. 2011; 9: 98.
45. McKay J. A., Mathers J. C. Diet induced epi-
genetic changes and their implications for 
health. Acta Physiol. 2011; 202: 103-118.
46. Villagra A., Sotomayor E. M., Seto E. Histone 
deacetylases and the immunological net-
work: implications in cancer and inflamma-







J. J. E. Koopman, D. van Bodegom, D. van Heemst, R. G. J. Westendorp.
Handgrip strength, ageing and mortality in rural Africa.








MEASURING SENESCENCE THROUGH HANDGRIP STRENGTH • 8
Background • Muscle strength measured as handgrip strength declines 
with increasing age and predicts mortality. While handgrip strength is de-
termined by lifestyle through nutrition and physical activity, it has almost 
exclusively been studied in western populations with a sedentary lifestyle. 
This study aims to investigate the age pattern of handgrip strength and its 
relation with mortality in a population characterised by a predominance 
of malnutrition and manual labour.
Methods • From a traditional African rural population in Ghana, 923 com- 
munity-dwelling individuals aged 50 years and older were included. De-
mographic characteristics were registered. At baseline, height, body mass 
index (BMI), and handgrip strength were measured and compared with 
those in a western reference population. Survival of the participants was 
documented during a period of up to two years.
Results • Handgrip strength was dependent on age, sex, height, and BMI. 
Compared with the western reference population, handgrip strength was 
lower due to a lower height and BMI, but declined with age similarly. Risk 
of mortality was lower in participants having higher handgrip strength, 
with a hazard ratio of 0.94 per kg increase (p = 0.002). After adjustment 
for age, sex, tribe, socioeconomic status, drinking water source, height, 
and BMI, only handgrip strength remained predictive of mortality.
Conclusion • In a traditional rural African population characterised by mal- 
nutrition and manual labour, handgrip strength declines with age and in-
dependently predicts mortality similarly to western populations. Hand-
grip strength can be used as a universal marker of biological age.
Muscle strength measured as handgrip 
strength is widely used as a simple and 
robust marker of biological age. Hand-
grip strength declines with increasing age 
in different ethnicities, especially after 
the age of 50 years.1-7 At both middle and 
high ages, low handgrip strength is asso-
ciated with increased risks of future dis-
ability;8-14 of age-related diseases such as 
the metabolic syndrome,15 cardiovascular 
disease,16,17 diabetes mellitus,18 and cogni-
tive impairment,12,19 of hospitalisation,13,20 
and of treatment-related complications.13 
Moreover, low handgrip strength predicts 
all-cause mortality13-15,21-23 as well as mor-
tality due to cardiovascular disease6,24 and 
cancer.15,23,24 Consequently, low handgrip 
strength is considered as an accurate indi-
cator of frailty.25
Apart from age, sex, and ethnicity, hand-
grip strength is dependent on height, body 
mass index (BMI), nutritional status, and 
physical exercise.11,26-29 While these de-
terminants are closely related to lifestyle, 
research on handgrip strength has almost 
exclusively been conducted in western so-
cieties where an aff luent and sedentary 
lifestyle is omnipresent.3,30,31 In societies 
characterised by a predominance of mal-
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nutrition and manual labour, handgrip 
strength may be a reflection of dietary 
composition and muscle training rather 
than senescence. In addition, the associa-
tion between age, handgrip strength, and 
mortality may be mediated by age-related 
diseases and be attenuated when these are 
uncommon.27,32
This study investigates the age pattern of 
handgrip strength and its relation with 
mortality in a traditional rural African 
population where a sedentary lifestyle is 
absent and age-related diseases are un-
common.32-34 We show the age pattern of 
handgrip strength and it with that in a 
western reference population, we assess 
the individual characteristics that deter-
mine handgrip strength, and we assess 
whether handgrip strength predicts mor-
tality in this population.
Methods
Research area and participants
This study was conducted in the Garu-Tem-
pane District in the Upper East Region 
in Ghana. The area is rural, remote, and 
one of the least developed in the country. 
The vast majority of the inhabitants are 
involved in non-commercial agriculture 
performed by manual labour without prop-
er means of transportation or mechanised 
farming. Hospital care is absent. Infec-
tious diseases are highly endemic and con-
stitute the main causes of death, although 
the prevalence of human immunodeficien-
cy virus (HIV) is low (< 4%) compared with 
other African regions.35
Since 2002, we have kept a demographic 
registry of the population within a re-
search area of 375 km2 comprising 32 vil-
lages. During yearly visits, we registered 
the name, age, sex, tribe, and location of 
living of each inhabitant. In 2007, we de-
termined the property value of each house-
hold. From this value, an index of the soci-
oeconomic status with a standard normal 
distribution was calculated according to 
the Demographic and Health Survey meth-
od.36 In addition, we registered the main 
drinking water source of each household. 
Water from boreholes was classified as 
safe and water from open wells and rivers 
as unsafe, based on their pathogen con-
tents.37 Annual migration relative to the 
study population’s size was 2% into and 1% 
out of the research area. An elaborate de-
scription of this study population has been 
given elsewhere.32,34,36,37
Ethical approval was given by the Ethical 
Review Committee of Ghana Health Ser-
vices, the Committee Medical Ethics of 
Leiden University Medical Center, and the 
local chiefs and elders. Because of illiter-
acy, informed consent was obtained orally 
from the participants after explanation 
of the purpose and conduction of this re-
search project. Participation was only pro-
ceeded after verbal consent in the partici-
pant’s own language.
Measurements
In 2009 and 2010, we measured handgrip 
strength among 923 inhabitants aged 50 
and older, who were recruited in villages 
visited consecutively. To ensure maximal 
participation, we set up a mobile field work 
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station in the villages and, if necessary, 
brought less mobile participants by car. 
Reasons of exclusion included death of 
the individual since the last registration 
(n = 48), refusal of participation (n = 35), 
absence from the research area during our 
visits because of migration or travelling (n 
= 30), and other reasons (n = 46).
Handgrip strength in kilograms was 
measured using a calibrated Jamar hand 
dynamometer (Sammons Preston, Boling-
brook, IL, USA), while the participant was 
standing in an upright position with the 
arms unsupported parallel to the body. 
The width of the dynamometer’s handle 
was adjusted to each participant’s hand 
size. Participants were instructed to exert 
maximal force with each hand once. The 
handgrip strength of the hand with the 
highest measurement was registered. Body 
height and weight were measured with a 
calibrated length scale and weighing scale. 
BMI was calculated as body weight in kilo-
grams divided by squared body height in 
metres.
After the measurements in 2009 and 2010, 
follow-up data on 915 individuals (99.1%) 
were available in our demographic registry. 
Follow-up lasted until death, migration out 
of the research area, loss to follow-up or 
our last visit to the research area in 2011.
Reference population
To compare the Ghanaian study population 
with a western population, we retrieved 
data from the Leiden Longevity Study. 
This study included offspring of long-lived 
native Dutch siblings and the partners of 
the offspring without selection criteria 
on health or demographic characteristics. 
The design of the study has been previ-
ously described in more detail.38 We used 
data on age, sex, height, BMI and handgrip 
strength measured in 316 offspring and 311 
partners aged 50 to 80 years. Handgrip 
strength did not differ between offspring 
and partners. The measurements were per-
formed with the same hand dynamometer 
and in the same position as described for 
the Ghanaian study population.39
Analyses
Differences between both populations in 
mean values of height, BMI, and handgrip 
strength and in the decline in handgrip 
strength per year of age were determined 
by linear regression with age as an in-
dependent variable and were restricted 
to participants aged 50 to 80 years. De-
terminants of handgrip strength in the 
Ghanaian study population were assessed 
by linear regression including all par-
ticipants aged 50 to 97 years. Handgrip 
strength in the Ghanaian study population 
was standardised according to the age-
group- and sex-specific mean height and 
BMI in the Dutch reference population, 
using the regression coefficients obtained 
for these determinants in the Ghanaian 
study population. To investigate whether 
handgrip strength predicted mortality, we 
constructed Kaplan-Meier survival curves 
with left truncation to account for differ-
ent ages at baseline. Survival curves were 
separated between individuals classified 
as having low or high handgrip strength 
according to the age-group- and sex-spe-
cific medians. Hazard ratios were deter-
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mined by Cox regression with follow-up 
starting at the time of the measurements of 
handgrip strength.
Results
Table 8.1 shows the characteristics of the 
Ghanaian study population at the mo-
ment of handgrip strength measurement 
in 2009 or 2010. For comparison, we used 
data from a Dutch reference population 
including 316 men and 311 women aged 
50 to 80 years. As described previously 
for this population,39 mean height (with 
standard deviation) was 177.9 (7.7) cm in 
men and 165.7 (5.9) cm in women; mean 
BMI was 27.1 (4.1) kg/m2 in men and 26.4 
(4.6) kg/m2 in women and mean handgrip 
strength was 46.9 (8.1) kg in men and 29.3 
(5.5) kg in women. These values of height 
and BMI were higher than those in the 
Ghanaian study population adjusted for 
age (both p < 0.001).
Figure 8.1a shows that mean handgrip 
strength was lower in the Ghanaian study 
population compared with the Dutch 
reference population. Overall, the differ-
ence (with 95% confidence interval) was 
14.7 (13.6 to 15.8) kg in men and 5.7 (4.9 
to 6.4) kg in women (both p < 0.001). In 
the Ghanaian study population, handgrip 
strength declined with 0.4 (0.3 to 0.5) kg 
per year of age in men and with 0.3 (0.2 to 
0.4) kg per year of age in women (both p < 
0.001). For comparison, handgrip strength 
in the Dutch reference population declined 
with a slightly higher rate of 0.6 (0.5 to 0.7) 
kg per year of age in men up to the age of 
80 years (p = 0.046), with a similar rate in 
men up to the age of 75 years (p = 0.384) 
and with a similar rate in women (p = 
0.687).
Determinants of handgrip strength in the 
Ghanaian study population are described 
in Table 8.2. In a multivariate analysis of 
Table 8.1 • General characteristics of the Ghanaian study population
Men Women
Number of individuals 480 443
Age, median (iqr) years 67 (58–76) 61 (56–70)
Tribe, %
     Bimoba 69.5 68.6
     Kusasi 22.5 25.5
     other 8.1 5.9
Household property value, median (iqr) US$ 1008 (500–1700) 1196 (583–2108)
Access to safe drinking water, % 86.7 88.5
Weight, kg 50.6 (7.9) 45.5 (7.6)
Height, cm 167.5 (6.8) 157.9 (6.8)
BMI, kg/m2 18.0 (2.3) 18.2 (2.6)
Handgrip strength, kg 31.3 (8.7) 23.6 (5.9)
Data are presented as means with standard deviations unless specified otherwise. Iqr: 
interquartile range. BMI: body mass index.
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demographic and anthropometric charac-
teristics, handgrip strength in both sexes 
was higher in individuals with a higher 
age, with a higher height and with a higher 
BMI. When this analysis was not stratified 
by sex, handgrip strength was 6.0 (5.0 to 
7.0) kg higher in men (p < 0.001).
Figure 8.1b shows that the differences in 
handgrip strength between the Ghanaian 
study population and the Dutch reference 
population were attenuated when handgrip 
strength in the Ghanaian study population 
was standardised according to the age-
group- and sex-specific mean height and 
BMI of the Dutch reference population. 
Hereby accounting for the differences in 
height and BMI between both populations, 
handgrip strength was similar in men (p 
= 0.350) and 1.7 (0.9 to 2.4) kg higher in 
Ghanaian women (p < 0.001). Standard-
ised handgrip strength declined with age 
with similar rates in men (p = 0.067) and 
women (p = 0.233) in both populations.
Figure 8.2 shows how mortality is predict-
ed by handgrip strength in the Ghanaian 
study population. Data on follow-up were 
available for 476 men and 439 women. 
From the baseline measurements in 2009 
and 2010 through the end of follow-up in 
2011, we recorded 1492 person-years and 
46 deaths. Mean individual follow-up was 
20 (6) months. Individuals were classified 
as having low or high handgrip strength ac-
cording to the age-group- and sex-specific 
medians. Risk of mortality was lower in 
individuals with high handgrip strength, 
with a hazard ratio of 0.45 adjusted for age 
and sex (p = 0.010).
Figure 8.1 • Handgrip strength per sex 
and per age group in the Ghanaian study 
population compared with the Dutch ref-
erence population. A comparison of mean 
handgrip strength with 95% confidence inter- 
vals per 5-year age category and per sex as 
observed in the Ghanaian study population 
and the Dutch reference population (A).39 
Idem after standardisation of the individu-
al handgrip strength measurements in the 
Ghanaian study population according to the 
age-group- and sex-specific height and BMI 
of the Dutch reference population (B).39
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Determinants of mortality in the Ghana-
ian study population are described in 
Table 8.3. While handgrip strength, age, 
and BMI determined mortality in the uni-
variate analysis, only handgrip strength 
determined mortality in the multivariate 
analysis with a hazard ratio of 0.94 per 
kg increase (p = 0.016). The association 
between handgrip strength and mortality 
in the univariate analysis remained un-
changed after the adjustments in the mul-
tivariate analysis. In the multivariate anal-
ysis, the association of handgrip strength 
with mortality was not different between 
Table 8.2 • Determinants of handgrip strength in the Ghanaian study population
Men Women
Difference in handgrip 
strength (95% CI), kg
Difference in handgrip 
strength (95% CI), kg
Age, per year -0.3 (-0.3 to -0.2) ** -0.2 (-0.2 to -0.1) **
Tribe, Bimoba vs other +1.3 (-0.1 to +2.6) +0.1 (-0.9 to +1.1)
Socioeconomic status, per SD +0.1 (-0.4 to +0.6) -0.1 (-0.4 to +0.3)
Safe drinking water, vs unsafe +1.1 (-0.8 to +2.9) +1.1 (-0.3 to +2.5)
Height, per cm +0.3 (+0.2 to +0.4) ** +0.3 (+0.2 to +0.3) **
BMI, per kg/m2 +1.3 (+1.0 to +1.6) ** +0.6 (+0.4 to +0.8) **
Data are presented as kilograms difference in handgrip strength per unit increase for 
continuous variables or between categories for categorical variables. Differences are 
shown with 95% confidence intervals (95%CI) and are adjusted for all other variables. SD: 
standard deviation. ** p < 0.001.
Figure 8.2 • Handgrip 
strength as a predictor of 
mortality in the Ghanaian 
study population. Age-spe-
cific survival is dependent 
on handgrip strength in the 
Ghanaian study population. 
Handgrip strength is classi-
fied as low or high accord-
ing to the age-group- and 
sex-specific medians. The 
hazard ratio (HR) is given for 
individuals with high hand- 
grip strength relative to those 
with low handgrip strength, 
adjusted for age and sex.
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individuals below or above the age of 65 
(p = 0.920), between men and women (p = 
0.380), between individuals with a low or 
high BMI (p = 0.188), or between individu-
als with a low or high socioeconomic status 
(p = 0.890).
Additional adjustment for family relations 
by clustering on the household level did 
not materially change the results.
Discussion
This study aims to study the age pattern 
of handgrip strength and its relation with 
mortality in a traditional rural African 
population with a non-western lifestyle. 
Handgrip strength was lower compared 
with a western reference population due 
to a lower height and BMI, but it declined 
with age with a similar rate. Lower levels 
of handgrip strength predicted mortali-
ty independent of its other determinants 
related to nutritional and socioeconomic 
status. Its predictive value was compara-
ble with that known for western popula-
tions.6,13,21,24
The Ghanaian study population contrasts 
sharply with western populations, as a 
sedentary lifestyle is absent and age-re-
lated diseases are uncommon.32-34 Be-
cause handgrip strength is dependent on 
nutritional status,29 this contrast is most 
relevantly characterised by a low BMI 
and near absence of obesity (Chapter 9 
of this thesis).32 In line with this, hand-
grip strength was closely related to BMI 
and low compared with a Dutch reference 
population due to a lower BMI. Besides 
nutrition, handgrip strength is associated 
with physical activity and socioeconomic 
status.26,27,40-42 Unlike western populations, 
almost all inhabitants in the research area 
engage in lifelong physical exercise. Man-
Table 8.3 • Determinants of mortality in the Ghanaian study population
Univariate Multivariate
Difference in handgrip 
strength (95% CI), kg
Difference in handgrip 
strength (95% CI), kg
Handgrip strength, per kg 0.94 (0.90 to 0.98) * 0.94 (0.89 to 0.99) *
Age, per year 1.05 (1.02 to 1.08) * 1.02 (0.99 to 1.06)
Sex, men vs women 1.44 (0.79 to 2.62) 1.71 (0.76 to 3.84)
Tribe, Bimoba vs other 1.61 (0.80 to 3.25) 1.62 (0.79 to 3.31)
Socioeconomic status, per SD 0.81 (0.63 to 1.06) 0.88 (0.68 to 1.14)
Safe drinking water, vs unsafe 0.92 (0.39 to 2.18) 1.09 (0.46 to 2.57)
Height, per cm 0.99 (0.95 to 1.02) 1.00 (0.95 to 1.05)
BMI, per kg/m2 0.81 (0.72 to 0.92) * 0.90 (0.79 to 1.03)
Data are presented as hazard ratio per unit increase for continuous variables or com-
paring categories for categorical variables. Differences are shown with 95% confidence 
intervals (95%CI) and are adjusted in the multivariate analysis for all other variables. SD: 
standard deviation. * p < 0.05.
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ual labour in farming and housekeeping is 
necessary for subsistence up to the highest 
ages. Meanwhile, mechanical means of 
farming and transportation are lacking. 
Most inhabitants live in poverty33 and 
common property is confined to cattle, 
fertiliser, and iron roofing.36 Despite these 
differences, the variation in handgrip 
strength in the Ghanaian study population 
was similar to that in the Dutch reference 
population and as reported for other west-
ern populations.2,43,44 Moreover, handgrip 
strength declined with age in these popu-
lations similarly.
Few other studies have described hand-
grip strength in traditional lean popula-
tions in Africa. Absolute levels of handgrip 
strength have been reported to be up to 
4 kg lower in rural Kenya, rural Malawi, 
and among refugees from Rwanda com-
pared with those found at similar ages 
in the Ghanaian study population.31,45,46 
Handgrip strength in these populations 
was also, though less, dependent on BMI. 
The decline in handgrip strength with age 
was similar to that in the Ghanaian study 
population. In a population-wide study in 
South Africa, handgrip strength did not 
differ between ethnicities or between rural 
and urban areas, but it was associated with 
age, anthropometry, and health.30 None of 
these studies related handgrip strength 
with mortality.
As a western reference population, we used 
the Leiden Longevity Study.39 Handgrip 
strength in this study is slightly higher 
compared with other western populations. 
This difference can be a result of interna-
tional variations in the level of handgrip 
strength, while the declines with age are 
similar.4 Alternatively, this difference can 
be a result of variations in body position 
during the measurements. Body position 
influences the estimation of handgrip 
strength, although it is not likely to influ-
ence its decline with age or its relation with 
mortality.47-50 When using reference data 
from a meta-analysis of handgrip strength 
in twelve western study populations with 
a body position different from the Leiden 
Longevity Study, the decline in handgrip 
strength with age was similar to that in the 
Ghanaian study population.7 Suitably, the 
body position during the measurements in 
the Ghanaian study population was identi-
cal to that in the Leiden Longevity Study.
This study has the following limitations. 
First, handgrip strength was measured 
only once, while it might have been valua-
ble to relate individual age-related changes 
in handgrip strength with anthropometry 
and mortality. Second, nutritional status 
was documented by BMI, while it might 
have been valuable to relate dietary com-
position and physical activity with the 
level of handgrip strength as well as its 
predictive value of mortality, but these 
determinants were not formally docu-
mented. Lastly, because diseases were not 
registered, the possible effects of diseases 
on handgrip strength could not be studied 
and neither could handgrip strength be as-
sessed as a predictor of morbidity. 
In conclusion, this study shows that hand-
grip strength declines with age with a 
similar rate and functions equally well as 
an independent predictor of mortality in a 
traditional rural African population com-
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pared with western populations. Across 
divergent environments, in different pop-
ulations, and despite variations in life-
style, handgrip strength can be easily and 
universally used to identify frail people at 
increased risk of mortality.
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Background • To test the inflammatory origin of cardiovascular disease, 
as opposed to its origin in a western lifestyle, we conducted a population- 
based assessment of the prevalences of cardiovascular risk factors and 
cardiovascular disease in an inflammation-prone African population, inclu- 
ding electrocardiography and ankle-arm index measurement.
Methods • In a traditional population in rural Ghana, characterised by ad- 
verse environmental conditions and a high infectious load, we studied a 
population-based sample of 924 individuals aged 50 years and older. We 
registered median values of cardiovascular risk factors, including waist 
circumference, body mass index (BMI), blood pressure, and markers of 
glucose and lipid metabolism and inflammation. We assessed the preva-
lences of myocardial infarction detected by electrocardiography and pre- 
valence of peripheral arterial disease detected by ankle-arm index. We 
compared the results with known prevalences in American and European 
populations.
Results • As compared with western populations, we found that Ghana-
ians had more proinflammatory profiles and less cardiovascular risk fac-
tors, including obesity, dysglycæmia, dyslipidæmia, and hypertension. The 
prevalence of cardiovascular disease was also lower. Definite myocardial 
infarction was present in 1.2% (95% CI: 0.6 to 2.4). Peripheral arterial 
disease was present in 2.8% (95% CI: 1.9 to 4.1).
Conclusion • Taken together, our data indicate that for the pathogenesis 
of cardiovascular disease inflammatory processes alone do not suffice and 
additional factors, probably lifestyle-related, are mandatory.
The pathogenesis of cardiovascular dis-
ease has long been described as an accu-
mulation of lipids in a dysfunctional en-
dothelial wall, driven by lifestyle-related 
factors such as smoking, dyslipidæmia, 
dysglycæmia, obesity, and hypertension. 
Since the end of the millennium, it has 
been commonly accepted that inflamma-
tory processes play a prominent role in 
atherosclerosis, reclassifying cardiovas-
cular disease as a chronic inflammatory 
disorder.1-3 Still, the exact balance between 
lifestyle and inflammation in its causality 
has remained unclear. There are both in-
dications of subendothelial lipid retention4 
and inflammation1 as being the primary 
causative factor.
The lifestyle-related risk factors are main-
ly present in western societies, which have 
experienced an epidemiologic and demo-
graphic transition. In these countries, car- 
diovascular disease is one of the major 
causes of morbidity and the most common 
cause of mortality. In developing coun-
tries, where these risk factors are absent, 
infectious diseases prevail.5 Without the 
public health care of western societies, 
infectious diseases are highly lethal. Se-
lectively those individuals that resist the 
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high infectious pressure by a strong in-
f lammatory response will survive, result-
ing in a population expressing a selectively 
proinflammatory immune system.6-10 If 
cardiovascular disease is an inflammato-
ry disease, it can be expected to be pro-
voked by such a proinflammatory status. 
Indeed, with the progressing control of 
lethal infectious diseases, cardiovascular 
pathology is becoming more frequent in 
developing countries, especially in sem-
ideveloped environments where a western 
lifestyle concurs with a high infectious 
load.5,11,12 Within western countries, the 
cardiovascular risk of migrants from de-
veloping countries remains elevated.12-14 
Inflammatory markers are used to predict 
cardiovascular risk.2,3 These figures rein-
force the dominant role of inflammation 
in cardiovascular pathogenesis. However, 
the occurrence of cardiovascular disease 
in the remote and rural regions of devel-
oping countries, where a high infectious 
load induces proinflammatory phenotypes 
but a western lifestyle is absent, has in-
frequently been studied.15-17 Knowledge on 
these data can further unravel the roles of 
lifestyle and inflammation as the origins 
of cardiovascular disease.
We have conducted a large population 
study in rural Ghana in West Africa. This 
study population has only recently started 
to experience an epidemiologic transition; 
the elderly form not only a subgroup that 
has survived the pretransitional past, but 
have also been exposed to a pretransition-
al environment during the largest part of 
their lives.18 Previous immunologic and 
genetic studies have shown this popula-
tion to exhibit a proinflammatory immune 
status.8-10 A previous study in a compara-
ble population of forager-horticulturalists 
in Bolivia provided a first indication of a 
low prevalence of cardiovascular disease 
in populations where a western lifestyle 
is uncommon.7 Our study population con-
cerns a purely horticultural population 
where lifestyle-related risk factors are 
even more exceptional. This study firstly 
extends previous observations with a de-
tailed assessment of cardiovascular health 
in a traditional African population, includ-
ing electrocardiography and ultrasound 
measurement of ankle-arm indexes.
Methods
Research area
The Upper East Region in Ghana is remote, 
rural, and one of the least developed re-
gions of the country. The vast majority of 
the inhabitants are involved in non-com-
mercial agriculture performed by manual 
labour.19 The yearly per capita income av-
erages US$ 135;20 88% of the households 
lives in poverty.21 Infectious diseases are 
the main causes of death.22
Since 2002, we have registered and fol-
lowed a traditional horticultural popula-
tion in the Garu-Tempane District in the 
Upper East Region occupying a research 
area of 375 km2 with approximately 25 000 
inhabitants living in 32 villages. Families 
are polygamous and live as extended fam-
ilies in compounds. Annual migration rel-
ative to the study population’s size was 2% 
into and 1% out of the research area.18 Hos-
pital care is absent; the nearest physician 
is at 40 kilometres’ distance. Vaccination 
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of children has recently been introduced. 
Sewage disposal systems are non-existent.
Life expectancy at birth is 59 years. Based 
on changes in age-specific mortality rates 
over time, we have shown epidemiologic 
transition in this population to have start-
ed only recently with declines in mortal-
ity rates at low ages. Generations aged 
50 years or more are unaffected by these 
changes and conform to a pretransitional 
pattern of survival.18
All inhabitants have been registered and of 
each are known the name, age, sex, tribe, 
and location of living. We determined the 
lifetime fertility, defined as the median 
number of born children per postrepro-
ductive woman, based on fertility data 
gathered in the research area in 2003.23 
For each household, we determined the 
household property value in 2007 accord-
ing to the Demographic and Health Survey 
method.24 In 2008, we determined the 
prevalences of infections by malaria spe-
cies by PCR of blood samples and those of 
infections by helminths and protozoa by 
PCR of stool samples.25 A more elaborate 
description of this cohort has been given 
elsewhere.18,23,24 This study was conducted 
within this cohort.
Ethical approval was given by the Ethical 
Review Committee of Ghana Health Ser-
vices, the Committee Medical Ethics of 
Leiden University Medical Center, and by 
the local chiefs and elders. Because of illit-
eracy, informed consent was obtained oral-
ly from the participants. A consent form 
was designed with an explanation on the 
purpose and conduction of this research 
project. This form was to be read out to 
each participant in his own language; 
consent was given verbally in the local 
language. Participation was only proceed-
ed after verbal consent of the participant. 
The full text of the form was approved by 
the Ethical Review Committee of Ghana 
Health Services.
Participants
Based on our demographic cohort registra-
tion up to 2009, we targeted all inhabitants 
aged 50 years and older, counting 2684 
individuals. We consecutively visited the 
villages in our research area during two 
field visits in 2009 and 2010 to approach 
the targeted inhabitants. Inclusion was re-
stricted by the duration of both field visits. 
To ensure maximal participation, we set 
up a mobile field work station in different 
villages and, if necessary, brought less mo-
bile participants by car. We included 924 
individuals, of whom 610 also underwent 
electrocardiographic measurement. Of the 
approached inhabitants, 4.4% could not 
participate due to death of the individual 
since the last registration, 3.2% refused 
participation, 2.8% was absent from the 
research area during our visit because of 
migration or travelling, and 4.2% did not 
participate for other reasons. At the sta-
tion, the identity of the participant was 
confirmed, the personal data in the cohort 
registration was checked, and clinical and 
electrocardiographic investigations were 
performed. In addition, blood plasma sam-
ples of 266 individuals were available from 
2008. On these, biochemical investiga-
tions were performed.
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Clinical measurements
Height and weight were measured by a 
calibrated length scale and weighing scale. 
Body mass index (BMI) was calculated as 
weight divided by squared height. Waist 
circumference was measured while stand-
ing by a measure tape at umbilical lev-
el. In a lying and resting position, blood 
pressure was measured at one arm using 
a calibrated sphygmomanometer and a 
Littman stethoscope. Hypertension was 
determined by these blood pressures and 
classified as stage I, stage II, or isolated 
systolic hypertension. Hypertension was 
defined as stage I for systolic blood pres-
sures of 140 to 160 mmHg and/or dias-
tolic blood pressures of 90 to 100 mmHg, 
as stage II for systolic blood pressures of 
160 mmHg onward and/or diastolic blood 
pressures of 100 mmHg onward, and as 
isolated systolic hypertension for systol-
ic blood pressures of 140 mmHg onward 
with diastolic blood pressures below 90 
mmHg.26 Systolic blood pressures were 
measured on the dorsalis pedis artery and 
the posterior tibial artery at both ankles 
using a calibrated sphygmomanometer and 
a Doppler ultrasound machine (ImexDOP 
CT+, Natus-Nicolet, Golden, CO, USA). As 
a measure of peripheral arterial disease, 
the ankle-arm index was calculated by di-
viding the average systolic pressure of both 
arteries of each ankle by the systolic arm 
pressure. An index below 0.9 of either an-
kle indicates peripheral arterial disease.27 
Glucose whole blood concentration was 
measured on a capillary blood sample from 
a finger (Accutrend Plus, Roche, Rotkreuz, 
Switzerland). Whole blood concentrations 
are circa 11% lower than plasma concentra-
tions.
Biochemical measurements
In 2008, venous blood samples were col-
lected in the morning, carried on ice, cen-
trifuged within four hours, after which 
plasma was kept frozen during storage and 
transportation at minimally -20 °C.9 Blood 
samples were analysed in our institution’s 
Central Laboratory for Clinical Chemistry. 
Circulating plasma levels were determined 
for triglycerides, total cholesterol, apolipo-
protein-B100 (apoB100), apolipoprotein-A1 
(apoA1), C-reactive protein (CRP), and 
interleukin-6 (IL6). Measurements of tri-
glycerides and total cholesterol were per-
formed with colorimetric assays (Modular 
P800, Roche, Rotkreuz, Switzerland), of 
apoB100, apoA1, and CRP with high-sensi-
tivity immunoturbidimetric assays (Cobas 
Integra, Roche, Rotkreuz, Switzerland), 
and of IL6 with sandwich chemilumines-
cent immunoassay (Evidence Investigator 
Biochip, Randox, Crumlin, UK). All bio-
chemical markers were measured in plas-
ma; these concentrations are circa 3% low-
er than serum concentrations.27 ApoB100 
is associated with low-density lipoprotein 
(LDL) cholesterol, apoA1 with high-den-
sity lipoprotein (HDL) cholesterol. The 
apoB100 concentration and the ratio of the 
concentrations of apoB100 over apoA1 are 
strongly predictive risk factors of cardio-
vascular disease.27 CRP and IL6 are proin-
flammatory markers.
Cutoff values for cardiovascular risk fac-
tors were derived from the standardly used 
guidelines of the Adult Treatment Panel 
III27 and the Joint National Committee on 
Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure.26 Other 
guidelines were used for criteria not in-
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cluded herein, including the concentration 
of apoB100 and the ratio of the concentra-
tions of apoB100 over apoA128 and the con-
centration of CRP.29 No commonly accept-
ed cutoff value is available for IL6.
Electrocardiographic measurements
A twelve-lead electrocardiogram (ECG) 
was recorded for twenty seconds in a lying 
and resting position (AT-104 PC, Schil-
ler, Baar, Switzerland). All ECGs were 
assessed by an experienced cardiologist 
according to the Minnesota criteria.30 The 
cardiologist was blinded for the partici-
pants’ characteristics other than age and 
sex. The ECGs were classified for indica-
tions of myocardial infarction, being ab-
sent, possibly, or definitively present and 
for myocardial ischæmia-like changes, be-
ing absent, minor, or major. For both, the 
localisations were classified, being anteri-
or, septal, inferior, and/or lateral. Merely 
anteriorly localised ischæmia-like changes 
were excluded from the analyses (6.4%), as 
these are reported to be little specific in 
African ethnicities.31-33 Indications of defi-
nite infarction included major and moder-
ate pathological Q waves and QS patterns 
(codes 1-1 and 1-2). Indications of possible 
infarction included minor pathological Q 
waves and QS patterns (code 1-3). Definite 
ischæmia-like changes included major ST 
depression, T wave inversion, and ST el-
evation (codes 4-1, 4-2, 5-1, 5-2, and 9-2). 
Minor ischæmia-like changes included mi-
nor ST depression, T wave inversion, and 
complete left bundle branch block (codes 
4-3, 4-4, 5-3, 5-4, and 7-1).
Reference populations
We compared the findings from our tradi-
tional African study population with those 
of western populations. As reference pop-
ulations, we used three population-based 
studies in the United States and Europe 
for individuals at ages from 45 or 50 years. 
Data on the general population in the Unit-
ed States were derived from the National 
Health and Nutrition Examination Survey 
(NHANES) for the prevalences of elec-
trocardiographically measured coronary 
arterial disease (n = 6201, median age 
63 years, 45.3% men),34 the prevalence of 
peripheral arterial disease measured by 
ankle-arm index (n = 1868, median age 61 
years, 48.4% men), the prevalence of hy-
pertension (n = 2135, median age 62 years, 
46.6% men), and the distributions of car-
diovascular risk factors and inflammatory 
markers (n = 2323, median age 62 years, 
46.1% men).35 Data on the general Europe-
an population were derived from a study 
in Belgium for the prevalences of electro-
cardiographically measured coronary ar-
terial disease (n = 29 419, median age 52 
years, 77.7% men)36 and from the CoLaus 
Study in Switzerland for the prevalence of 
hypertension and the distributions of car-
diovascular risk factors and inflammatory 
markers (n = 3515, median age 61 years, 
45.4% men).37,38 In the cases of Belgian 
prevalences of electrocardiographic ab-
normalities and the Swiss distribution of 
IL6, only sex-split data were available. For 
comparability, both were graphically dis-
played as averages weighed by the number 
of individuals per sex. For the reference 
populations, the use of antihypertensive 
medication was included in the definition 
of hypertension, the use of antidiabetic 
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medication was included in the definition 
of diabetes, and the use of antidyslip-
idæmic medication was included in with-
in the definition of elevated levels of total 
cholesterol or LDL cholesterol. Otherwise, 
applied definitions and cutoff values were 
identical as described for our study.
Analyses
Confidence intervals were calculated by 
Wilson’s formula for prevalences and using 
the binomial distribution for medians. In-
dividual associations of presence of cardi-
ovascular disease with cardiovascular risk 
factors, inflammation, and socioeconomic 
status were tested by logistic regression 
analysis, including age and sex as depend-
ent variables. Statistical analyses were 
performed with PASW Statistics 18 (SPSS, 
Chicago, IL, USA).
Results
Table 9.1 provides a description of the de-
mographic, socioeconomic, and infectious 
characteristics of the study population that 
participated in the electrocardiographic 
investigations. The overrepresentation of 
women and a heightened socioeconomic 
status compared with the total cohort pop-
ulation are results of the selection on age. 
Otherwise, the baseline characteristics of 
the study population that participated in 
the electrocardiographic investigations 
were similar to those of the study popula-
tions that participated in the clinical and 
biochemical investigations as well as to 
those throughout the total cohort popula-
tion.
Table 9.1 • General characteristics of the Ghanaian study population
Number of individuals 610
Men, n (%) 169 (27.5)
Age, years 66 (56–74)
Lifetime fertility, children per woman 7 (6–9)
Number of households 422
Household property value, US$ 1050 (500–1936)
Indidivuals infected by, %
     malaria species 77.5
     helminths 21.4
     protozoa 100.0
Data are presented as medians with interquartile ranges unless specified otherwise. The 
characteristics are given for the study population aged 50 years and older that participat-
ed in the electrocardiographic investigations. Lifetime fertility is expressed as the number 
of born children per woman aged 45 years or more.
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Cardiovascular risk factors
Table 9.2 summarises the clinical and bi-
ochemical investigations for the detection 
of cardiovascular risk factors concerning 
body size, blood pressure, glucose metabo-
lism, lipid metabolism, and inflammation. 
Hypertension was classified as stage I, 
stage II, or isolated systolic hypertension. 
Plasma glucose concentrations were used 
to detect elevated cardiovascular risk from 
5.6 mmol/l onward and to detect diabetes 
mellitus from 7.0 mmol/l onward.27 The 
balance between HDL and LDL cholesterol 
was represented by the ratio of the plasma 
concentrations of apoB100 over apoA1. As 
markers of the inflammatory status, plas-
ma concentrations of CRP and IL6, both 
proinflammatory cytokines, were used. In 
our study population, median levels of car-
diovascular risk factors were low and prev-
alences of obesity, hypertension, dysgly-
cæmia or diabetes, and dyslipidæmia were 
low. The prevalence of moderately elevated 
levels of CRP was low.
In Figure 9.1, the distributions of cardio-
vascular risk factors in our study popula-
tion are compared with those in the west-
ern reference populations. Over the age of 
50 years in Ghana, lower median values 
or prevalences were found for all cardio-
vascular risk factors describing body size, 
blood pressure, and glucose and lipid me-
tabolism compared with the United States 
and Europe. For the inflammatory mark-
ers, median levels of CRP were lower, but 
levels of IL6 were higher.
Cardiovascular disease
Table 9.3 shows the prevalences of car-
diovascular disease in our study popu-
lation. We used electrocardiography to 
detect coronary arterial disease, classi-
fied as possible or definite myocardial 
infarction and minor or definite myocar-
dial ischæmia-like changes. Prevalences 
of myocardial infarction and myocardial 
ischæmia-like changes were low. We used 
measurement of ankle-arm index to detect 
peripheral arterial disease, defined as an 
ankle-arm index below 0.9 of either leg. 
The prevalence of peripheral arterial dis-
ease was low; median ankle-arm indexes 
were high.
As shown in Figure 9.2, the prevalences of 
both coronary and peripheral arterial dis-
ease in Ghana were lower compared with 
the western reference populations, using 
identical clinical and electrocardiographic 
criteria. A similar pattern was found for 
myocardial ischæmia-like changes. Moreo-
ver, Ghanaian prevalences of coronary and 
peripheral arterial disease increased less 
with age.
Individual associations
For the individuals affected by cardiovas-
cular disease, no associations could be 
found with cardiovascular risk factors, in-
f lammation, or socioeconomic status.
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Table 9.2 • Cardiovascular risk factors in the Ghanaian study population
Men Women
Clinical measurements (n = 480) (n = 444)
Waist circumference, cm 77 (73–81) 76 (72–80)
     ≥ 102 (♂) or ≥ 88 (♀) cm 0.0 (0.0 to 0.8) 7.4 (5.3 to 10.3)
Body mass index, kg/m2 18.1 (16.5–19.4) 18.1 (16.6–19.7)
     ≥ 25.0 kg/m2 0.2 (0.0 to 1.2) 1.4 (0.6 to 2.9)
Diastolic blood pressure, mmHg 75 (70–80) 70 (65–75)
Systolic blood pressure, mmHg 120 (110–135) 120 (110–135)
Hypertension
     Stage I 16.7 (13.6 to 20.3) 13.7 (10.8 to 17.3)
     Stage II 9.0 (6.7 to 11.9) 8.8 (6.5 to 11.8)
     Isolated systolic 15.7 (12.7 to 19.2) 16.2 (13.1 to 19.9)
Glucose, mmol/l 3.8 (3.3–4.4) 4.0 (3.6–4.5)
     ≥ 5.6 mmol/l 6.0 (4.3 to 8.6) 6.3 (4.5 to 9.1)
     ≥ 7.0 mmol/l 1.0 (0.4 to 2.4) 1.4 (0.6 to 3.0)
Biochemical measurements (n = 94) (n = 172)
Triglycerides, mmol/l 0.80 (0.68–0.95) 0.95 (0.76–1.21)
     ≥ 1.7 mmol/l 4.3 (1.7 to 10.4) 6.4 (3.6 to 11.1)
Total cholesterol, mmol/l 3.04 (2.49–3.51) 3.24 (2.81–3.74)
     ≥ 5.2 mmol/l 1.1 (0.2 to 5.8) 1.7 (0.6 to 5.0)
ApoB100, g/l 0.54 (0.47–0.64) 0.58 (0.49–0.69)
     ≥ 0.9 g/l 2.1 (0.6 to 7.4) 2.9 (1.3 to 6.7)
Ratio of apoB100 over apoA1 0.58 (0.45–0.68) 0.52 (0.43–0.66)
     ≥ 0.9 (♂) or ≥ 0.8 (♀) 5.3 (2.3 to 11.9) 12.8 (8.7 to 18.7)
C-reactive protein, mg/l 1.06 (0.34–3.77) 0.95 (0.44–2.35)
     3.0–10.0 mg/l 19.1 (12.5 to 28.3) 11.6 (7.7 to 17.3)
Interleukin-6, ng/l 2.28 (1.47–3.23) 1.84 (1.37–2.42)
Distributions are given as medians with interquartile ranges, prevalences are given as per- 
centages with 95% confidence intervals describing the proportion meeting the indicated 
cutoff value, all for those aged 50 years and older. Hypertension was classified as stage I 
for diastolic blood pressures of 90 to 100 mmHg and/or systolic blood pressures of 140 to 
160 mmHg, as stage II for diastolic blood pressures from 100 mmHg onward and/or sys-
tolic blood pressures from 160 mmHg onward, and as isolated systolic for systolic blood 
pressures from 140 mmHg onward with diastolic blood pressures lower than 90 mmHg. 
ApoA1: apolipoprotein-A1. ApoB100: apolipoprotein-B100.
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Figure 9.1 • Age patterns of cardiovascular risk factors in the Ghanaian study 
population compared with those in the American and European reference pop-
ulations. Distributions are given as medians. Prevalences of hypertension are given 
as percentages, including stage I, stage II, and isolated systolic hypertension. Values 
for age represent midpoints of age intervals, because of different age groups used in 
the reference populations. Europ.: Europeans. Amer.: Americans. Ghan.: Ghanaians.
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Discussion
This study aims to determine cardiovascu-
lar health in a traditional rural population 
in Ghana in West Africa from the age of 
50 years onward. The study population is 
demographically and economically charac-
terised by an underdeveloped pretransito-
ry status relative to western countries. In 
this adverse environment, individuals are 
exposed to a high infectious load, favour-
ing survival of those with a proinflam-
matory immune status. Compared with 
American and European populations, we 
found common proinflammatory profiles, 
but low prevalences of cardiovascular risk 
factors associated with a western lifestyle, 
including obesity, hypertension, dysg-
lycæmia or diabetes, and dyslipidæmia. 
In this population, prevalences of coro-
nary and peripheral arterial disease as 
measured by electrocardiography and an-
kle-arm index were correspondingly low.
For some cardiovascular risk factors no 
formal determination was possible, in-
cluding smoking behaviour, alcohol use, 
diet composition, and lack of physical 
exercise. Tobacco is self-grown and beer 
is self-brewed. The availability of both is 
dependent on the harvest, as commercial 
distribution of cigarettes and alcoholic 
beverages is locally absent. Their regular 
use is more or less a social taboo. Based 
on our long-lasting experiences, regular 
smoking and drinking among men is com-
mon, estimated to concern one third and 
two thirds of the population, respectively, 
but the quantities are likely to be limited 
when compared with developed countries. 
Women do not publicly smoke or drink, but 
we presume women to exhibit these be-
haviours privately in smaller proportions. 
Physical inactivity is exceptional and 
western diet is absent. It should be noted 
that most inhabitants in the research area 
provide for their own living by non-com-
Table 9.3 • Cardiovascular disease in the Ghanaian study population
Men Women
Electrocardiographic measurements (n = 168) (n = 439)
Myocardial infarction
     definite 1.8 (0.6 to 5.1) 0.9 (0.4 to 2.3)
     possible 4.2 (2.0 to 8.4) 2.1 (1.1 to 3.8)
Myocardial ischæmia-like changes
     definite 13.7 (9.3 to 19.7) 10.0 (7.6 to 13.2)
     minor 2.4 (0.9 to 6.0) 3.2 (1.9 to 4.6)
Clinical measurements (n = 480) (n = 444)
Ankle-arm index 1.16 (1.10–1.24) 1.14 (1.06–1.22)
Peripheral arterial disease 2.3 (1.3 to 4.1) 3.4 (2.1 to 5.5)
Prevalences are given as percentages with 95% confidence intervals) and distributions are 
given as medians with interquartile ranges, all for those aged 50 years and older. Periph-
eral arterial disease was defined as an ankle-arm index below 0.9.
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Figure 9.2 • Age patterns of cardiovascular disease in the Ghanaian study sample 
compared with those in the American and European reference populations. Prev-
alences are given as percentages. Peripheral arterial disease was defined as an ankle-arm 
index below 0.9. Definite myocardial infarction was detected by electrocardiography. Val-
ues for age represent midpoints of age intervals, because of different age groups used for 
the reference populations.
mercial agriculture performed by manual 
labour. The scarcity of electricity and ma-
chinery necessitates physical exercise for 
farming and housekeeping. Transportation 
is almost always by foot or bicycle. The sa-
vannah climate is dry with only one rainy 
season of variable duration, hindering ag-
riculture. The limited variety of crops that 
can be grown in this environment — such 
as millet, corn, okra, beans, onions, and 
tomatoes — and the omnipresent low social 
economic standard restrict the ingestion of 
fat and glucose. Commercial distribution 
of conserved food has remained financially 
unattainable for most.
Although the prevalence of cardiovascular 
disease was low, cardiovascular disease 
was not absent in our study population. 
This indicates that low prevalences of 
obesity, dysglycæmia or diabetes, and 
dyslipidæmia do not entirely prevent the 
occurrence of cardiovascular disease. 
The presence of hypertension is relatively 
uncommon, but still present in about one 
fifth of the population. It may be relatively 
important for cardiovascular pathogene-
sis in this population. Moreover, some do 
smoke and drink, but the consumption 
and attribution are difficult to estimate. 
Other factors independent of lifestyle, such 
as genotype, may also render individuals 
susceptible. In line with this, for those few 
who are affected, we have been unable to 
find any association with the cardiovascu-
lar risk factors as measured in this study. 
In this study, genotypes have not been as-
sessed. Recently, we have collected mouth 
swabs in our study population for genetic 
analyses in future research.
Previous research on risk factors of cardio-
vascular disease has shown that in Africa, 
equal to western populations, cardiovas-
cular disease can be mainly attributed 
to obesity, dysglycæmia, dyslipidæmia, 
smoking, and hypertension.11-13 Pathoge-
netic mechanisms have been described by 
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which lifestyle-related risk factors drive 
cardiovascular disease.4,40 However, these 
studies are based on urban regions with 
westernised risk profiles. Data from popu-
lations without a western lifestyle, as our 
study population, are needed to confirm 
that these lifestyle-related risk factors are 
primarily responsible for cardiovascular 
disease to develop.
In our study population, all individuals 
were infected by protozoa, while infec-
tions by helminths and malaria species 
were highly endemic. This high infec-
tious load, together with little public and 
personal hygiene and little medical care, 
renders infectious diseases as the main 
cause of death. Previously, we have shown 
that selectively those individuals that ex-
press a proinflammatory immune system 
survive up to older ages.8-10 This selection 
of a proinflammatory status is confirmed 
by the higher levels of the proinflamma-
tory cytokine IL6 in our study population 
compared with western populations. Dif-
ferent from IL6, we found lower levels of 
the inflammatory marker CRP in our study 
population compared with western pop-
ulations. Plasma levels of CRP are highly 
elevated during acute infections. During 
chronic, subclinical infections, CRP levels 
may not be elevated. In populations en-
demic for infections by malaria and hel-
minth species, these levels can be rather 
within the normal range.41-43 Probably, in 
these instances, a systemic inflammatory 
response is not elicited, as the immune 
system has become effectively able to re-
strain the pathogens or has become toler-
ant. Distinctive to chronic infections, how-
ever, chronic non-infectious inflammatory 
disorders are associated with moderately 
elevated levels of CRP.29 Likely, instead of 
being a risk factor, these moderately ele-
vated levels are an effect of the pathophys-
iological inflammatory processes and thus 
a marker of cardiovascular disease.44-46 In 
line with this, we found less moderately 
elevated levels in our study population 
compared with western populations. Sim-
ilar results have been obtained in other 
developing populations with high rates 
of infectious diseases in Southern Amer-
ica.47,48 The comparisons of CRP and IL6 
levels with those in western populations 
are consistent when using other reports 
from western populations.49,50
Although we show that inflammation alone 
is not sufficient to cause cardiovascular 
disease, inflammation still plays a major 
role in its pathogenesis. This is reflected by 
the high prevalences of cardiovascular dis-
ease in regions where a western lifestyle co-
incides with a high infectious load.5,11-13 In 
addition, migrants from developing regions 
are affected by cardiovascular disease in 
western populations at younger ages and 
with higher mortality.11-14 These popula-
tions are likely to have developed a proin-
flammatory immune status and are there-
by probably more susceptible to develop 
inflammatory disease, such as cardiovas-
cular disease. Even in developed countries, 
such predisposing processes can be effec-
tuated through adverse environmental 
conditions.51,52 These notions are support-
ed by the observation of higher levels of 
CRP in African Americans compared with 
European Americans50,53 and the beneficial 
effects of antidyslipidæmic therapy in indi-
viduals with elevated CRP.54
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This study has several limitations. First, 
for the registration of glucose and lipid 
parameters, blood samples have been tak-
en in the morning. Although breakfast is 
uncommon, participants have not been 
requested to fast. Observed glucose and 
triglyceride levels could have been over-
estimated in this population and fasted 
values could be even lower than reported 
here. This reinforces the present interpre-
tation of the study. Second, we have not 
been able to cover all cardiovascular risk 
factors, leaving smoking, alcohol use, diet 
composition, physical exercise, and genetic 
factors. Third, because of selection on age, 
women are overrepresented, demanding 
some prudence in the interpretation of the 
data for men.
Electrocardiographic criteria are reliable 
for the distinction of myocardial infarc-
tion. However, myocardial ischæmia-like 
changes are less distinctive.36 Apart from 
coronary arterial disease, other disorders 
can effectuate these changes in repolari-
sation.33 Moreover, in African ethnicities, 
these changes in repolarisation are little 
specific for coronary arterial disease.31,32,55 
Therefore, true prevalences of cardiovas-
cular disease might be even lower than 
reported in this study. Unknown as well 
remain possible confounding selective 
processes. In our study population, the 
mortality due to cardiovascular disease 
is undetermined. If high, those affected 
could have deceased before being detected. 
When a selection exists for physically fit 
individuals to survive, those prone to de-
velop cardiovascular disease might not live 
to older ages. However, these suppositions 
are contradicted by our observation of the 
few cases that were found with a slightly 
increasing trend with age.
This study determines the population-wide 
prevalences of peripheral and coronary 
arterial disease in a traditional African 
population by measurement of ankle-arm 
index and electrocardiography. These 
prevalences have not been described ear-
lier for developing populations without 
a western lifestyle in relation to lifestyle 
and inflammation. First, this knowledge 
is of importance for underdeveloped pop-
ulations themselves to guide preventive 
and curative policies. Worldwide, the 
prevalence of cardiovascular disease is 
rapidly increasing, especially in devel-
oping regions parallel to urbanisation 
and westernisation.11,12 As we show, also 
in these regions, it can be worthwhile to 
emphasise on the research and preven-
tion of lifestyle-related risk factors for the 
control of cardiovascular disease. Second, 
this knowledge is of equal importance 
for western societies. Of today’s African 
Americans, a large majority is genetically 
related to traditional populations in West 
Africa.39 Predominantly these and other 
migrant populations suffer from a burden 
of cardiovascular disease, even after life-
long residence in western society.11-14 It re-
mains unclear to what extent this disparity 
can be explained by biological, socioeco-
nomic, and cultural differences. Possibly, 
these ethnicities have been programmed 
through selection or through development 
to be more proinflammatory. Nonetheless, 
our study confirms that preventive and cu-
rative policies may be expected to be suc-
cessful when addressing particular aspects 
of lifestyle.
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In conclusion, we have shown that in a tra-
ditional non-western African population, 
despite promotion of inflammation, car-
diovascular disease infrequently develops 
because of low prevalences of lifestyle-re-
lated cardiovascular risk factors compared 
with American and European popula-
tions. Together, these results indicate that 
cardiovascular disease is not primarily 
caused by inflammatory processes, but a 
western lifestyle is a prerequisite for its 
development. This provides even further 
arguments to prioritise the promotion of a 
healthy lifestyle, both in developed and in 
developing countries.
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Background • In western societies, atrial fibrillation is an increasingly 
common finding among the elderly. Established risk factors of atrial fibril-
lation include obesity, diabetes, hypertension, and cardiovascular disease. 
Atrial fibrillation has almost exclusively been studied in western popula- 
tions where these risk factors are widely present. Therefore, we studied 
the epidemiology of atrial fibrillation in a traditional African population.
Methods • In rural Ghana, among 924 individuals aged 50 years and old-
er, we recorded electrocardiograms to detect atrial fibrillation. As estab-
lished risk factors, we documented waist circumference, body mass index 
(BMI), capillary glucose level, blood pressure, and electrocardiographic 
myocardial infarction. In addition, we determined circulating levels of inter- 
leukin-6 (IL6), a proinflammatory cytokine, and C-reactive protein (CRP), 
a marker of systemic inflammation. We compared the risk factors with 
reference data from the general population of the USA.
Results • Atrial fibrillation was detected in only three cases, equalling 0.3% 
(95% CI: 0.1 to 1.0). Waist circumference, BMI, and capillary glucose levels 
were very low. Hypertension and myocardial infarction were uncommon. 
Circulating levels of IL6 were similar, but those of CRP were lower com-
pared with the USA.
Conclusion • Atrial fibrillation is very scarce in this traditional African popu- 
lation. Its low prevalence compared with western societies can be explained 
by the rareness of its established risk factors, which are closely related 
to lifestyle, and by possible unmeasured differences in other risk factors 
or genetic factors.
Atrial fibrillation is a common finding 
among elderly in western societies. Its pre- 
valence increases with age and mounts to 
10 to 20% after the age of 80 years.1,2 Due 
to ageing of western populations and im-
proved survival from other cardiovascular 
disorders, the prevalence of atrial fibrilla-
tion has grown over time and is expected 
to continue growing. As it leads to a height- 
ened risk of thromboembolism, cerebro-
vascular accidents, and congestive heart 
failure, its public health burden has grown 
concurrently.3,4
The majority of the cases of atrial fibril-
lation can be attributed to the established 
risk factors obesity, diabetes, hyperten-
sion, prior cardiac disease, and smoking. 
Hypertension is the most important of 
these, responsible for at least one fifth of 
the cases.5,6 Still, questions remain about 
the pathogenesis of atrial fibrillation. It is 
postulated that, next to these risk factors, 
inflammation plays an important role in 
the pathogenesis of atrial fibrillation, but 
this has not yet been confirmed.1,7 Moreo-
ver, it is not clearly understood why atrial 
fibrillation is less commonly detected in 
African Americans, while they are more 
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often affected by obesity, diabetes, and hy-
pertension than European Americans.5,8,9 
However, the epidemiology of atrial fibril-
lation has been studied almost exclusively 
in western societies,1,3 where obesity, diabe-
tes, hypertension, cardiovascular disease, 
and systemic inflammation are widely 
present among the elderly.10 Little is known 
about the prevalence of atrial fibrillation 
in non-western societies, such as in rural 
Africa.11,12 Knowledge about the risk of atri-
al fibrillation in the context of different 
environmental and genetic influences may 
provide more insight in its pathogenesis.13
This study investigates the epidemiology 
of atrial fibrillation in a traditional ru-
ral African population where a sedentary 
lifestyle is absent. We used electrocardi-
ography to detect atrial fibrillation among 
inhabitants aged 50 years and older. Es-
tablished risk factors of atrial fibrillation 
have been documented, such as obesity, 
dysglycæmia, hypertension, and myocar-
dial infarction. Circulating levels of in-
terleukin-6 were measured as a marker of 
proinflammatory immune activation and 
circulating levels of C-reactive protein as a 
marker of systemic inflammation.
Methods
Research area
The Upper East Region is remote, rural, 
and one of the least developed regions of 
Ghana. The vast majority of the inhabitants 
is involved in non-commercial agriculture 
performed by manual labour.14 The year-
ly per capita income averages US$ 135;15 
88% of the households lives in poverty.16 
Infectious diseases are the main causes of 
death.17
Since 2002, we have registered and fol-
lowed a traditional horticultural popu-
lation in the Garu-Tempane District in 
the Upper East Region. This population 
occupies a research area of 375 km2 with 
approximately 25 000 inhabitants living 
in 32 villages. Annual migration relative to 
the study population’s size was 2% into and 
1% out of the research area.18,19 Hospital 
care is absent; the nearest physician is at 
40 kilometres’ distance. Sewage disposal 
systems are non-existent.
All inhabitants have been registered in a 
demographic database, including the name, 
age, sex, tribe, and household. We have 
determined the lifetime fertility, defined 
as the total number of children born per 
postreproductive woman aged 45 years 
or more, based on fertility data gathered 
in the research area in 2003.19 For each 
household, we have determined the house-
hold property value in 2007 according 
to the Demographic and Health Survey 
method.14 In 2008, we have determined 
the prevalences of infections by malaria 
species by PCR of blood samples and those 
by helminths and protozoa by PCR of stool 
samples.20 A more elaborate description of 
this cohort has been given elsewhere.14,18,19
Ethical approval was given by the Ethi-
cal Review Committee of Ghana Health 
Service, the Committee Medical Ethics 
of Leiden University Medical Center, and 
by the local chiefs and elders. Because of 
illiteracy, informed consent was obtained 
orally from the participants. A consent 
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form with an explanation on the purpose 
and conduction of this research project 
was read out to each participant in his own 
language. The full text of the form was ap-
proved by the Ethical Review Committee 
of Ghana Health Service.
Participants
Within the registered population, we 
aimed to estimate the prevalences of atri-
al fibrillation and its risk factors among 
individuals aged 50 years and older. For 
this, we set up a mobile field station in 
different villages during two field visits in 
2009 and 2010. From here, all eligible in-
habitants were approached. Inclusion was 
limited by the duration of the field visits. 
To ensure maximal participation and to 
avoid selective inclusion of healthy elderly, 
we brought less mobile participants by car. 
Of the approached inhabitants, 4.4% could 
not participate due to death since the last 
registration, 3.2% refused participation, 
2.8% was absent from the research area 
during our visit because of migration or 
travelling, and 4.2% did not participate for 
other reasons.
At the field work station, the identity of the 
participant was confirmed, the personal 
data in our registration were checked, and 
clinical and electrocardiographic meas-
urements were performed. In addition, 
blood plasma samples were available of 
266 individuals randomly selected across 
age groups in 2008. On these samples bi-
ochemical measurements were performed.
Electrocardiographic measurements
A twelve-lead electrocardiogram was re-
corded twice for ten seconds in a lying and 
resting position (AT-104 PC, Schiller, Baar, 
Switzerland). All electrocardiograms were 
assessed by an experienced cardiologist 
according to the Minnesota criteria. The 
cardiologist was blinded for the partici-
pants’ characteristics other than age and 
sex. A subset of the electrocardiograms (n 
= 610) was assessed for myocardial infarc-
tion.21 The heart rate was described using 
both recordings. Bradycardia was defined 
as a sinus rhythm below 60/min on either 
recording. Tachycardia was defined as a si-
nus rhythm over 100/min on either record-
ing. The electrocardiograms were classi-
fied as whether or not displaying atrial 
fibrillation or atrial f lutter (codes 8-3-1, 
8-3-2, 8-3-3, and 8-3-4).
Clinical and biochemical measurements
We performed clinical measurements on 
those participating in the electrocardiogra- 
phic measurements. We measured height, 
weight, waist circumference, glucose capil-
lary blood concentration, and blood pres-
sure. Body mass index (BMI) was calcu-
lated as weight divided by squared height 
(kg/m2). Hypertension was defined as a 
systolic blood pressure of 140 mmHg or 
higher and/or a diastolic blood pressure of 
90 mmHg or higher.22 We performed bio-
chemical measurements on venous blood 
samples to measure circulating plasma 
levels of interleukin-6 (IL6) and C-reactive 
protein (CRP).23
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Reference population
To compare our results with a western pop-
ulation, we derived data on the prevalences 
of the risk factors of atrial fibrillation from 
studies performed in the general popula-
tion of the USA. Age and ethnicity-specific 
distributions of BMI and CRP and the prev-
alence of hypertension were derived from 
the National Health and Nutrition Exam-
ination Survey (NHANES) performed in 
1999-2000.24 For the USA, the definition 
of hypertension was extended to include 
individuals using antihypertensive medi-
cation. Distributions of IL6 for European 
and African Americans of 65 years of age 
or older were derived from a publication by 
Cohen and colleagues.25
Analyses
Prevalences of atrial fibrillation were cal-
culated as the number of cases divided by 
the total number of inhabitants per 10-year 
age group and given as percentages. Confi-
dence intervals were calculated using Wil-
son’s formula for prevalences and using the 
Number of individuals 924
Men, n (%) 480 (51.9)
Age, years 66 (56–73)
Age groups, n (%)
     50–59 years 307 (33.2)
     60–69 years 291 (31.5)
     70–79 years 242 (26.2)
     80+ years 84 (9.1)
Lifetime fertility, children per woman 7 (6–9)
Number of households 636
Household property value, US$ 1077 (533–1942)
Waist circumference, cm 76 (72–81)
Body mass index, kg/m2 18.1 (16.5–19.5)
Capillary glucose, mmol/l 3.9 (3.4–4.4)
Blood pressure, mmHg
     diastolic 70 (65–80)
     systolic 120 (110–135)
Hypertension, % 24.2
Myocardial infarction, % 1.2
Individuals infected by, %
     malaria species 77.7
     helminths 21.5
     protozoa 100.0
Interleukin-6, ng/l 1.9 (1.4–2.7)
C-reactive protein, mg/l 1.0 (0.4–2.7)
Table 10.1 • General 
characteristics of the 
Ghanaian study pop-
ulation. Data are pre-
sented as medians with 
interquartile ranges un-
less specified otherwise. 
Lifetime fertility was de-
termined in women aged 
45 years or more. Hyper-
tension was defined as a 
systolic blood pressure of 
140 mmHg or higher and/
or a diastolic blood pres-
sure of 90 mmHg or high-
er. Myocardial infarction 
represents electrocardio- 
graphically detected defi- 
nite myocardial infarction 
determined in 610 indi-
viduals. Infections were 
determined in 261 indi- 
viduals of whom blood 
and stool samples were 
available. Circulating lev-
els of interleukin-6 (IL6) 
and C-reactive protein 
(CRP) were measured in 
venous plasma samples 
of 266 individuals.
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binomial distribution for medians. Statis-
tical analyses were performed with SPSS 
Statistics 20 (IBM, Armonk, NY, USA).
Results
Table 10.1 provides a description of the 
demographic characteristics, the estab-
lished risk factors of atrial fibrillation, and 
infectious and inflammatory markers for 
the Ghanaian study population aged 50 
years and older. In the study population, 
the prevalences and levels of the estab-
lished risk factors, including obesity, dys-
glycæmia, hypertension, and myocardial 
infarction, were very low. The levels of the 
inflammatory markers IL6 and CRP are 
described. Infectious diseases were highly 
prevalent. These characteristics were sim-
ilar between the entire registered popula-
tion, the study population selected for the 
electrocardiographic and clinical meas-
urements, and the subpopulation in which 
the biochemical measurements were per-
formed, except for minor differences in the 
distributions of age and sex. The similari-
ties remained after stratification by sex.
Electrocardiograms were obtained from 
921 participants, of whom 479 were men 
(52.0%). The median (with interquartile 
range) heart rate was 71 (63–80) per min-
ute. Sinus bradycardia and tachycardia 
were present in 159 (17.3%) and 32 (3.5%) 
individuals.
Figure 10.1 compares the age-specific 
prevalences of atrial fibrillation with those 
in the USA. Of 921 participants, three in-
dividuals had atrial fibrillation, equalling 
0.3% (95% CI: 0.1 to 1.0). Compared with 
both European and African Americans, 
prevalences of atrial fibrillation were very 
low in the Ghanaian study population.
Table 10.2 shows characteristics of the 
three cases with atrial fibrillation in the 
Ghanaian study population. Of these 
three, one was woman and two were men. 
The first two were affected by hyperten-
sion. The third case was a smoker. Only for 
the latter case inflammatory markers were 
known; compared with the entire study 
population as well as the USA, these levels 
were low for both IL6 and CRP.
Figure 10.2 compares the distributions 
over age of the most important established 
risk factors of atrial fibrillation and com-
pares the levels of the inflammatory mark-
ers with known distributions and levels 
Figure 10.1 • Atrial fibrillation in the 
Ghanaian study population and the 
USA. Age-specific prevalences are given 
as percentages with 95% confidence in-
tervals. Ages represent midpoints of age 
intervals. As references, prevalences are 
given for European and African Americans 
in the general population of the USA.
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in the USA, separated for European and 
African Americans. The levels of BMI and 
hypertension in the Ghanaian study popu-
lation were lower than those of both Euro-
pean and African Americans. The levels of 
IL6 were comparable with, but the levels of 
CRP were lower than those of both Euro-
pean and African Americans.
Discussion
In this study we showed that atrial fibril-
lation was very scarce after the age of 50 
years in a traditional rural population in 
Africa. The near absence of atrial fibrilla-
tion in the Ghanaian study population con-
firms the low prevalences that have been 
found by a few studies in other traditional 
African populations. In rural Tanzanians 
aged 70 years and older, its prevalence was 
0.7%.11 In the South African Bantu popu-
lation, atrial fibrillation was detected in 
0.2% of patients attending a cardiac clinic 
but not diagnosed with cardiac disease.26 
In patients from the Bantu population hos-
pitalised because of cardiac failure, it was 
present in 12%.27
The prevalence of atrial fibrillation in ur-
ban African populations is higher than 
those in rural African populations. In a 
South-African study covering both urban 
and rural communities, atrial fibrillation 
was detected in 2% of Africans over the 
age of 30 years.28 In two large cardiologic 
hospitals, 4.6% and 5.5% of the admitted 
patients had atrial fibrillation at relatively 
low ages.29,30 Among cardiologic hospitals 
across several Sub-Saharan African coun-
tries, atrial fibrillation was found in 18% of 
cases with acute heart failure.31
The prevalence of atrial fibrillation in 
western populations is higher than those in 
rural African populations. Several studies 
in patient populations and the general pop-
ulations of the USA and Western Europe 
have reported its prevalence to rise from 
less than 2% around the age of 50 years up 
to 10 to 20% after the age of 80 years.1 In 
the general population of the USA, similar 
increases with age have been described for 
both European and African Americans.2
The low prevalence of atrial fibrillation 
in rural African populations compared 
Table 10.2 • Characteristics of the three cases with atrial fibrillation in the Ghana-
ian study population
Case Sex Age HR RR BMI Gluc Smok Isch Infa SES
1 ♀ 76 104 140/85 21.8 3.2 – – – 420
2 ♂ 76 80 165/80 17.5 3.1 – – – 530
3 ♂ 76 104 125/80 19.1 3.8 + – – 1030
HR: ventricular heart rate (/min). RR: systolic/diastolic blood pressure (mmHg). BMI: 
body mass index (kg/m2). Smok: smoking. Gluc: capillary blood glucose concentration 
(mmol/l). Isch: electrocardiographic myocardial ischæmia-like repolarisation abnormali-
ties. Infa: electrocardiographic infarction. SES: household value (US$). Smok, Isch, and 
Infa, are designated as present (+) or absent (–).
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with urban African and western popula-
tions can be explained by a similarly lower 
prevalence of its established risk factors, 
including obesity, diabetes, hypertension, 
and cardiovascular disease. These risk 
factors are closely related to a sedentary 
lifestyle.5,10 With the transition, urbanisa-
tion, and ageing of African populations, a 
sedentary lifestyle is adopted and the prev-
alence of atrial fibrillation rises.12,30
Interestingly, cases of atrial fibrillation de-
scribed in African populations are accom-
panied by underlying cardiac disorders in 
Figure 10.2 • Risk factors of atrial fibrillation in the Ghanaian study population 
and the USA. As established risk factors, the distribution of body mass index (BMI) is 
given as age-specific median levels and prevalences of hypertension are given as age-spe-
cific percentages. Hypertension was defined as a systolic blood pressure of 140 mmHg or 
higher and/or a diastolic blood pressure of 90 mmHg or higher, and, for the USA, treat-
ment with antihypertensive medication. As proinflammatory markers, distributions of in-
terleukin-6 (IL6) and C-reactive protein (CRP) are given as median levels for individuals 
aged 65 or 50 years and older, respectively. For the Ghanaian study population, 95% con-
fidence intervals are given. As references, prevalences are given for European and African 
Americans in the general population of the USA. These data were derived from NHANES 
1999-200024 and from Cohen and colleagues.25
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proportions up to 90%, which contrasts 
with the large proportion of idiopathic 
cases described in western populations.3,4 
Mostly, these cardiac disorders concern 
hypertensive cardiopathy and rheumat-
ic valvular heart disease.12,27,29,30 In the 
Ghanaian study population, two of the 
three cases suffered from hypertension. 
This relationship between cardiac disease 
and atrial fibrillation supports that atrial 
fibrillation may be mainly propagated by 
obesity, diabetes, hypertension, and cardi-
ovascular disease.
Recently, inflammation has been pos-
tulated to play an important role in the 
pathogenesis of atrial fibrillation.7 In the 
Ghanaian study population the level of 
IL6, an instigator of a proinflammatory 
response, was similar to that in the gener-
al population of the USA. Earlier we have 
shown that the study population is bio-
chemically and genetically enriched with 
proinflammatory markers, probably due to 
the endemic high infectious load.23,32,33 On 
the other hand, the level of CRP, a marker 
of systemic inflammation, was lower com-
pared with the USA. Similarly, we have 
previously reported that the median level 
of CRP as well as the prevalence of mild-
ly elevated levels of CRP was lower in the 
study population compared with the gen-
eral population in the Netherlands. This 
difference was attributable to a lower BMI 
in the Ghanaian study population.34 To-
gether, these findings may indicate that, 
while the capacity to generate an inflam-
matory response is preserved, systemic in-
f lammation is uncommon in the Ghanaian 
study population.
Mendelian randomisation has shown that 
an elevation of CRP is rather an effect than 
a cause of atrial fibrillation.35 This inter-
pretation is supported by observations that 
deny an association between CRP level 
and history of atrial fibrillation, but con-
firm that CRP is elevated during episodes 
of atrial fibrillation or due to coexistence 
of hypertension or obesity.36-38 Inflamma-
tory processes related to atrial fibrillation 
seem to be caused by ischæmic or oxidative 
injury of atrial myocytes, which is again 
caused by obesity, diabetes, hypertension, 
and cardiac disease.39,40 In the Ghanaian 
study population, hypertension is present 
in only about a quarter and obesity, dysg-
lycæmia, and cardiovascular disease are 
rare. The low levels of CRP match with the 
close relation between these risk factors 
and inflammation. We have observed a 
similar pattern when studying inflamma-
tion in relation to peripheral and coronary 
arterial disease in this study population 
(Chapter 9 of this thesis).21
While we found almost no atrial fibrilla-
tion in the Ghanaian study population, 
hypertension was present in a considerable 
proportion. Similarly, in western popula-
tions, African ethnicities are more affect-
ed by obesity, diabetes, and hypertension, 
but less often develop atrial fibrillation 
compared with European ethnicities.5,8,11 
Meanwhile, the associations between these 
risk factors and atrial fibrillation are sim-
ilar in both ethnicities.5,9,41,42 A solution of 
this paradox may be provided by the higher 
sensitivity that seems required for methods 
to detect atrial fibrillation in Africans com-
pared with Europeans.43 However, more 
research in different populations is needed 
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to unravel the interactions between envi-
ronmental and genetic risk factors.13
The low prevalence of atrial fibrillation in 
the Ghanaian study population may also 
be a result of a lack of risk factors other 
than those measured in this study. No 
data was available on the prevalence of 
rheumatic heart disease, which is a com-
mon cause of atrial fibrillation in African 
populations.12,29,30 Furthermore, we had no 
information on thyroid disease, smoking, 
and alcohol use, which are risk factors of 
atrial fibrillation in western populations.3,4
Differences between ethnicities in the risks 
of atrial fibrillation are possibly caused 
by genetic factors. Multiple genetic poly-
morphisms have been associated with an 
elevated risk of atrial fibrillation, mainly 
in studies on populations from Europe-
an decent. Yet, the effects of these asso-
ciations are modest and differ between 
ethnicities.44,45 The lower prevalence of 
atrial fibrillation among African Ameri-
cans compared with European Americans 
may be a result of a lower frequency of 
genetic variants that predispose to atrial 
fibrillation among Africans. As African 
Americans show great genetic similarity 
with populations in West Africa, where the 
Ghanaian study population is located,46 a 
lower frequency of such genetic variants 
may likewise explain why atrial fibrillation 
was scarce in the Ghanaian study popula-
tion. However, this remains speculative: 
one report states that European genetic 
admixture does not explain the differences 
in prevalence of atrial fibrillation between 
European and African Americans,47 while 
another report contradicts this.48 More-
over, if the frequency of genetic variants 
that predispose to atrial fibrillation would 
be lower among African Americans, the 
greater prevalence of atrial fibrillation 
among African Americans compared with 
the Ghanaian study population reinforces 
the essential role of lifestyle-related fac-
tors rather than such genetic variants.
The scarcity of atrial fibrillation in our 
study population can also be explained by 
selective survival of unaffected individu-
als. When sufficient medical care is absent, 
patients with atrial fibrillation may de-
cease early from the underlying disorders 
or complications, such as cardiac disease 
or stroke. A study on patients with atrial 
fibrillation in rural Tanzania reports that 
8 out of 15 died within a year after detec-
tion.11 In a larger group in Cameroon one-
year mortality was 30%, of which more 
than half was of cardiovascular origin. Of 
the survivors, 18% experienced cerebrovas-
cular accidents.12 On the other hand, with 
relatively low risk scores12,30 atrial fibril-
lation in these populations seems unlikely 
to be so severely lethal to render infinitesi-
mal prevalence estimates. In line with this, 
we have determined in another study,49 
by means of verbal autopsy on 1263 of the 
1406 deaths that were registered in our co-
hort population, that only 2.7% died from 
cardiovascular causes. For those who died 
at the age of 50 years or older, this was 
4.5%.
This study on atrial fibrillation in a tradi-
tional rural African population has limi-
tations. First, the use of two subsequent 
electrocardiographic recordings of ten 
seconds may be insufficient to detect all 
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cases of atrial fibrillation. More elaborate 
screening techniques used in western pop-
ulations yield more reliable estimates of 
its prevalence; this difference in method-
ology hampers the comparison of our re-
sults with data from western populations. 
Second, the documentation of the cardio-
vascular risk factors lacks information on 
history and family history of cardiovascu-
lar disease. Third, due to different life ex-
pectancies, the number of elderly aged 50 
years and older is lower in our population 
than in western populations. Fourth, due 
to the cross-sectional nature of this study, 
presence or absence of causality in the re-
lationships between the established risk 
factors, systemic inflammation, and atrial 
fibrillation cannot be demonstrated.
The data on atrial fibrillation and its risk 
factors in the Ghanaian study population 
are not necessarily generalisable to other 
African populations, as they vary geneti-
cally and culturally.46 In the same manner, 
the comparison between the Ghanaian 
study population and the general popula-
tion of the USA may not reflect a universal 
difference between African and western 
populations. Comparisons between diver-
gent populations are informative, but also 
complicated. As described above, some 
possible differences between the Ghanaian 
study population and the general popula-
tion of the USA remain largely unknown. 
More research in different non-western 
populations is needed to overcome the 
limitations of this study and to extend the 
scarce knowledge on atrial fibrillation in 
such populations.13
In conclusion, we have shown that atrial 
fibrillation is nearly absent in a traditional 
rural population in Ghana. The low preva-
lence compared with western societies can 
be explained by the rareness of its estab-
lished risk factors, including obesity, dia-
betes, hypertension, and cardiac disease, 
as well as systemic inflammation, which 
are closely related to a sedentary lifestyle 
and uncommon in this population. Future 
research is needed to elucidate the roles of 
other risk factors and genetic factors.
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Background • Heart rate and heart rate variability are associated with 
functional impairment, morbidity, and mortality in western populations. 
It is unclear whether these associations are mediated by lifestyle-related 
cardiovascular risk factors. Therefore, we studied these associations in a 
population where an affluent sedentary lifestyle is absent and risk factors 
of cardiovascular disease and diabetes are rare.
Methods • Among 822 community-dwelling inhabitants aged 50 years 
and older in a traditional rural African population in Northeast Ghana, we 
measured cardiovascular risk factors, including body mass index (BMI), 
waist circumference, glucose level, diastolic and systolic blood pressure, 
and ankle-arm index. Heart rate and heart rate variability, measured as 
SDNN and RMSSD, were derived from electrocardiograms (ECGs) record-
ed at rest. Physical function was determined by handgrip strength. Mor-
tality was documented during a follow-up period of two years.
Results • Heart rate increased slightly with age and was dependent on 
BMI, glucose level, and diastolic blood pressure. Heart rate variability de-
creased with age and was not dependent on cardiovascular risk factors. 
Heart rate was associated with neither handgrip strength nor mortality. A 
lower heart rate variability was associated with lower handgrip strength 
and a higher risk of mortality, independent of age, sex, tribe, and cardio-
vascular risk factors.
Conclusion • Heart rate variability, but not heart rate, is associated with 
handgrip strength and mortality in a traditional rural African population, 
which indicates that this association is independent of lifestyle-related 
cardiovascular risk factors and probably a reflection of a universal deteri-
oration of the body’s autonomic regulation during ageing.
Heart rate and heart rate variability at rest 
are established risk factors of various forms 
of morbidity and mortality. In the gener-
al population, a high heart rate and a low 
heart rate variability are associated with 
an accelerated progression of atheroscle-
rosis1-3 and predict hypertension, coronary 
heart disease, heart failure, stroke, and 
cardiovascular death.1-8 In addition to 
cardiovascular disease, a high heart rate 
and a low heart rate variability are associ-
ated with insulin resistance and diabetes 
mellitus6,9-11 and predict mortality due to 
cancer12 and all-cause mortality.3,10 A low 
heart rate variability not only marks mor-
bidity and mortality, but is also associated 
with measures of functional impairment, 
such as a weak handgrip strength.13,14
Two explanations can be given for the as-
sociations of heart rate and heart rate var-
iability with functional impairment, mor-
bidity, and mortality. On one hand, these 
associations are attributed to the deteri-
oration of the autonomic nervous system 
during ageing.13,14 The autonomic nervous 
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system continuously adjusts the heart 
rate in response to changes in physiolog-
ic conditions to maintain hæmodynamic 
stability. A high heart rate and a low heart 
rate variability are thought to reflect dys-
function of the f lexible autonomic regula-
tion of the heart rate in particular and of 
the body’s functioning in general.6,10 On 
the other hand, a high heart rate and a 
low heart rate variability can be brought 
about by the risk factors of age-related 
diseases such as cardiovascular disease 
and diabetes. Heart rate and heart rate 
variability depend on body mass index 
(BMI),2,6,10,15-18 lipid levels,2,6,10,15,17 glucose 
levels,6,10,15 blood pressure,2,6-8,10,15,16,18 in-
f lammation,10,19 nutrition,20 and physical 
inactivity.6,10,16,18 While these risk factors 
are closely related to lifestyle, research 
on heart rate and heart rate variability 
has almost exclusively been conducted in 
western societies with an aff luent seden-
tary lifestyle and high prevalences of these 
risk factors. It has therefore been difficult 
to determine whether or not heart rate and 
heart rate variability are associated with 
functional impairment, morbidity, and 
mortality independently of cardiovascular 
risk factors.1-4 To disentangle the effects of 
ageing and the lifestyle-related cardiovas-
cular risk factors, the associations of heart 
rate and heart rate variability with func-
tional impairment, morbidity, and mortali-
ty should also be studied in societies where 
an aff luent sedentary lifestyle is absent 
and these risk factors are rare.
We investigated the associations of heart 
rate and heart rate variability with hand-
grip strength and mortality among older 
persons in a traditional rural African pop- 
ulation. In this population, contrary to wes- 
tern populations, food is scarce, lifelong 
manual labour is necessary for subsist-
ence, and obesity, hyperlipidæmia, dia-
betes, hypertension, and cardiovascular 
diseases are rare (Chapters 9 and 10 of 
this thesis).21-23 We have recently shown 
that handgrip strength strongly and inde-
pendently predicts mortality in this popu-
lation (Chapter 8 of this thesis).24
Methods
Research area
This study was conducted in the Garu-Tem-
pane District in the Upper East Region 
in Ghana. The area is rural, remote, and 
one of the least developed in the country. 
The vast majority of the inhabitants are 
involved in non-commercial agriculture 
performed by manual labour without prop-
er means of transportation or mechanised 
farming. Hospital care is absent. Infec-
tious diseases are highly endemic and con-
stitute the main causes of death, although 
the prevalence of human immunodeficien-
cy virus (HIV) is low (< 4%) compared with 
other African regions.25
Since 2002, we have kept a demographic 
registry of the population within a research 
area of 375 km2 comprising 32 villages. 
During yearly visits we registered the 
name, age, sex, tribe, and location of living 
of each inhabitant. In 2007 we determined 
the property value of each household. 
From this value, an index of the socioeco-
nomic status with a standard normal dis-
tribution was calculated according to the 
Demographic and Health Survey method.26 
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In addition, we registered the main drink-
ing water source of each household. Water 
from boreholes was classified as safe and 
water from open wells and rivers as unsafe, 
based on their pathogen contents and their 
effects on survival.27 Annual migration rel-
ative to the study population’s size was 2% 
into and 1% out of the research area. Elab-
orate descriptions of this study population 
have been given elsewhere.21-24,26
Ethical approval was given by the Ethical 
Review Committee of Ghana Health Ser-
vices, the Committee Medical Ethics of 
Leiden University Medical Center, and the 
local chiefs and elders. Because of illiter-
acy, informed consent was obtained orally 
in the participant’s own language after ex-
planation of the purpose and conduction of 
this research project. The study conforms 
to the ethical guidelines of the Declaration 
of Helsinki.
Participants and measurements
In 2009 and 2010 we conducted measure-
ments in the morning among 924 inhab-
itants aged 50 years and older, who were 
recruited in villages visited consecutively. 
To ensure maximal participation, we set up 
a mobile field work station in the villages 
and, if necessary, brought less mobile par-
ticipants by car. Reasons of non-participa-
tion were death of the individual since the 
last registration (n = 48), refusal of partic-
ipation (n = 35), absence from the research 
area during our visits because of migration 
or travelling (n = 30), and other reasons (n 
= 46).
Height, weight, and waist circumference 
were measured and BMI was calculated 
as weight in kilograms divided by squared 
height in metres. Glucose level was meas-
ured in a random capillary blood sample 
from a finger (Accutrend Plus, Roche, Rot- 
kreuz, Switzerland). Blood pressure was 
measured on one arm in a lying and rest-
ing position. Systolic blood pressures were 
measured on the dorsalis pedis artery 
and the posterior tibial artery of both an-
kles with a Doppler ultrasound machine 
(ImexDOP CT+, Natus-Nicolet, Golden, 
CO, USA). As a measure of peripheral ar-
terial disease, the ankle-arm index was 
calculated by dividing the average systolic 
pressure at the ankles by the systolic arm 
pressure.23
Twelve-lead electrocardiograms (ECGs) 
were obtained as two sequential recordings 
of ten seconds in a lying and resting po-
sition (AT-104 PC, Schiller, Baar, Swit-
zerland). Three participants with atrial 
fibrillation, described in Chapter 10 of this 
thesis,22 were excluded from the analyses. 
The recordings of the other participants 
displayed sinus rhythm with positive P 
waves in leads I and II and uniform QRS 
complexes. The timing of the QRS com-
plexes was identified automatically. All 
recordings were manually reviewed in 
detail to verify the automatic identifica-
tion of QRS complexes and to ensure that 
only normal RR intervals were included 
in the analyses. Recordings with ectopic 
complexes were excluded from the anal-
yses, except for twelve participants with 
an ectopic complex in the last two seconds 
of the recording, in which cases all com-
plexes from the ectopic complex onward 
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were excluded. Heart rate in beats per 
minute (bpm) and two measures of heart 
rate variability in milliseconds (ms) were 
determined based on standard methods.28 
Heart rate variability was calculated as the 
standard deviation of normal RR intervals 
(SDNN) and as the root mean square of the 
differences between successive normal RR 
intervals (RMSSD).
Handgrip strength was measured using a 
calibrated Jamar hand dynamometer (Sam- 
mons Preston, Bolingbrook, IL, USA) while 
the participant was standing in an upright 
position with the arms unsupported paral-
lel to the body. Participants were instruct-
ed to exert maximal force with each hand 
once. The handgrip strength of the hand 
with the highest measurement was regis-
tered.29
Data on mortality after the measurements 
in 2009 and 2010 were available from the 
demographic registry. Follow-up started at 
the time of the measurements and lasted 
until death, migration out of the research 
area, loss to follow-up, or our last visit to 
the research area in 2011.
Analyses
Because of their skewed distributions, 
SDNN and RMSSD were transformed log-
arithmically. Changes in heart rate and 
heart rate variability with age were as-
sessed using linear regression with age and 
sex as independent variables. Changes in 
the variances of heart rate and heart rate 
variability with age were assessed using 
Levene’s test comparing 5-year age groups. 
Associations of heart rate and heart rate 
Number of individuals 822
Men, n (%) 421 (51.2)
Age, years 65 (56–72)
Tribe, n (%)
     Bimoba 572 (69.6)
     Kusasi 195 (23.7)
     other 55 (6.7)
Household property value, US$ 1085 (516–1944)
Safe drinking water, n (%) 721 (87.7)
Waist circumference, cm 77 (72–81)
Body mass index, kg/m2 18.1 (16.6–19.6)
Blood pressure, mmHg
     diastolic 70 (65–80)
     systolic 120 (110–135)
Ankle-arm index 1.15 (1.08–1.23)
Heart rate, bpm 70 (62–78)
Heart rate variability, ms
     SDNN 19.6 (13.6–29.3)
     RMSSD 18.0 (11.4–28.4)
Table 11.1 • General 
characteristics of the 
Ghanaian study pop-
ulation. Data are pre-
sented as medians with 
interquartile ranges un-
less specified otherwise. 
Heart rate variability was 
calculated as the stand-
ard deviation of normal 
RR intervals (SDNN) and 
as the root mean square 
of the differences be-
tween successive normal 
RR intervals (RMSSD). 
Bpm: beats per minute.
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variability with handgrip strength were 
tested with three linear regression models: 
one without adjustments; one minimally 
adjusted for age, sex, tribe, and height; and 
one fully adjusted for height and all demo-
graphic and cardiovascular characteristics 
shown in Table 11.1. Hazard ratios were de-
termined by three Cox regression models: 
one without adjustments; one minimally 
adjusted for age, sex, and tribe; and one 
fully adjusted for all demographic and 
cardiovascular characteristics shown in 
Table 11.1. In the fully adjusted models, the 
associations of heart rate with handgrip 
strength and mortality were adjusted for 
SDNN, but the results were similar when 
adjusting for RMSSD instead. The analyses 
were performed with SPSS Statistics 20 
(IBM, Armonk, NY, USA).
Results
Table 11.1 provides the demographic and 
cardiovascular characteristics of the Gha- 
naian study population. Of the 924 indi-
viduals who participated in the measure-
ments, 822 could be included with data 
on heart rate, heart rate variability, and 
handgrip strength. Both measures of heart 
rate variability, SDNN and RMSSD, corre-
lated with Spearman’s ρ = 0.83 (p < 0.001). 
After logarithmic transformation, median 
(with interquartile range) SDNN was 2.98 
ln ms (2.61–3.38), median RMSSD was 
2.89 ln ms (2.43–3.35), and their correla-
tion remained similar with Pearson’s r = 
0.84 (p < 0.001).
Figure 11.1 shows the distributions of heart 
rate and heart rate variability over age. 
As age increased one year, heart rate in-
creased with 0.15 bpm, SDNN decreased 
Figure 11.1 • Distributions of heart rate and heart rate variability over age in 
the Ghanaian study population. The data represent age-specific medians (continuous 
lines) and interquartile ranges (dashed lines) of heart rate and heart rate variability. Heart 
rate variability was calculated as the standard deviation of normal RR intervals (SDNN) 
and as the root mean square of the differences between successive normal RR intervals 
(RMSSD). Bpm: beats per minute.
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PART II • MEASURING SENESCENCE THROUGH MORBIDITY
with 0.013 ln ms, and RMSSD decreased 
with 0.016 ln ms (all p < 0.001). The vari-
ances of heart rate and heart rate variabili-
ty were constant with age.
As shown in Table 11.2, we explored the 
determinants of heart rate and heart rate 
variability in a multivariate model includ-
ing all demographic and cardiovascular 
characteristics. Heart rate was higher in 
older individuals, in women, in individu-
als with a lower BMI, in individuals with 
a higher glucose level, and in individuals 
with a higher diastolic blood pressure. 
Both SDNN and RMSSD were lower in old-
er individuals, higher in individuals with a 
higher wealth index, and lower in individ-
uals with a higher heart rate.
Heart rate, heart rate variability, and 
handgrip strength
Table 11.3 describes the associations of 
heart rate and heart rate variability with 
handgrip strength. Handgrip strength was 
lower in individuals with a higher heart 
rate and higher in individuals with a high-
er SDNN or RMSSD (all p < 0.001). After 
adjustment for age, sex, tribe, and height, 
heart rate was not associated with hand-
grip strength, but handgrip strength re-
mained higher in individuals with a higher 
SDNN (p = 0.009) or RMSSD (p = 0.013). 
After additional adjustment for other de-
mographic and cardiovascular character-
istics, these associations did not change 
(p < 0.025). When stratifying the fully ad-
Figure 11.2 • Estimates of handgrip strength per tertiles of heart rate and heart 
rate variability in the Ghanaian study population. The data represent estimated 
means of handgrip strength per tertiles of heart rate and heart rate variability. Heart 
rate variability was calculated as the standard deviation of normal RR intervals (SDNN) 
and as the root mean square of the differences between successive normal RR intervals 
(RMSSD). The estimated means were fully adjusted for age, sex, tribe, height, drinking 
water source, body mass index, waist circumference, glucose level, diastolic and systolic 
blood pressure, ankle-arm index, and heart rate or heart rate variability (p values for 
trends). Bpm: beats per minute.
p = 0.019 p = 0.023p = 0.605
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justed model, the association of heart rate 
variability with handgrip strength was not 
different between men and women, indi-
viduals younger and older than 65 years, or 
individuals with and without underweight, 
defined as a BMI below 18.5 kg/m2.
Figure 11.2 provides estimates of hand-
grip strength per tertiles of heart rate and 
heart rate variability, adjusted for all de-
mographic and cardiovascular characteris-
tics. From the lowest to the highest tertile 
of heart rate, handgrip strength declined 
non-significantly with 0.57 kg. From the 
lowest to the highest tertile of SDNN, 
handgrip strength increased with 1.00 kg. 
From the lowest to the highest tertile of 
RMSSD, handgrip strength increased with 
1.12 kg.
Heart rate, heart rate variability, and 
mortality
Table 11.4 describes the associations of 
heart rate and heart rate variability with 
mortality. Data on follow-up were availa-
ble for 814 (99.0%) participants and com-
prised 1396 person-years and 42 deaths. 
Heart rate was not associated with mor-
tality. Heart rate variability was inversely 
associated with mortality: risk of mor-
tality was lower in individuals with a 
higher SDNN (p = 0.006) or RMSSD (p = 
0.048). After adjustment for age, sex, and 
tribe, these associations remained simi-
lar and remained significant for SDNN (p 
= 0.021), but lost significance for RMSSD 
(p = 0.121). After additional adjustment 
for other demographic and cardiovascular 
characteristics, the associations remained 
similar.
Sensitivity analyses
To examine the consistency of the results, 
we repeated the analyses in restricted 
groups of participants. Firstly, we excluded 
twelve participants who had shown ectop-
ic complexes in the last two seconds of the 
ECG. The associations of heart rate with 
handgrip strength and mortality remained 
absent in the minimally and fully adjusted 
models. The associations of heart rate vari-
ability with handgrip strength and mortal-
ity remained similar. Secondly, we exclud-
ed 28 participants with sinus arrhythmia, 
defined as the presence of consecutive nor-
mal RR intervals differing by more than 
120 ms. The associations of heart rate with 
handgrip strength and mortality remained 
absent in the minimally and fully adjust-
ed models. The associations of heart rate 
variability with handgrip strength were 
strengthened; their associations with mor-
tality remained similar (data not shown).
Discussion
This study aims to assess whether heart 
rate and heart rate variability at rest are 
associated with handgrip strength and 
mortality among older persons in a tra-
ditional rural African population where 
obesity, hyperlipidæmia, diabetes, hyper-
tension, and cardiovascular diseases are 
rare (Chapters 9 and 10 of this thesis).21-23 
Heart rate increased slightly with age and 
was dependent on BMI, glucose level, and 
diastolic blood pressure. Heart rate var-
iability decreased with age and was not 
dependent on cardiovascular risk factors. 
Heart rate was associated with neither 
handgrip strength nor mortality. A lower 
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heart rate variability was associated with 
lower handgrip strength and, correspond-
ing with our previous report that low 
handgrip strength predicts mortality,24 a 
higher risk of mortality. These associations 
were independent of age, sex, tribe, and 
cardiovascular risk factors.
This study is the first to investigate heart 
rate and heart rate variability in relation 
to physical function and mortality in tra-
ditional Africa. Few studies have assessed 
heart rate at rest and its associations with 
cardiovascular risk factors in rural African 
populations and have reported results that 
are in accordance with our results. Heart 
rate was, compared with the Ghanaian 
study population, similar in rural Tanzani-
an populations8,30 and among hypertensive 
patients attending hospitals in different 
Sub-Saharan countries,31 but higher in a 
population close to our research area with 
younger participants and higher preva-
lences of cardiovascular risk factors.32 In 
these populations, heart rate was constant 
with age, higher in women, and positively 
related with blood pressure and lipid lev-
els, although less strongly than in western 
populations.8,16,30,32 Heart rate was found to 
be higher in Congolese children and ado-
lescents with a lower socioeconomic status 
and with malnutrition or obesity.33 Heart 
rate variability has been measured only in 
hospitals in several Sub-Saharan countries 
and without assessing its associations with 
physical function, morbidity, or mortali-
ty. In these studies, heart rate variability 
declined with age and was higher in wom-
en.30,31
Heart rate and heart rate variability at rest 
vary across populations and ethnicities 
due to both genetic and environmental 
factors,16,30,34 which complicates compari-
sons between populations. Still, the study 
of heart rate and heart rate variability in 
populations without an aff luent sedentary 
lifestyle aids the solution of questions that 
remain despite the research conducted in 
western populations. Heart rate in western 
populations is higher in women and de-
pendent on various cardiovascular risk fac-
tors, as in the Ghanaian study population, 
but it has been inconsistently described 
to decrease, be constant, or increase with 
age.7,8,15-18 Conflicting results have also 
been reported on differences in heart rate 
between European and African Ameri-
cans.11,35-37 A study comparing Americans 
of European origin, Americans of African 
origin, and American immigrants from 
Ghana without hypertension, cardiovascu-
lar disease, and diabetes found no differ-
ences in heart rate.38 Other studies showed 
that differences in heart rate between Eu-
ropean and African Americans can be at-
tributed to cardiovascular risk factors.37,39 
The findings from traditional African pop-
ulations reinforce the possibility that heart 
rate is dependent on cardiovascular risk 
factors rather than age and that it is only 
associated with functional impairment, 
morbidity, and mortality when these risk 
factors are present. As a biological expla-
nation, cardiovascular risk factors such 
as obesity, hyperlipidæmia, hypertension, 
and diabetes can increase heart rate by in-
ducing hæmodynamic alterations, cardiac 
conduction abnormalities, and sympathet-
ic hyperactivation.6,10,15,40
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Heart rate variability decreases with age 
in western populations as in the Ghanaian 
study population and other African pop-
ulations.2,16,17,41-43 Heart rate variability in 
the Ghanaian study population was similar 
to that in different western populations 
investigated with comparable methodol-
ogies, despite differences in cardiovascu-
lar risk factors.44-47 Although conflicting 
results have been reported on differences 
in heart rate variability between European 
and African Americans, these differences 
seem independent of cardiovascular risk 
factors.34,41,48 Not only in the Ghanaian 
study population, but also in western pop-
ulations heart rate variability has been re-
ported to be unaffected by cardiovascular 
risk factors.18,34,42,49 These findings, com-
bined with those from traditional African 
populations, suggest that heart rate varia-
bility is associated with functional impair-
ment, morbidity, and mortality through 
mechanisms independent of cardiovascu-
lar risk factors. Most likely, heart rate vari-
ability declines during ageing as a result of 
a deteriorating autonomic regulation of the 
heart rate that occurs across populations 
with different lifestyles.13,14,20,50 More re-
search in populations without an aff luent 
sedentary lifestyle is required to substanti-
ate our interpretations.
Since a high heart rate is a long-established 
predictor of morbidity and mortality, it is 
regarded as a potential therapeutic target 
of cardiovascular disease.1,3,7 While phar-
macological lowering of the heart rate has 
been found to benefit patients with heart 
failure, it fails to do so in patients without 
heart failure.51 In line with our study, it is 
posited that the heart rate is accelerated 
not as a cause, but as an effect of cardio-
vascular disease.1,51 It could be that in the 
detection and prevention of cardiovascular 
disease the role of heart rate is overrated, 
while that of heart rate variability has re-
mained underrated.
This study has the following limitations. 
Firstly, ECGs were recorded during 20 
seconds, while longer recordings are of-
ten preferred.28 Heart rate variability in 
short recordings cannot be measured by 
frequency-domain methods, cannot be 
compared with longer recordings used in 
most studies, and is determined with less 
precision. However, SDNN and RMSSD 
as measures of heart rate variability can 
be used to investigate short recordings28 
and several studies of similarly short re-
cordings have demonstrated that these 
measures are associated with morbidity 
and mortality.44-47 Moreover, the less pre-
cise determination of heart rate variability 
in short recordings is thought to result in 
underestimation rather than overestima-
tion of the true associations.45,47 Second-
ly, mortality was registered during only a 
short follow-up period, which attenuates 
the statistical power of the mortality anal-
yses. Thirdly, associations of heart rate 
and heart rate variability with incidence 
of morbidity could not be assessed, since 
diseases were not registered. Lastly, the 
effects of some lifestyle-related risk fac-
tors on heart rate and heart rate variability 
could not be studied. Although nutritional 
status was reflected by BMI, dietary com-
position, physical activity, and smoking 
were not formally documented.
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In conclusion, this study shows that a high 
heart rate is not, but a low heart rate varia-
bility is associated with handgrip strength 
and mortality among older persons in a 
traditional rural African population as it is 
in western populations. This suggests that 
the association of heart rate with physi-
cal function and mortality as described 
in western populations is predominantly 
mediated by lifestyle-related risk factors 
of cardiovascular disease and diabetes. 
By contrast, the association of heart rate 
variability with physical function and mor-
tality probably reflects a universal deteri-
oration of the body’s autonomic regulation 
during ageing. Across various environ-
ments, heart rate variability can be meas-
ured to predict functional impairment and 
mortality.
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In this thesis, we measure senescence in 
human populations, defined as an increase 
in the risks of dysfunction, disease, and 
death with chronological age. In Part I of 
this thesis we investigate how a popula-
tion’s senescence rate can be measured 
through the increase in mortality rate with 
age. In Part II of this thesis we investigate 
how senescence can be measured through 
the increase in morbidity with age in a 
non-western population and thus be com-
pared with the senescence process in west-
ern populations.
The rate of senescence
A population’s senescence rate is classical-
ly measured as the increase in mortality 
rate with age on a logarithmic scale, which 
is described by the Gompertz model’s pa-
rameter γ. This measure has been criti-
cised and, as an alternative, it has been 
proposed to measure a population’s senes-
cence rate as the increase in mortality rate 
with age on an absolute scale.1
Some who have criticised the classical mea- 
sure of a population’s senescence rate have 
fallen back to measures of senescence that 
summarise the varying levels of mortality 
throughout the entire life in a single age- 
independent constant, such as the mean 
lifespan.2 As such measures are not in-
formative about the age pattern of mortal-
ity, they cannot improve on the classical 
measure.3
Others have designed new approaches 
other than measuring the increase in mor-
tality rate on an absolute scale. Notably, it 
has been put forward that age patterns of 
mortality rates can be separated into two 
dimensions: the pace of senescence and 
the shape of senescence. The pace of se-
nescence captures the time during which 
mortality occurs and can be described by 
life expectancy or maximum lifespan. The 
shape of senescence does not depend on 
time, but captures the extent to which mor-
tality changes independently of the pace of 
senescence.4 Although this approach pro-
vides a thoughtful conceptual view on the 
measurement of senescence5 and is already 
applied to characterise senescence pro-
cesses,6,7 the assumptions underlying the 
separation of both dimensions of senes-
cence have never been empirically tested.
We are the first to empirically verify an 
alternative measure of a population’s se-
nescence rate, derived from the increase in 
its mortality rate with age on an absolute 
scale (Chapter 3 of this thesis).8 We have 
tested this measure by applying it to pop-
ulations that are known to have different 
senescence rates. We have confirmed that 
this alternative measure yields valid senes-
cence rates, whereas the classical measure 
yields invalid senescence rates. We have 
demonstrated how senescence rates can 
be determined according to the alternative 
measure by using the derivative function 
of the Gompertz model. This principle can 
be applied to any model of the age pattern 
of a mortality rate other than the Gom-
pertz model. Furthermore, to overcome 
the limitations of such models, we have 
demonstrated how senescence rates can be 
determined according to the same princi-
ple by using a non-parametric method that 
does not require any modelling of mortal-
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ity rates (Chapter 4 of this thesis).9 This 
method can be applied to any age pattern 
of a mortality rate.
The validity of the increase in mortality 
rate on a logarithmic scale as a measure of 
the senescence rate can also be questioned 
on mathematical grounds. According to 
the Gompertz model, the increase in mor-
tality rate m with age t equals m’(t) = γ and 
has the unit per year of age.10 Non-para-
metrically, this increase equals:
 ln(m’(t)) = m’(t) / m(t) (12.1)
which likewise has the unit per year of age. 
By contrast, the senescence rate measured 
as the increase in mortality rate on an ab-
solute scale — which is according to the 
Gompertz model:
 m’(t) = α γ eγ t (12.2)
and is non-parametrically described as:
 m’(t) = dm / dt (12.3)
— is expressed with the unit deaths per 
person-year per year of age, thus mortality 
rate per year of age. The latter unit match-
es best with the definition of senescence as 
the increase in mortality rate with age.
The Gompertz model’s parameter γ is not 
by itself a measure of a population’s senes-
cence rate, but the senescence rate is de-
scribed by the model’s derivative function 
that is dependent on both parameter α and 
γ. Moreover, it is not necessary to model 
the age pattern of a mortality rate to meas-
ure the senescence rate. It follows that the 
parameters of the Gompertz model — or 
of any other model of the age pattern of a 
mortality rate — cannot be interpreted to 
have specific biological meanings. Such an 
interpretation assumes that mortality can 
be partitioned in intrinsic mortality due to 
senescence and extrinsic mortality inde-
pendent of senescence. We have substanti-
ated in Chapter 5 of this thesis11 why this 
assumption is false. Accordingly, the func-
tion of the parameters is limited to their 
original function, that is to fit and describe 
the age pattern of a mortality rate merely 
mathematically.
Figure 12.1 illustrates the mathematical 
meanings of both parameters of the Gom-
pertz model. Variation in α as well as in 
γ affects the decrease in survival with 
age, the distribution of deaths over age, 
and the increase in mortality rate with 
age and, thus, affects the senescence rate. 
Conversely, the differences in these age 
patterns that are brought about by varia-
tion in either parameter cannot be distin-
guished as either reflecting a difference in 
the senescence rate or not.
The way of senescence
Because much is unknown about senes-
cence in populations without a western 
lifestyle, we have studied senescence in a 
traditional rural African population in one 
of the least developed regions of Ghana 
(Chapters 7 through 11 of this thesis). This 
population contrasts sharply with western 
populations: its environment is not aff lu-
ent and sedentary, but typified by poverty, 
limited nutrition, regular hunger, contin-
uous physical activity, and many endemic 
infectious diseases.
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Variation in α
Figure 12.1 • The effects of variation in the Gompertz model’s parameters α and 
γ on the age patterns of a population’s survival, deaths, and mortality rate. In the 
left panels, α is 0.001, 0.003, and 0.007 from black to grey and γ is constantly 0.06. In 
the right panels, γ is 0.06, 0.07, 0.08 from black to grey and α is constantly 0.001. Others 
have assessed these effects similarly.12
Variation in γ
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In some respects, the way of senescence is 
similar in the Ghanaian study population 
and western populations. We have shown 
that handgrip strength declines with age 
and predicts mortality similarly in both 
types of populations (Chapter 8 of this 
thesis).13 Heart rate variability at rest also 
declines with age and is associated with 
handgrip strength and mortality similarly 
in both types of populations (Chapter 11 of 
this thesis).14 Handgrip strength and heart 
rate variability apparently reflect biolog-
ical age and senescence across different 
environments and different lifestyles.
In other respects, our studies show that 
the way of senescence is different in this 
non-western population as compared with 
western populations (Chapters 9 and 10 
of this thesis).15,16 Senescence does not 
manifest as sharp increases with age in 
the prevalences of cardiovascular disease 
— including coronary arterial disease, pe-
ripheral arterial disease, and atrial fibril-
lation — and diabetes mellitus. It neither 
manifests as an increase in heart rate at 
rest, which is associated with disease and 
death in western populations. Meanwhile, 
risk factors of cardiovascular disease, dia-
betes mellitus, and an increased heart rate 
— including obesity, dyslipidæmia, and 
hypertension — are absent or uncommon. 
Because their risk factors are closely relat-
ed to a western lifestyle, the development 
of diseases such as cardiovascular disease 
and diabetes mellitus and the increase in 
heart rate during senescence are likely 
consequences of a western lifestyle.
In western populations, chronic smoulder-
ing inflammation arises during senescence 
and is associated with the diseases that are 
related to senescence, among which cardi-
ovascular disease and diabetes mellitus. 
It has been proposed that inflammation 
plays an essential role in the causation of 
senescence and senescence-related diseas-
es.17-22 In the Ghanaian study population, a 
high burden of infectious diseases and an 
enrichment of a proinflammatory immune 
system23,24 have not resulted in chronic 
smouldering inflammation, cardiovas-
cular disease, or diabetes mellitus.15,16,25 
Other studies have confirmed that chron-
ic smouldering inflammation in western 
populations is rather an effect than a cause 
of cardiovascular disease, diabetes melli-
tus, and their risk factors, of which most 
notably obesity.26-29 In the Ghanaian study 
population and other similar non-west-
ern populations, inflammation is rather 
acute and attributable to infectious diseas-
es.25,30-32
Cardiovascular disease is closely related 
to senescence in western populations. Its 
pathogenesis consists of an accumulation 
of damage in the vascular wall and the 
heart during ageing due to a disturbance of 
the blood f low, a deposition of lipids, and 
a maladaptive inflammatory response.33,34 
These processes are associated with mark-
ers of senescence at the molecular and cel-
lular level.35,36 During life, these processes 
lead to dysfunction and disease of the ves-
sels and heart37-39 and are associated with 
the occurrence of other age-related dis-
orders.40,41 By contrast, the environment 
and lifestyle in non-western populations 
expose their inhabitants to other kinds of 
bodily damage. Rather than high levels of 
lipids and chronic smouldering inflam-
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mation, damage accumulates during their 
lives as a consequence of malnutrition and 
acute inflammation evoked by infectious 
diseases. The different kinds of damage 
lead to different kinds of dysfunction and 
disease. Senescence in non-western pop-
ulations is not characterised by cardio-
vascular disease, but by diseases that are 
unfamiliar from a western point of view.
The rate and way of senescence
Our investigations of the rate of senescence 
and the way of senescence in human popu-
lations converge when we apply our meth-
od of measuring a population’s senescence 
rate in order to compare the senescence 
rates of the Ghanaian study population 
with those of a western population.
Figure 12.2 shows the age patterns of the 
causes of death in the general population 
of the USA and the Ghanaian study popu-
lation. As is well known for western pop-
ulations, most deaths during adolescence 
and young adulthood are due to traumata, 
while most deaths at higher ages are due 
to non-infectious diseases such as cardi-
ovascular disease, diabetes mellitus, and 
cancer (Figure 12.2a). By contrast, in the 
Ghanaian study population, most deaths 
are due to infectious diseases at any age, 
while deaths due to non-infectious diseas-
es account for a minority of deaths (Fig-
ure 12.2b). The way of senescence differs 
between this non-western population and 
western populations.
Figure 12.3a shows the age patterns of the 
mortality rates of the general population 
of the USA and the Ghanaian study popu-
A • USA
B • Ghana
Figure 12.2 • Age patterns of causes 
of death in the general population of 
the USA (A) and in the traditional rural 
Ghanaian study population (B). Data on 
the general population of the USA are from 
1990 through 2010 and were derived from 
CDC WONDER.49 Data on the Ghanaian stu-
dy population are from 2003 through 2011 
and were obtained by verbal autopsy.50,51 
Differences in the coding between both 
sources have been equalised.
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lation on a logarithmic scale. Conforming 
to the Gompertz model, these mortality 
rates increase linearly during adulthood. If 
these linear increases would be interpret-
ed according to the classical method, the 
senescence rate of the general American 
population would be estimated higher than 
that of the Ghanaian study population. 
However, if we calculate their senescence 
rates from the increase in their mortality 
rates on an absolute scale, another conclu-
sion is drawn. Figure 12.3b shows the se-
nescence rates calculated in this manner. 
Despite the different ways of senescence, 
the rates of senescence are similar in both 
populations.
As discussed in Chapters 1 and 5 of this 
thesis,11 senescence is the result of intrin-
sic and extrinsic stressors that damage the 
human body in interaction. The compari-
son of populations with different environ-
ments and lifestyles discloses the effects of 
extrinsic stressors from the environment: 
the way of senescence differs between the 
Ghanaian study population and western 
populations. Meanwhile, our findings of 
similar declines in handgrip strength and 
heart rate variability with age and of sim-
ilar senescence rates in these different 
environments hint at causes of senescence 
that are intrinsic to the human body and 
render it susceptible to damage and dete-
rioration.
It has been hypothesised that the human 
species exhibits a specific fixed senescence 
rate.42 This hypothesis is enfeebled by 
our observation that senescence rates can 
vary within a population, as described in 
Chapters 3 and 4 of this thesis.8,9 Yet, the 
Figure 12.3 • Age patterns of mortality 
rates (A) and senescence rates (B) in 
the general population of the USA and 
in the traditional rural Ghanaian study 
population. Data on the general popu-
lation of the USA are from 1990 through 
2010 and were derived from CDC WON-
DER.49 Data on the Ghanaian study popula-
tion are from 2003 through 2011 and were 
registered as described elsewhere.52,53 The 
mortality rates and senescence rates are 
shown with 95% confidence intervals. The 
senescence rates were calculated from the 
increase in the mortality rates with age on 
an absolute scale, as described in Chapter 
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mortality rates of both non-western and 
western populations and of both individu-
als with and without end-stage renal dis-
ease increase exponentially with age on 
an absolute scale and thereby conform to 
the Gompertz model. The same holds for 
the mortality of animal models and the 
decay of inanimate objects.43 Even more, 
an exponential age pattern is observed in 
the performance of sportsmen44 and in 
markers of cellular senescence.45-48 The 
Gompertzian age pattern seems to be uni-
versal. Different interactions of intrinsic 
and extrinsic stressors lead to different 
senescence processes and different causes 
of death, but apparently underlie similar 
exponential increases in mortality rate 
with age.
Limitations
When measuring a population’s senescence 
rate from the increase in mortality rate, we 
do not account for the potential effects of 
population heterogeneity. As explained in 
Chapter 4 of this thesis,9 differences in the 
age patterns of mortality rates between 
subgroups of a population can produce an 
age pattern of the mortality rate for the 
population as a whole that does not reflect 
the age patterns of the subgroups. To verify 
that our findings are not distorted by popu-
lation heterogeneity, our studies can be re-
peated in homogeneous populations, which 
is practically possible by studying the 
mortality of inbred animals housed under 
standardised conditions. We have tried to 
approach this goal by stratifying the study 
population into known subgroups; this 
has not refuted our conclusions. More so-
phisticated statistical methods have been 
developed to investigate the potential ef-
fects of population heterogeneity, which 
merit integration in our future studies.
It is sometimes objected that the meas-
urement of a population’s senescence rate 
from the increase in mortality rate is ham-
pered by the level of the mortality rate. For 
example, patients with end-stage renal dis-
ease who receive dialysis treatment have 
mortality rates that greatly exceed those 
of the general population. It is reasoned 
that high mortality rates cannot increase 
as much as low mortality rates. However, 
this line of reasoning is often based on the 
mortality rates as shown on a logarithmic 
scale. When the mortality rates are shown 
on an absolute scale, they increase expo-
nentially in the patients on dialysis as well 
as in the general population (Figure 3.1). 
Furthermore, we have not been able to 
discover any effect of the level of the mor-
tality rate on the increase in the mortality 
rate by adjusting for follow-up and by lon-
gitudinally examining the age patterns of 
the mortality rates of subgroups of patients 
with end-stage renal disease.54 To further 
assess this objection, it is worthwhile to 
test our method in cohort studies with life-
long follow-up.
A distinction must be made between the 
level of a mortality rate and the increase in 
mortality rate with age. We base the meas-
urement of the senescence rate on the latter 
only. One may want to correct the increase 
in mortality rate on an absolute scale for 
the absolute level of the mortality rate, for 
example by m’(t) / m(t). However, as men-
tioned above, m’(t) / m(t) = [ln m(t)]’. Thus, 
such a correction renders a measure that is 
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equal to the increase in mortality rate on 
a logarithmic scale, equally relative, and 
equally invalid. Moreover, theoretically, if 
it is accepted that senescence at the popu-
lation level is defined as an increase in the 
risks of disease and death with increasing 
age and that a population does not senesce 
if its mortality rate is constant with age,55,56 
it follows that senescence is equally absent 
in populations with mortality rates that 
are constant with age, but differ from each 
other. Nonetheless, when comparing pop-
ulations, for example the Ghanaian study 
population and the general population of 
the USA (Figure 12.3), it remains valuable 
to compare the increases in their mortali-
ty rates with age as well as their mortality 
rates per se.
Others have objected that our method of 
measuring a population’s senescence rate 
is scientifically incomplete, because it does 
not link the changes in the population’s 
mortality rate with the biological chang-
es in the senescing bodies of the individ-
uals.57 This is true for any measure of a 
population’s senescence rate. While senes-
cence at the individual level determines se-
nescence at the population level, the meas-
urement of senescence at the population 
level cannot always be related directly to 
senescence at the individual level, for ex-
ample due to population heterogeneity as 
explained above. These limitations can be 
largely overcome with data from cohorts 
with lifelong follow-up, in homogeneous 
populations such as animal models, or by 
means of statistical methods that take into 
account population heterogeneity. Moreo-
ver, it is worthwhile to investigate whether 
and how the methods for measuring senes-
cence rates from the increase in mortality 
rate, as proposed here, can also be used 
to measure senescence in individuals, for 
example from the decrease in handgrip 
strength with age.
When comparing the senescence process 
in different populations — for example 
between patients on dialysis and patients 
with a functioning transplant or between 
western and non-western populations — it 
seems that one compares chalk and cheese. 
Only the fittest patients on dialysis are 
eligible for transplantation. Western and 
non-western populations differ not only 
in their lifestyles, but also in their health 
care systems, climates, and genetics. Still, 
it is our aim to compare these populations 
precisely because they differ.58,59 We make 
use of the facts that patients on dialysis 
senesce faster than patients with a func-
tioning transplant and that western popu-
lations have developed into more aff luent 
and sedentary societies than non-western 
populations. To be able to discern which 
of the differences exactly contribute to the 
differences in the senescence process, it 
is necessary to make similar comparisons 
between other populations.
One of the differences that is inherent to 
the comparison of western and non-west-
ern populations is the great inequality in 
health care facilities. Consequently, studies 
of the prevalence of disease in non-west-
ern populations are at risk of a survival 
bias: individuals may die from the disease 
before it can be detected. Have we found 
little cardiovascular disease and diabetes 
mellitus because these diseases are highly 
lethal in the Ghanaian study population? 
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Causes of death in this population have 
been determined by means of verbal au-
topsy.50,51 Infectious diseases are the main 
cause of death and deaths due to cardio-
vascular disease and endocrine disease are 
uncommon, accounting for 3% of all deaths 
and 5% of the deaths with a known cause 
(Figure 12.2b).50 In other non-western pop-
ulations, physical autopsy studies have as 
well shown that cardiovascular disease is 
uncommon up to high ages.60-62 These fig-
ures support that cardiovascular disease 
is verily uncommon in non-western popu-
lations.
Implications for biomedical 
research
For gerontological research it is of quintes-
sential importance to determine and com-
pare senescence rates of populations. The 
classical measure of the senescence rate, 
derived from the increase in mortality 
rate on a logarithmic scale, is extensively 
used to study the process of senescence. It 
is employed to compare senescence rates 
between species and environments and to 
explain the evolutionary underpinnings 
of senescence.63-66 It is applied to animal 
models to assess whether genetic and en-
vironmental interventions, such as dietary 
restriction, affect the rate of senescence or 
delay the onset of senescence.67-73 It is used 
in human populations to compare senes-
cence rates across calendar years,42,65,66,74,75 
birth cohorts,66,75,76 and ethnicities.77 We 
have, however, demonstrated that senes-
cence rates should not be measured as the 
increase in mortality rate on a logarithmic, 
but rather on an absolute scale.1,8,9
Our studies have shown that the results 
and interpretations of studies can be rad-
ically different when senescence rates are 
measured as the increase in mortality rate 
on an absolute instead of a logarithmic 
scale. A population with a higher senes-
cence rate compared with another popu-
lation according to the increase in their 
mortality rates on a logarithmic scale, can 
have a lower senescence rate according to 
the increase in their mortality rates on an 
absolute scale. Two populations with dif-
ferent senescence rates according to the 
increase in their mortality rates on a loga-
rithmic scale, can have similar senescence 
rates according to the increase in their 
mortality rates on an absolute scale. It is 
necessary to examine whether and to what 
extent this is true for previous studies and 
to reevaluate the interpretations of these 
studies. For example, dietary restriction is 
thought to decrease the senescence rate in 
rodents, since it slows the increase in their 
mortality rates on a logarithmic scale.73 
However, the effect of dietary restriction 
on the increase in mortality rate on an ab-
solute scale has not been studied, while it 
may lead to another conclusion.
Although a logarithmic scale serves the vis- 
ualisation of age patterns of mortality rates, 
the widely adopted habit to interpret the 
slope of their straight lines as the senes-
cence rate should be abandoned. In addi- 
tion, the closely related assumption that in- 
trinsic mortality due to senescence and ex- 
trinsic mortality independent of senescence 
can be separated should be left. Rather, 
senescence rates should be presented and 
judged in their relation to age separately 
from the age patterns of mortality rates.
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Implications for western 
populations
In western populations, senescence is ac-
companied by sharp increases in the prev-
alences of non-infectious diseases such as 
cardiovascular disease and diabetes. These 
senescence-related diseases are generally 
regarded as inevitable consequences of a se- 
nescence process that is intrinsic to the hu- 
man body. Indeed, atherosclerosis is already 
present in young adults,78-80 has been found 
in ancient mummies,81 and cardiovascular 
disease and diabetes mellitus are not entire- 
ly absent in non-western populations.60-62
Still, senescence-related diseases can better 
be considered as lifestyle-related diseases. 
Our studies support the notion that the 
senescence process is not intrinsic and in-
tractable, but malleable and much depend-
ent on the environment.11,15,16 The essential 
role of the environment in the causation 
of senescence-related diseases has been 
confirmed by others and for other diseas-
es that are attributed to senescence.82 In 
the absence of a western lifestyle, cardio-
vascular disease and diabetes mellitus are 
uncommon even in the eldest.
From an evolutionary perspective, the 
diseases that arise during senescence in 
western populations are, at least partly, at-
tributable to a mismatch between, on one 
hand, the genetic variants that have been 
selected during a long history in harsh 
environments and, on the other hand, the 
modern aff luent environment that has 
been experienced by only very few genera-
tions.83,84 Prolonged selection of thrifty and 
proinflammatory genetic variants have be-
stowed humans with qualities, desires, and 
impulses that predispose to these diseases, 
but are not so simply suppressed. Preven-
tion and treatment of senescence-related 
diseases such as cardiovascular disease 
and diabetes mellitus will be more suc-
cessful when they are aimed at improve-
ments of the environment rather than the 
genetic predisposition.82,85 If food is less 
readily available and less energy-rich, 
physical activity is an everyday habit, and 
infections may once in a while evoke an 
inflammatory response, our thrifty and 
proinflammatory natures are well suited 
and our senescence process is bettered.
Implications for non-western 
populations
In non-western populations, senescence is 
not accompanied by sharp increases with 
age in the prevalences of non-infectious 
diseases such as cardiovascular disease 
and diabetes mellitus because of the ab-
sence of a western lifestyle. Instead, in-
fectious diseases dominate non-infectious 
diseases up to the highest ages. Differ-
ences in the environment explain why the 
inhabitants of these populations senesce 
in a different way compared with western 
populations. The question how they se-
nesce remains, however, open to further 
scrutiny.
Meanwhile, western lifestyles are quickly 
spreading over the world and only few pop-
ulations have not yet been pervaded. The 
emergence of western lifestyles goes hand 
in hand with the emergence of obesity, dys-
lipidæmia, hypertension, cardiovascular 
disease, and diabetes mellitus.86-88
Whereas western lifestyles have developed 
over a few generations in western popula-
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tions, it is introduced within a generation 
in non-western populations. This renders 
non-western populations at an increased 
risk of suffering from the diseases that are 
caused by a western lifestyle because of 
three reasons. Firstly, these populations 
have experienced the selective pressures 
exerted by harsh environments until very 
recently. Thrifty and proinflammatory 
gene variants that predispose to these dis-
eases are present in these populations.89 
Secondly, these populations have expe-
rienced a harsh environment at low age, 
when genes are epigenetically tuned to 
the environment. It has been established 
that exposure to hunger and infectious 
diseases early in life increases the risk of 
cardiovascular disease and diabetes melli-
tus when these conditions have improved 
later in life, at least partly through epige-
netic mechanisms.90-93 Thirdly, because of 
the poor environment, ideals of unhealthy 
foods, corpulence, and physical inactivity 
are culturally preserved.94-97 Accordingly, a 
western lifestyle is eagerly adopted and its 
consequences are liked.
The prevention of lifestyle-related diseases 
by environmental interventions is, there- 
fore, especially urgent in non-western pop-
ulations where a western lifestyle has re-
cently been or is currently introduced. Un- 
fortunately, most public health policies con- 
cerning these regions have remained near-
sighted and focus on hunger, infectious dis- 
eases, and maternal and child mortality. 
This is meaningfully exemplified by the 
current endeavours of the United Nations to 
formulate Sustainable Development Goals. 
Out of seventeen proposed goals, only one 
addresses health directly with the inten-
tion to „ensure healthy lives and promote 
well-being for all at all ages”. Out of the 
thirteen statements, in which this goal is 
subdivided, only one specifically address-
es „non-communicable diseases”, together 
with „mental health and well-being”.98
Conclusions
In this thesis, we show that a population’s 
senescence rate should not be measured, 
following the classical method, as the in-
crease in mortality rate with age on a log-
arithmic scale, but rather as its increase 
on an absolute scale. We present how this 
novel method can be applied to both mod-
elled and non-modelled mortality rates. 
The novel method yields conclusions that 
are radically different from those provided 
by the classical method. The novel method 
also acknowledges that senescence results 
from an interaction between bodily and 
environmental factors. This interaction 
becomes apparent when we compare the 
senescence process in a non-western pop-
ulation with that in western populations. 
In some respects, the way of senescence 
is similar, as handgrip strength and heart 
rate variability at rest decline similarly 
with age. The rate of senescence is similar 
too. In other respects, the way of senes-
cence is different, as cardiovascular dis-
ease and diabetes mellitus are uncommon 
up to the highest ages. This indicates that 
the senescence process can be modulated 
through the environment and lifestyle. We 
suggest that the senescence process can 
be ameliorated when environmental in-
terventions unite the best of both worlds: 
a non-western lifestyle, which is nutrition-
ally thrifty and physically active, together 
with western standards of public health.
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As humans grow older, the structures and 
functions of their bodies deteriorate. This 
process is referred to as senescence. In hu-
man populations, senescence leads to an 
increase in the risks of dysfunction, dis-
ease, and death with chronological age. 
In this thesis, we measure senescence in 
human populations from the increase in 
these risks.
In Part I of this thesis we investigate how 
a population’s senescence rate can be meas- 
ured through the increase in mortality rate 
with age. Classically, it is measured as the 
increase in mortality rate with age on a 
logarithmic scale. In Chapter 3 we test this 
measurement by applying it to patients with 
end-stage renal disease on dialysis treat-
ment, who are clinically known to suffer 
from accelerated senescence, and we com-
pare them with patients with a functioning 
kidney transplant and the general popula-
tion from which these patients originate. 
We demonstrate that the classical meth-
od to measure a population’s senescence 
rate is inaccurate, since it attributes lower 
senescence rates to the patients on dialy-
sis than the patients with a functioning 
transplant and the general population. We 
demonstrate that a novel method, which 
measures a population’s senescence rate 
through the increase in mortality rate on 
an absolute scale, is valid, since it attrib-
utes the highest senescence rates to the 
patients on dialysis. We explain how se-
nescence rates can be calculated accord-
ing to the novel method using the deriva-
tive function of the Gompertz model. In 
Chapter 4 we demonstrate how the same 
method can be applied non-parametrical-
ly without modelling mortality rates. This 
overcomes the disadvantages of the Gom-
pertz model and other models of the age 
pattern of a mortality rate. Since it is of 
quintessential importance for gerontolog-
ical research to accurately determine and 
compare senescence rates of populations, 
senescence rates should not be measured 
as the increase in mortality rate on a loga-
rithmic, but rather on an absolute scale. As 
we show, both methods can yield radically 
different results and interpretations.
The classical method to measure a popula-
tion’s senescence rate through the increase 
in mortality rate on a logarithmic scale is 
based on the assumption that mortality is 
caused by two independent mechanisms: 
intrinsic mortality would result from the 
body’s senescence unrelated to the envi-
ronment, while extrinsic mortality would 
result from environmental hazards unre-
lated to the body’s senescence. In Chap-
ter 5 we explain that the novel method to 
measure a population’s senescence rate 
through the increase in mortality rate on 
an absolute scale is inconsistent with this 
assumption. Moreover, we show that alleg-
edly intrinsic and extrinsic mortality have 
an exponentially increasing age pattern in 
common. Theories of senescence as well 
as epidemiological and biological data in-
dicate that stressors from within the body 
and from its environment cause senes-
cence and death in interaction. Together, 
we conclude that the roles of the body and 
its environment in the causation of senes-
cence cannot be separated. Reversely, the 
senescence process depends on the charac-
teristics of both the body and its environ-
ment.
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In Part II of this thesis we investigate how 
senescence can be measured through the 
increase in morbidity with age in a tradi-
tional rural African population without a 
western lifestyle and thus be compared 
with the senescence process in western 
populations. In Chapter 7 we describe that 
this population is enriched with genetic 
variants associated with a proinflammato-
ry immune response, probably due to the 
high burden of infectious diseases. It has 
been proposed that inflammation plays 
an essential role in the causation of senes-
cence and senescence-related diseases. In 
this population, these genetic variants are 
associated with a high handgrip strength, 
which is regarded to indicate a low biolog-
ical age.
In Chapter 8 we investigate whether hand-
grip strength predicts mortality in the 
traditional African population as it does in 
western populations. Although handgrip 
strength depends on body mass index, it 
declines with age and predicts mortality 
independently of socioeconomic, nutrition-
al, and cardiovascular status. Handgrip 
strength functions as a measure of biologi-
cal age and senescence in this non-western 
as in western populations.
In Chapters 9 and 10 we document that 
cardiovascular disease — including coro-
nary arterial disease, peripheral arterial 
disease, and atrial fibrillation — and di-
abetes mellitus are rare up to the highest 
ages, whereas these diseases dominate the 
senescence process in western populations. 
Meanwhile, risk factors of cardiovascular 
disease and diabetes mellitus — including 
obesity, dyslipidæmia, and hypertension — 
are absent or uncommon. Inflammation 
alone appears to be insufficient for these 
diseases to occur. Because the risk factors 
are closely related to a western lifestyle, 
diseases such as cardiovascular disease 
and diabetes mellitus are likely to develop 
during senescence as a consequence of a 
western lifestyle.
In Chapter 11 we study the associations of 
heart rate and heart rate variability at rest 
with handgrip strength and mortality in 
the traditional African population. While 
heart rate is dependent on cardiovascular 
risk factors and is associated with neither, 
heart rate variability declines with age 
and is associated with handgrip strength 
and mortality independently of these risk 
factors and similarly to western popula-
tions. Heart rate variability, but not heart 
rate, ref lects biological age and senescence 
across different environments with differ-
ent lifestyles.
The way of senescence in this non-west-
ern population is partly similar and partly 
very different as compared with western 
populations. At the same time, the rate of 
senescence, as measured as the increas-
es in mortality rate with age, is similar in 
both types of populations. This exemplifies 
that senescence depends on the interaction 
between bodily and environmental factors 
and indicates that the senescence process 
can be modulated through the environ-
ment and lifestyle. We suggest that the se-
nescence process can be ameliorated when 
environmental interventions unite the best 
of both worlds: a non-western lifestyle to-










Met het ouder worden verslechteren de 
structuren en functies van het menselijke 
lichaam. Dit proces wordt veroudering 
genoemd. In populaties van mensen leidt 
veroudering tot een toename in de risico’s 
op ziekte en sterfte met het toenemen van 
de chronologische leeftijd. In dit proef- 
schrift meten we veroudering in populaties 
van mensen aan de hand van de toename 
in deze risico’s.
In Deel I van dit proefschrift onderzoeken 
we hoe de verouderingssnelheid van een 
populatie kan worden afgemeten aan de 
toename in het sterftecijfer over de leef- 
tijd. Traditioneel wordt de verouderings- 
snelheid afgemeten aan de toename in het 
sterftecijfer over de leeftijd op een logarith- 
mische schaal. In Hoofdstuk 3 testen we 
deze meetwijze door haar toe te passen op 
patiënten met eindstadiumnierfalen die 
worden behandeld met dialyse. Het is be- 
kend dat deze patiënten een klinisch beeld 
vertonen van versnelde veroudering. We 
vergelijken hen met patiënten met een 
functionerend niertransplantaat en de al- 
gemene bevolking waaruit deze patiën- 
ten afkomstig zijn. We tonen aan dat de 
traditionele methode om de verouderings- 
snelheid van een populatie te meten fou- 
tief is, aangezien zij een lagere veroude- 
ringssnelheid toekent aan dialysepatiënten 
dan aan patiënten met een functionerend 
transplantaat en de algemene bevolking. 
We tonen aan dat een nieuwe methode, die 
de verouderingssnelheid van een populatie 
afmeet aan de toename in het sterftecijfer 
op een absolute schaal, juist is, aangezien 
zij de hoogste verouderingssnelheid toekent 
aan de dialysepatiënten. We leggen uit hoe 
de verouderingssnelheid kan worden bere- 
kend volgens de nieuwe methode door ge- 
bruik te maken van de afgeleide functie 
van het Gompertz-model. In Hoofdstuk 4 
laten we zien hoe dezelfde methode niet- 
parametrisch kan worden toegepast zon- 
der modellering van de sterftecijfers. Zo 
kunnen de nadelen worden omzeild van het 
Gompertz-model en andere modellen die 
het verloop van het sterftecijfer over de 
leeftijd beschrijven. Omdat het van wezen- 
lijk belang is voor het onderzoek naar ver- 
oudering dat verouderingssnelheden van 
populaties correct kunnen worden vastge- 
steld en vergeleken, dienen verouderings- 
snelheden niet te worden afgemeten aan 
de toename in het sterftecijfer op een loga- 
rithmische schaal, maar op een absolute 
schaal. Zoals we laten zien, kunnen beide 
methoden radicaal verschillende uitkom- 
sten en interpretaties opleveren.
De traditionele methode om de veroude- 
ringssnelheid van een populatie af te meten 
aan de toename in het mortaliteitscijfer op 
een logarithmische schaal is gebaseerd op 
de aanname dat sterfte veroorzaakt wordt 
door twee onafhankelijke mechanismen: 
intrinsieke sterfte zou voortkomen uit 
veroudering van het lichaam onafhankelijk 
van diens omgeving, extrinsieke sterfte zou 
voortkomen uit de omgeving onafhankelijk 
van de veroudering van het lichaam. In 
Hoofdstuk 5 leggen we uit dat de nieuwe 
methode om de verouderingssnelheid van 
een populatie af te meten aan de toename 
in het mortaliteitscijfer op een absolute 
schaal onverenigbaar is met deze aanname. 
Bovendien laten we zien dat zowel de 
vermeende intrinsieke als de vermeende 
extrinsieke sterfte exponentieel toenemen 
over de leeftijd. Theorieën over veroudering 
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alsook epidemiologische en biologische ge- 
gevens wijzen aan dat stressoren vanuit het 
lichaam en vanuit diens omgeving in wis- 
selwerking veroudering en sterfte veroor- 
zaken. Op basis hiervan concluderen we 
dat het lichaam en diens omgeving niet 
kunnen worden gescheiden als oorzaken 
van veroudering. Omgedraaid: het veroude- 
ringsproces hangt af van de eigenschappen 
van zowel het lichaam als diens omgeving.
In Deel II van dit proefschrift onderzoeken 
we hoe veroudering afgemeten kan wor- 
den aan de toename in ziekte over de leef- 
tijd in een traditionele Afrikaanse platte- 
landspopulatie zonder westerse leefstijl 
en hoe het verouderingsproces van deze 
populatie aldus kan worden vergeleken met 
dat in westerse populaties. In Hoofdstuk 
7 beschrijven we dat deze populatie is 
verrijkt met genetische varianten die zijn 
geassocieerd met een pro-inflammatoire 
immuunrespons, waarschijnlijk als gevolg 
van de hoge infectiedruk. Er is geopperd 
dat ontsteking een essentiële rol speelt in 
het ontstaan van veroudering en van ziek- 
ten gerelateerd aan veroudering. We tonen 
echter aan dat deze genetische varianten 
geassocieerd zijn met een hoge knijpkracht, 
wat wordt beschouwd als een teken van 
een lage biologische leeftijd.
In Hoofdstuk 8 onderzoeken we of knijp- 
kracht een voorspeller is van sterfte in de 
traditionele Afrikaanse populatie zoals in 
westerse populaties. Hoewel knijpkracht 
afhankelijk is van de lichaamsomvang, 
neemt zij af over de leeftijd en voorspelt 
zij sterfte onafhankelijk van de socio- 
economische positie, voedingsstatus en 
cardiovasculaire gezondheid. Knijpkracht 
functioneert als een maat van biologische 
leeftijd en veroudering in deze niet-wes- 
terse zoals in westerse populaties.
In Hoofdstukken 9 en 10 documenteren 
we dat hart- en vaatziekten — waaronder 
coronair vaatlijden, perifeer vaatlijden en 
boezemfibrillatie — en diabetes melli- 
tus zeldzaam zijn tot op de hoogste 
leeftijden, terwijl deze ziekten het veroude- 
ringsproces in westerse populaties over- 
heersen. Tegelijkertijd zijn risicofactoren 
van hart- en vaatziekten en diabetes 
mellitus — waaronder obesitas, dyslipi- 
dæmie en hypertensie — afwezig of zeld- 
zaam. Ontsteking op zichzelf blijkt niet 
voldoende voor het teweegbrengen van 
deze ziekten. Aangezien de risicofactoren 
nauw gerelateerd zijn aan een westerse 
leefstijl, ontstaan ziekten zoals hart- en 
vaatziekten en diabetes mellitus tijdens 
veroudering waarschijnlijk als een gevolg 
van een westerse leefstijl.
In Hoofdstuk 11 bestuderen we de asso- 
ciaties van de hartfrequentie en de varia- 
biliteit van de hartfrequentie met knijp- 
kracht en sterfte in de traditionele Afri- 
kaanse populatie. Terwijl de hartfrequentie 
afhankelijk is van cardiovasculaire risico- 
factoren en geassocieerd is met geen van 
beide uitkomsten, neemt de variabiliteit 
van de hartfrequentie af over de leeftijd 
en is zij geassocieerd met knijpkracht en 
sterfte zoals in westerse populaties. De 
variabiliteit van de hartfrequentie, maar 
niet de hartfrequentie zelf, weerspiegelt 
de biologische leeftijd en veroudering in 




De wijze van veroudering is deels verge- 
lijkbaar en deels verschillend in deze niet- 
westerse populatie vergeleken met westerse 
populaties. Tegelijkertijd is de snelheid van 
veroudering, gemeten aan de toename in 
het mortaliteitscijfer over de leeftijd, ver- 
gelijkbaar in beide typen populaties. Dit 
illustreert dat het verouderingsproces af- 
hangt van de wisselwerking tussen licha- 
melijke en omgevingsfactoren en toont aan 
dat het verouderingsproces kan worden 
beïnvloed door de omgeving en leefstijl. Wij 
stellen voor dat het verouderingsproces kan 
worden verbeterd wanneer aanpassingen 
van de omgeving het beste van beide werel- 
den verenigen: een niet-westerse leef- 
stijl in combinatie met volksgezondheids- 
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